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Individuals with severe mental illness (SMI- schizophrenia, schizoaffective disorder and 
bipolar disorder) experience higher levels of morbidity and mortality than the general 
population. An important policy goal is to reduce this gap. Investigating the contributory 
role of physical illness is of key importance to unpacking the associations between SMI and 
detrimental outcomes, such as premature mortality and frequent hospital admissions. This 
thesis builds on recent advances to data extraction technologies to investigate the above. 
 
Objectives  
• To describe the relative contributions of major disease groups to the gap in life 
expectancy between individuals with SMI and the general population. 
• To describe the most common reasons for admission to non-psychiatric hospitals by 
individuals with SMI and the relative frequencies of these admissions compared to 
the general population. 
• As a proof of principle for ascertaining meaningful symptom profiles from routine 
mental health record text fields, to describe the prospective association between 
number of recorded negative symptoms and mental healthcare outcomes 




• To describe the association with mortality and hospitalisation for each of six 
symptom dimensions (positive, negative, manic, disorganisation, catatonic and 
depressive) extracted from the clinical records of individuals with SMI. 
 
Methods  
Information for SMI cohorts were derived from the Clinical Record Interactive Search (CRIS), 
a de-identified electronic patient records data resource. Data on mortality were extracted 
using existing linkages between CRIS and death certification (Office for National Statistics). 
Life expectancy estimates were used to explain the contributions of specific causes of death 
to the gap. Using Hospital Episode Statistics data, frequencies of and causes for non-
psychiatric hospital admissions in SMI were compared to those in the catchment general 
population. Symptoms within clinical record text fields were ascertained using a range of 
natural language processing algorithms, and were assessed for their associations with 
mortality and hospitalisation outcomes. 
 
Results  
Natural causes accounted for 79.2% of lost life-years in women and 78.6% in men. Deaths 
from circulatory disorders accounted for more life-years lost in women than men (22.0% 
versus 17.4%, respectively), as did deaths from cancer (8.1% versus 0%), but the 




Commonest discharge diagnosis categories were urinary conditions, digestive conditions, 
unclassified symptoms, neoplasms, and respiratory conditions. SARs were raised for most 
major categories, except neoplasms where risk was significantly lower. Hospitalisation risks 
were specifically higher for poisoning and external causes, injury, endocrine/metabolic 
conditions, haematological, neurological, dermatological, infectious and non- specific (‘Z-
code’) causes. The five commonest specific ICD-10 diagnoses at discharge were ‘chronic 
renal failure’ (N18), a non-specific code (Z04), ‘dental caries’ (K02), ‘other disorders of the 
urinary system’ (N39), and ‘pain in throat and chest’ (R07), all of which were higher than 
expected (SARs ranging 1.57–6.66). 
Proof of concept analyses showed negative symptoms were associated with younger age, 
male gender and single marital status, and with increased likelihood of hospital admission 
(OR 1.24, 95% CI 1.10 to 1.39), longer duration of admission (β-coefficient 20.5 days, 95% CI 
7.6–33.5), and increased likelihood of readmission following discharge (OR 1.58, 95% CI 1.28 
to 1.95). 
Cox regression analyses detected significant effect of positive (HR 1.08, 95% CI 1.03- 1.16), 
negative (HR 1.09 95% CI 1.02- 1.16) and catatonic (HR 1.09 95% CI 1.03- 1.16) symptoms on 
mortality with adjustment of age, sex, employment, marital status and ethnicity. Linear 
regression analyses detected significant effect of manic (β-coefficient 0.09, 95% CI 0.02- 
0.15), catatonic (β-coefficient 0.08, 95% CI 0.02- 0.15) and depressive (β-coefficient 







Clinically, findings from this thesis confirm that SMI has a substantial negative impact on 
physical health, associated with increased mortality and morbidity. Of clinical relevance, the 
findings showed differences in burden depending on types of symptoms recorded in health 
records. From a policy context, the gap in life expectancy and increased non-psychiatric 
hospitalisation, accounted for by a broad range of causes, need to be addressed 
systematically. Interventions should focus on a whole system approach to improve health 
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Outline of the thesis 
 
Chapter 1- This chapter aims to introduce the conditions that collectively form severe 
mental illness, its domains of psychopathology and dimensions of psychosis. Electronic 
health records (EHRs) are recognised as a valuable source of data and the use of natural 
language processing as a methodology to extract meaningful approaches to obtain clinical 
information. This can be viewed as an opportunity in the context of the described 
implications of physical illness and inequalities that individuals with severe mental illness 
experience. The chapter concludes with a summary of key issues identified.  
  
Chapter 2- Provides a literature review of predictors of mortality for individuals with serious 
mental illnesses.  
 
Chapter 3- Provides a summary of the gaps in the literature identified. 
 
Chapter 4- Presents overall thesis objectives and individual project rationale and aims. 
 




Chapter 6- Investigates the major disease groups that contribute to the gap in life 
expectancy between individuals with severe mental illness and the general population. 
Given the life expectancy gap between people with severe mental illness and the general 
population persists and may even be widening, this chapter aims to estimate contributions 
of specific causes of death to the gap. 
The chapter is based on the following peer-reviewed paper-  
Jayatilleke N, Hayes RD, Dutta R, Shetty H, Hotopf M, Chang CK, Stewart R. Contributions of 
specific causes of death to lost life expectancy in severe mental illness. European Psychiatry. 
2017 Mar 17;43:109-115. 
 
Chapter 7- Investigates the commonly recorded reasons for acute care hospitalisation in 
people with severe mental illness. Given that severe mental illness is associated with worse 
general health, but reasons for admissions to general hospitals have received little 
investigation, this chapter aims to compare frequencies of non-psychiatric hospital 
admission by major diagnostic categories between people with SMI and the general 
population. 
The paper reporting this chapter is currently under peer review  
Jayatilleke N, Hayes RD, Chang CK, Stewart R. Acute general hospital admissions in people 




Chapter 8- Investigates the relationship between negative symptoms identified in the 
clinical records of a large sample of patients with schizophrenia using natural language 
processing and clinical outcomes. 
The chapter is based on the following peer-reviewed paper-  
Patel R*, Jayatilleke N*,  Broadbent M, Chang CK, Foskett N, Gorrell G, Hayes RD, Jackson R, 
Johnston C, Shetty H, Roberts A, McGuire P, Stewart R. Negative symptoms in schizophrenia: 
a study in a large clinical sample of patients using a novel automated method. BMJ Open. 
2015 Sep 7;5(9):e007619. 
* contributed equally 
 
Chapter 9- Investigates symptoms in the electronic clinical records of a large mental 
healthcare cohort of patients with schizophrenia, schizoaffective disorder, or bipolar 
disorder using natural language processing and assesses their relationship with all-cause 
mortality and hospitalisation index. 
The paper reporting this chapter is currently under peer review  
Jayatilleke N, Chang CK, Stewart R. Symptoms identified in electronic medical records for 
individuals with severe mental illness by natural language processing in relation to general 
mortality and hospitalisation [In submission].  
 
Chapter 10- Considers all findings from the previous chapters in relation to existing 
research. I also discuss the strengths and limitations of the thesis and consider how my 
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findings fit into the wider context of patients with serious mental illnesses. I further discuss 




1 Introduction  
 
1.1 Chapter outline 
This chapter aims to introduce the conditions that collectively form severe mental illness, its 
domains of psychopathology and dimensions of psychosis. All mental disorders can be 
debilitating; however, for the purposes of this thesis, severe mental illness (SMI) refers to 
schizophrenia, schizoaffective disorder and bipolar disorders. Despite psychiatric diagnoses 
reportedly having a high reliability (Van Os et al, 2003), there is substantial heterogeneity 
within SMI diagnoses and the validity of the constructs has been frequently questioned.  
Psychotic symptoms are to some extent unique to individuals and there are wide individual 
differences in the severity and course of the underlying disorders and level of functioning in 
individuals with the same disorder (Cowen 2018). To answer my study questions, I have 
extracted the data from a large electronic health record (EHR) based case register in London 
and the context for this will also be introduced in this chapter.  EHRs are a relatively novel 
source of data whose value and application are just beginning to be appreciated (Stewart R, 
et al 2009; Fernandes AC, et al 2013; Perera G, et al 2016). The chapter concludes with a 




1.2 Severe mental illness and its constituent disorders 
1.2.1 Component ‘SMI’ conditions  
 
The International Classification of Diseases, 10th edition (ICD-10) diagnoses of schizophrenia 
(F20.x), schizoaffective disorder (F25.x) and/or bipolar disorder (F31.x) that collectively form 
SMI have substantial impacts on individuals’ cognitive, affective, behavioural and physical 
state (Stahl 2013) with the potential to cause long-term disability. 
 
Schizophrenia is characterised by profound disruptions in thinking, affecting language, 
perception, and sense of self (Cowen 2018). Its manifestations include psychotic 
experiences, such as auditory hallucinations and delusions, but is often also accompanied by 
so-called ‘negative symptoms’ and a broader impairment in functioning resulting in a 
reduced capability to earn a livelihood, the disruption of studies and social isolation (WHO 
2017).  
 
Bipolar disorder is characterised by episodes of mania (abnormally elevated mood or 
irritability and related symptoms with severe functional impairment or psychotic symptoms 
for 7 days or more) or hypomania (abnormally elevated mood or irritability and related 
symptoms with decreased or increased function for 4 days or more) and episodes of 




Schizoaffective disorder is an episodic disorder characterised by both affective and 
schizophrenic symptoms prominent within the same episode of illness: mostly 
simultaneously, but at least within a few days of each other (WHO 2017).  
These constituent disorders and associated illness episodes can be further sub-categorised, 





Table 1:1 - Schizophrenia, schizoaffective disorder and bipolar disorder classification 
International Classification of Diseases version 10 (ICD-10) 
F20 Schizophrenia   
F20.0 Paranoid schizophrenia   
F20.1 Hebephrenic schizophrenia   
F20.2 Catatonic schizophrenia   
F20.3 Undifferentiated schizophrenia   
F20.4 Post-schizophrenic depression   
F20.5 Residual schizophrenia   
F20.6 Simple schizophrenia   
F20.8 Other schizophrenia   
F20.9 Schizophrenia, unspecified 
F25 Schizoaffective disorders   
F25.0 Schizoaffective disorder, manic type   
F25.1 Schizoaffective disorder, depressive type   
F25.2 Schizoaffective disorder, mixed type  
F25.8 Other schizoaffective disorders  
F25.9 Schizoaffective disorder, unspecified 
F31 Bipolar affective disorder   
F31.0 Bipolar affective disorder, current episode hypomanic  
F31.1 Bipolar affective disorder, current episode manic without psychotic symptoms  
F31.2 Bipolar affective disorder, current episode manic with psychotic symptoms   (.20 




F31.3 Bipolar affective disorder, current episode mild or moderate depression   (.30 
Without somatic syndrome   .31 With somatic syndrome) 
F31.4 Bipolar affective disorder, current episode severe depression without psychotic 
symptoms  
F31.5 Bipolar affective disorder, current episode severe depression with psychotic 
symptoms  
(.50 With mood-congruent psychotic symptoms   .51 With mood-incongruent psychotic 
symptoms) 
F31.6 Bipolar affective disorder, current episode mixed   
F31.7 Bipolar affective disorder, currently in remission   
F31.8 Other bipolar affective disorders 





1.2.2 The aetiology of SMI 
 
The exact aetiology for this group of conditions is not clear but is considered to be 
multifactorial (Cowen 2018). Biological theories have suggested a combination of genetic 
factors, structural and functional abnormalities in the brain and environmental 
contributions (Bellmaker R 2004; Picchioni & Murray 2007; Van Os & Kapur 2009).  
 
Family, twin and adoption studies indicate an important genetic contribution; however, it 
appears that a ‘liability to develop’ the disorder is what is inherited rather than a certainty 
of getting it, since even monozygotic twins show concordance rates substantially less than 
100% (Cowen 2018). Epidemiological studies have confirmed that psychiatric disorders 
more generally tend to co-occur within families (Sebat J et al. 2009).  Thus, if a person has a 
first-degree relative with schizophrenia, while their risk of schizophrenia is ten times higher 
than the average person’s, their risk of bipolar disorder or autism or epilepsy is also 
dramatically increased (Lichtenstein et al. 2009).  If these disorders are caused by single 
mutations then the implication is that any such mutation may result in a spectrum of 
symptoms in one individual, which leads to a diagnosis of disorder A, and in a different 
spectrum in another individual, which leads to a diagnosis of disorder B.  In all these cases, 
such mutations are associated with increased risk not to just one disorder but to many 
(Sebat J et al. 2009). 
 
There may be lowered functioning in the prefrontal areas of the brain and enlarged 
ventricles suggesting localised under-development(Cowen 2018). There is also some 
25 
 
evidence for the involvement of neurotransmitters, and alteration of neurotransmitter 
levels remains the mainstay of treatment; however, it is unlikely that a dysfunction of any 
single neurotransmitter system can account for a disorder as complex as schizophrenia, or 
that the pathologies identified to date only affect one neurotransmitter system. It has been 
suggested that schizophrenia is a “disconnection” syndrome which affects the organisation 
of neurones in the brain (Van Os & Kapur 2009). Clinically, all three conditions are 
heterogeneous and this may point to heterogeneous aetiology (Cowen 2018). It seems that 
genetics, neurodevelopmental problems, neurochemistry and abnormal connectivity, as 
well as psychosocial stressors (van Os et al. 2010), probably all contribute to developing the 
typical clinical presentation. Environmental contributions have an important role. In 
particular, for bipolar disorder, recent life events and interpersonal relationships contribute 
to the likelihood of onset and recurrence of bipolar mood episodes (Alloy et al. 2005). There 
is also evidence that high frequency of early life stressors are contributory (Leverich & Post 
2006). 
 
Several neurotransmitter system genes have been examined for their role in brain functions 
and their reported genetic associations with cognition (Cowen 2018). As a result, several 
genetic variations are emerging as having potential effects on neurocognitive deficits (Zai et 
al. 2017); these include genes with roles in the neurotrophic, serotonin, cell adhesion, and 
sodium channel systems. Another incomplete explanation is the dopamine hypothesis which 
is founded on two sources of evidence. First, it is recognised that dopaminergic agonists and 
stimulants can induce psychosis in healthy individuals and can worsen psychosis in an 
individual with SMI (Howes 2009). Second, most effective antipsychotic drugs have 
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recognised effects on the dopamine system. Furthermore, while dopaminergic functioning is 
already dysregulated in prodromal individuals who later progress to schizophrenia, it is not 
as marked as in individuals with the disorder, and there is further dysregulation from the 
prodrome to psychosis(Howes et al. 2016). It remains to be determined whether there is 
enrichment of genetic signal in other restricted gene sets relating to dopaminergic function, 
such as signal transduction and postsynaptic signalling. It is also possible that dopaminergic 
genes play a more prominent role in clinical subsets or in cases defined based on drug 
response(Howes et al. 2017). A third addition to this hypothesis accounts for the multiple 
environmental and genetic risk factors for the condition and proposes that these interact to 
funnel through one final common pathway of excess dopaminergic activity (Howes 2009). 
Figure 1.1 shows a model of genetic factors leading to psychotic symptoms through 
dopaminergic dysregulation. Genetic factors that lead to impaired regulation which leads to 
increased dopamine release. In addition how the individual responds to acute stress, with 
less blunted cortical dopamine and increased striatal dopamine leads to further sensitisation 
of the dopamine system(Howes et al. 2017). 
 
The combination of dopamine-related disturbances with other environmental and genetic 
factors may provide a framework linking the neurochemistry to symptoms experienced by 
individuals. It may also reveal why many disparate risk factors and functional and structural 
abnormalities are associated, for example, with schizophrenia but are not specific to 




Figure 1-1 -Model integrating genetic and environmental factors, dopaminergic 
dysregulation, and the development of psychotic symptoms 
 
(Abstracted from (Howes et al. 2017)) 
 





1.2.3 Epidemiology & treatment of SMI 
 
SMI is relatively rare but for those affected the impact can be lifelong. Schizophrenia affects 
around 0.3–0.7% of people at some point in their life while the lifetime prevalence of 
bipolar I disorder (mania and depression) is estimated at 1% of the adult population, and 
bipolar II disorder (hypomania and depression) affects approximately 0.4% of adults. 
Schizoaffective disorder is estimated to occur in 0.5 to 0.8% of people at some point in their 
life (Van Os & Kapur 2009; Ketter 2010). 
 
SMI disorders are usually treated with an individually tailored combination of therapy and 
medication. Early and prompt intervention is recommended for all disorders. In the UK 
National Health Service, most people with SMI are treated by community mental health 
teams with an aim to provide day-to-day support and treatment while enabling 
independence for the individual (Cowan 2018). A combination of professionals including 
mental health nurses, mental health occupational therapists, social workers, counsellors and 
psychotherapists, psychologists and psychiatrists may be involved. Treatment in the UK is 
generally encompassed within a ‘care programme approach’. An assessment of needs, care 
plan creation, nominated key worker and regular reviews are all fundamental to this model. 
People who have serious psychotic symptoms as the result of an acute episode may require 
a more intensive level of care including hospitalisation or care from crisis resolution teams. 
Compulsory detention may be required for the most serious acute episodes under the 
Mental Health Act (2007) if justified in the interests of the person's own health and safety or 




For schizophrenia, antipsychotic drugs are usually recommended as the initial treatment 
for the symptoms of an acute episode, and the mechanism of action generally includes 
blocking the effect of the neurotransmitter dopamine. Antipsychotics are usually effective 
on feelings of anxiety or aggression within a few hours of use, but may take several days or 
weeks to reduce other symptoms, such as hallucinations or delusional thoughts. 
Psychological treatment can help cope with the symptoms of hallucinations or delusions 
better. They can also help treat some of the negative and depressive symptoms, such as 
apathy or anhedonia. Psychological treatments for schizophrenia in conjunction with 
antipsychotic medication is recommended treatment approach (NICE 2014), and include 
cognitive behavioural therapy (CBT), family therapy and arts therapy. CBT for psychosis aims 
to help the patient identify thinking patterns that are causing unwanted feelings and 
behaviour, and learn to replace this thinking with more realistic and useful thoughts. Family 
therapy is a way of helping the family cope better with the condition involving a series of 
informal meetings discussing information about schizophrenia, exploring ways of supporting 
somebody with schizophrenia and deciding how to solve practical problems that can be 
caused by the symptoms of schizophrenia. Arts therapies are designed to promote creative 
expression to help develop socialisation, and have been shown to alleviate negative 
symptoms of schizophrenia in some people (NHS Choices 2017; Cowen 2018; NICE 2009). 
However, the evidence for adjunctive treatment modalities still remain questionable as 
referring individuals with the condition does not lead to improved global 
functioning(Crawford et al. 2012). 
 
For bipolar disorders, drug treatment includes mood stabilizers such as lithium, sodium 
valproate, lamotrigine, and carbamazepine, and second-generation antipsychotic agents 
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(Ketter 2010) with potential co-administration of antidepressants, anxiolytics/hypnotics, and 
other anticonvulsants. Antipsychotic agents and mood stabilisers provide the primary 
means for managing an acute manic or hypomanic relapse, with continuation of mood 
stabilisers with or without an antipsychotic agent to prevent relapse following recovery. 
Depressive episodes may be managed with antidepressant treatment, although with close 
monitoring for mania/hypomania consequently. Psychotherapeutic interventions may be 
used in the management of depressive episodes and to aid recovery and prevent relapse 
during periods of remission.  
 
For schizoaffective disorder, treatment can be a combination of that used for schizophrenia 
and bipolar disorder, however, it needs to be tailored to the individual’s specific symptoms 
and situation (Cowen 2018). Drug treatments, along with more psychosocial therapies, are 
often necessary to successfully treat schizoaffective disorder. Drug therapy usually can stop 
the patient's psychosis, but often only social and occupational rehabilitation therapies can 
overcome any associated problems such as unemployment, poverty and homelessness 





1.3 Domains of psychopathology and dimensions of psychosis 
 
1.3.1 Phenomenology of psychosis 
 
The construct of psychosis has long been debated. Several theories have been put forward 
dating back to the early 20th century. The multiple avenues led by the debate illustrates that 
the scientific status was never firmly established, anticipating continuing requests to rethink 
SMI.  Kraeplin was the first to dichotomise psychotic disorders into what were termed 
‘manic depressive insanity’ and ‘dementia praecox’ (Kraeplin 1893).  This distinction was 
primarily based on the course of the disorders where manic depression was said to have 
more of a relapsing and remitting course, with returns to health and full functioning 
between episodes, whereas dementia praecox was proposed as characterised by a more 
chronic and declining picture.  The term ‘dementia’ implied chronicity and praecox meant 
‘of the young’.  The term ‘schizophrenia’ was later introduced by Bleuler to replace 
dementia praecox, partly due to the fact that it did not only occur in younger people 
(Bleuler 1963). Bleuler continued to consider its course as a physical disease process but 
established that not everybody with the disorder underwent a progressive decline.  Bleuler 
specified its defining symptoms as affective flattening, looseness of associations between 
mental functions, ambivalence and autism – i.e. using the more negative psychotic 
symptoms as defining features; he regarded hallucinations and delusions as secondary 
symptoms (Heckers 2011).  The term “bipolar” — which signifies the polar opposites of 
mania and depression—first appeared in the American Psychiatric Association’s (AMA) 
Diagnostic and Statistical Manual of Mental Disorders (DSM) in its third revision in 1980 




Jaspers' model of “layers” of mental disorders is also of relevance, in which it was proposed 
that neurotic, endogenous, and organic mental disorders reflected three different layers of 
mental disorders, and psychotic symptoms could be found on both endogenous as well as 
organic levels (Jaspers 1973). The loss of reality which underpins hallucinations and 
delusions became important, and the term “psychosis” has been used variably to denote a 
core syndrome of hallucinations, delusions, and disordered thinking, or in a wider sense, to 
encompass all severe mental disorders. On this background of such clinical diversity and 
variability, Schneider introduced a ranking of psychotic symptomatology, bringing into the 
discussion the notion that when diagnosing and classifying mental disorders, some psychotic 
symptoms may be more important than others (Schneider 1959). Table 1.2 lists Schneider’s 




Table 1:2 - Schneider’s first rank symptoms 
 
Schneider’s first rank symptoms (1959)  
  
Auditory hallucinations:  
1. Audible thoughts: hearing one’s thoughts spoken aloud.  
2. Voices arguing: hearing two or more voices in disagreement or discussion. usually about the 
person referred to in the third person.  
3. Voices commenting on one’s actions as they occur.  
  
Ego boundary disturbance/ other perceptual and delusional experiences:  
4. Somatic passivity: the experience of bodily sensations imposed by an external agency – not 
simply the delusional interpretation of a bodily sensation.  
5. Thought withdrawal: experience of thoughts being taken from the mind by an external force.  
6. Thought insertion: that thoughts have literally been inserted into one’s mind by an external 
agency.  
7. Thought broadcasting: the experience of thoughts not being contained within the mind – that 
they are literally outside of the self in the public domain.  
8. Made feelings: the experience of feelings that have been literally imposed upon the person.  
9. Made impulses: an impulse to carry out an action that is felt not to belong to the person 
(although the actual performance of the act is).  
10. Made volitional acts: experience of one’s actions being controlled by an external force.  





In practice, the difficulty has been that many of the psychotic symptoms in the different 
disorders overlap, and diagnosis based on the more negative symptoms has not led to 
reliable discernment between illness and normality.  Kraepelin’s initial distinctions were 
based on observed course of illness, Bleuler’s approach focused on negative symptoms to 
distinguish schizophrenia, while Schneider’s alternative focus on more positive symptoms 
has become widely used as a set of experiences that are strongly indicative of schizophrenia 
(Gaebel & Zielasek 2015).  However, Hoch in 1912 and Kirby in 1913, both described 
patients with mixed features of schizophrenia and affective disorders which later 
established as schizoaffective disorder as their patients did not have the deteriorating 
course of dementia praecox but more like Kraeplin’s manic depressive psychosis group 
(Yogeswary K 2014). Therefore, the questionable extent to which the three disorders could 






1.3.2 The overlap between psychotic disorders  
 
Schizophrenia and bipolar disorder share many individual symptoms with certain 
combinations of these symptoms co-occurring often (Tondo et al. 2016).  The distinction 
between these two conditions may be clinically useful for treatment and prognosis. 
However, they can be considered as being on two ends at either end of a spectrum, with the 
intervening spaces filled in with a variety of other conditions or diagnostic labels including 
schizoaffective disorder.  While the ends of the spectrum might be quite different, each 
move along it might be more dimensional than categorical.  Recent genetic findings are 
much more congruent with a dimensional distinction than a categorical one and suggest 
substantial shared aetiology between psychotic disorders. Insel (Insel et al. 2010) suggests 
that within each diagnostic category there is a considerable degree of heterogeneity and 
that the diagnostic category in itself provides little information about future clinical 
outcomes.  Van Os (Van Os et al. 1997) suggests that there are overlapping genetic, 
neurobiological and clinical features between different categories of mental disorder. The 
genetic commonality has been further established as specific single-nucleotide 
polymorphisms are associated with a range of psychiatric disorders of childhood onset or 
adult onset which include bipolar disorder and schizophrenia (Cross-Disorder Group of the 
Psychiatric Genomics Consortium. 2013). Schizophrenia, in particular, is a highly heritable 
disorder with genetic risk is conferred by a large number of alleles. Also independent of 
genes expressed in brain, genes expressed in tissues are also associated which have 
immunity functions, providing support for a speculated link between the immune system 




1.2.2 Symptom classification, factor analysis approaches and dimensions of SMI 
 
In mental health research and clinical practice, it is often argued that the symptoms 
expressed by a patient in the course of their illness represent a more useful description of 
the disorder and indications for intervention than the concept of a diagnosis (Adam 2013; 
Chmielewski et al. 2014). While common conditions in mental health are represented in 
classification taxonomies such as the International Classification of Diseases (ICD) and 
Diagnostic and Statistical Manual (DSM) systems, the symptomatology of a condition is 
more often used in clinical practice to determine an appropriate treatment plan. This is due 
to the broad symptomatic manifestations of mental disorders, in the sense that, at a given 
time, a patient assigned a diagnosis (such as schizophrenia) can present with all, many or 
very few of the symptoms associated with the condition. This is particularly pertinent to 
clinical practice where diagnoses are not necessarily assigned using research criteria. The 
problems of diagnostic semantics are especially apparent in SMI where controversy is 
compounded by the high frequency of mental health co-morbidities and shortcomings in 
our current understanding of the biological underpinnings of mental disorders which in turn 
limit our ability to sub-classify the conditions.  
 
The lack of genetic and other objective tests for many mental disorders has led to a 
requirement for detailed, interpersonal observation of patients, cumulating in pragmatic 
symptomatology-based assessments (Anon 1983; Kirkpatrick B, Strauss GP 2011; Kring 2013; 
Kay et al. 1987; Axelrod et al. 1993). A common task in health research is to group patients 
with similar conditions into appropriate cohorts, which will almost inevitably require 
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ascertaining common factors pertinent to their disorder (Hersh 2007; Embi et al. 2005). The 
case for identifying symptoms of SMI as a source of data for mental health research is driven 
by widely recognised deficiencies of diagnostic categories alone for capturing mental 
disorders or providing adequate classes with which to cluster groups of patients for research 
or intervention. This is compounded by the lack of an inventory to capture symptomatology, 
as most research instruments would be considered overly cumbersome for routine clinical 
application outside specialist services. Furthermore, even if a fully structured instrument 
was identified as acceptable for use in initial assessment, obtaining real-time repeated 
measurements would present even more substantial challenges. 
 
The composition of psychosis from varying numbers of symptoms has led to the suggestion 
of deconstructing the entity according to these components. Factor analysis has been the 
most common approach in this respect: a statistical method used to describe variability 
among observed, correlated variables in terms of a potentially lower number of unobserved 
variables called factors (Yong 2013). Factor analysis aims to deal with data sets where there 
are large numbers of observed variables that are thought to reflect a smaller number of 
underlying/latent variables and varying solutions have been proposed for psychosis. There 
have been several factor analyses published. The Positive and Negative Syndrome Scale 
(PANSS) is frequently referenced and is a 30-item rating scale designed to assess dimensions 
of schizophrenia symptoms (Kay et al. 1987). Its items were originally grouped into scales 
for Positive Symptoms (7 items), Negative Symptoms (7 items), and General 
Psychopathology (16 items). Several factor-analytic studies have suggested that a five-factor 
model better captures PANSS structure in schizophrenia samples. In these studies, smaller 
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groupings of items represent Positive and Negative symptoms, with the remainder grouped 
to either Disorganised/Concrete, Excited or Depressed which over time does not appear to 
have shifted hugely from initial descriptions (Bell MD et al 1994; Wallwork et al. 2012).  If 
psychotic symptoms in the general population are taken into account, depressive and manic 
symptoms also come into play, reflecting the occurrence of signs and symptoms of 
psychosis in mental disorders (Gaebel & Zielasek 2015). A recent review of available studies 
on the dimensional structure of psychosis concluded that there is relatively consistent 
evidence, with the majority of the studies finding four or five dimensions, and with positive, 
negative, disorganisation, and affective symptom dimensions most frequently reported 
(Potuzak et al. 2012). Russo (2014) also concluded that symptoms of psychosis assume a 
multidimensional hierarchical structure which was stable over time and which showed good 
concordance with categorical diagnoses. The combined use of dimensional and categorical 
approaches to psychotic disorders was therefore concluded to be of clinical and research 
utility (Russo et al. 2014).  
 
A cluster of clinical symptoms encompassing, in several possible compositions, the 
psychopathologic domains of delusions, hallucinations, and disorganised thinking, 
supplemented by affective domains, is therefore the core of psychosis. These symptoms 
occur in different mental disorders as currently characterised with considerable overlap, 
although there are clearly symptoms that occur more often in schizophrenia compared with 
affective psychoses. This may indicate that the causes and pathological mechanisms of 
psychotic symptoms in affective disorders are different from those in schizophrenia and 
related disorders. These findings obviously raise some doubts about the clinical validity of 
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traditional diagnostic categories.  On the one hand, diagnoses may be arbitrarily defined 
constructs of limited usefulness that actually hamper medical practice and research.  
Alternatively, they may describe truly distinct phenotypic end-points reflecting real 
differences in current pathophysiology, despite similar mechanistic starting points.   
 
As described above, dimensional assessments capture potentially more meaningful 
variation in the combinations and severity of symptoms, which may help with treatment 
planning and the prediction of course and outcome (Allardyce, J. et al. 2007). Studies 
investigating associations of categorical and dimensional models with different clinical 
parameters have reported the superiority of dimensions over diagnostic equivalents to 
predict clinical course, outcome and treatment response (Van Os et al. 1997). The relative 
clinical utility of symptom dimensions versus conventional diagnostic categories in 
individuals with SMI with symptom dimensions rated at presentation better predicting 
outcomes such as time to first remission than a categorical diagnosis (Ajnakina et al. 2018). 
DSM-5 also takes a more dimensional approach, which proposes that a patient who 
presents with the signs and symptoms of psychosis should be assessed along eight 
dimensions: the five domains that define schizophrenia spectrum disorder, hallucinations, 
delusions, disorganised thought (speech), disorganised or abnormal motor behaviour 
(including catatonia) and negative symptoms as well as cognition, depression, and mania 
(American Psychiatric Association 2013). Each DSM-5 dimension should be assessed on a 
five-point scale ranging from 0 which denotes not present to 4 which denotes present and 
severe. At present, though, it is not clear how these dimensions will map onto models of 
human behaviour such as decision making and reward behaviour or neural circuits 
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(Gigerenzer 2011; Der-Avakian 2012). However, this initial proposal to integrate dimensions 




1.4 Physical illness in people with SMI 
 
Supplementing research on the direct consequences of mental distress arising from acute 
relapses in SMI, studies over a number of years have repeatedly shown that people with 
mental ill health die younger and a greater proportion have poor physical health, compared 
with the general population (Saha S 2007). Predictors of mortality and potential underlying 
pathways in relation to SMI will be more systematically reviewed in Chapter 2, but a broader 
overview of relevant issues and policy is provided here as an introduction. 
 
Mental ill health does not occur in isolation, and it has been estimated that 46 per cent of 
people with a mental health condition also have a long-term physical health diagnosis 
(Naylor C et al 2012). In particular, those with mental ill health have high rates of 
respiratory, circulatory and infectious disease, obesity, abnormal lipids and diabetes (DE 
Hert M, Correll et al 2011; Pendlebury & Holt 2010; Bill et al. 2017; De Hert M et al 2009). A 
Finnish study estimated that up to 50 per cent of the increased mortality in those with 
mental ill health was due to underlying physical health conditions (Joukamaa M 2001). 
When it comes to disease-specific mortality, the death rates from respiratory disease and 
diseases of the digestive system are four times higher in mental health service users 
compared with the general population and 2.5 times higher for death from circulatory 
diseases (Dorning, H. Davies, A. Blunt 2015). 
 
Drawing on information to date on these links between physical and mental health, a recent 
report from the Chief Medical Officer (Davies SC 2013) highlighted that approximately 60 
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per cent of the excess mortality in people with mental illness is avoidable. Considering 
physical health alongside mental health is imperative in order to address the disparities in 
life expectancy between those with and without mental ill health and one key area is to 
improve access to physical healthcare for those with mental ill health (Millard & Wessely 
2014). NHS England suggests that there is an excess of 40,000 deaths among SMI patients, 
which could be reduced if those patients received the same healthcare interventions as the 
general population (NHS England 2015). For example, UK National Institute of Health and 
Care Excellence (NICE) guidance states that everyone with schizophrenia should have an 
annual physical health check (NICE 2014), yet a national audit in 2012 found that only 29 per 
cent of people with SMI received appropriate physical health checks (Cooper S et al, 2012). 
People with schizophrenia are also half as likely to undergo coronary revascularisation as 
patients without mental ill health (Davies SC 2013).   
 
In the UK, at policy level, there has been greater focus at both national and local levels on 
achieving ‘parity of esteem’ for physical and mental health – to ensure that people are 
enabled to maintain both their physical and mental wellbeing (National Confidential Enquiry 
into Patient Outcome and Death (NCEPOD) 2017).  Nationally, a Mental Health Taskforce 
was formed to develop a five-year national strategy for mental health, covering access, 
choice of treatments and prevention (NHS England 2015).  These initiatives were 
accompanied by increased funding for mental health services, and the introduction of 
waiting time targets and quality standards for mental health services. In addition, a provider 
incentive payment was introduced to encourage secondary care mental health services to 
improve the physical healthcare of patients with mental health conditions.  For these policy 
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measures to be effective, it is important to better understand how those with mental ill 
health are using services and whether they can access care for their physical health needs. A 
Health and Social Care Information Centre review found higher rates of access to hospital 
services for those with mental ill health compared with those without – but no distinction 
was made to compare hospital use for underlying physical or mental healthcare diagnoses 
(Health and Social Care Information Centre. 2013). Additionally, as the care services and 
pathways for physical and mental health are often not linked, data are captured in different 
ways in different systems, making it difficult to explore quality of care for physical health in 





1.5 Wider health and healthcare inequalities 
 
Among individuals with SMI, issues with help seeking behaviour and the resulting 
marginalisation of individuals is apparent. Patient/illness factors (DE Hert et al. 2011a; De 
Hert et al. 2011b) lead to difficulty in understanding health care advice combined with the 
motivation required to adopt new changes in lifestyle, poor compliance with treatment, 
cognitive deficits, reduced pain sensitivity (induced by antipsychotic medication)(Sendt et al. 
2015). Poor communication and deficient social skills (e.g. as negative symptoms of 
schizophrenia)  potentially account for the shortened life-span of patients with SMI(Kessing 
LV, Vradi E, McIntyre RS 2015; DE Hert M 2011b).  An additional patient/illness factor is that 
psychiatric symptoms may render patients less inclined to discuss physical 
problems(Goodwin et al. 2016). Some doctors are uncomfortable dealing with psychiatric 
patients because the latter may be cognitively compromised which may impair or impede a 
doctor’s clinical assessment. The stigma of mental illness, often the result of disparaging 
media coverage and negative stereotypes surrounding psychiatric patients, are other 
hurdles that prevent people from seeking treatment. Furthermore, people with mental 
disorders may be less likely to see a primary care physician and therefore to receive other 
interventions such as screening for cancer. 
 
Unequal quality of healthcare provision could potentially explain much of the subsequent 
excess mortality(Goodwin et al. 2016). Psychiatrist-related factors are characterised by an 
over-emphasis on mental health to the exclusion of physical health, infrequent screening 
rates for metabolic abnormalities, omission of medical examination of patients because 
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physical complaints frequently are part of the psychiatric presentation, poor communication 
with the patient and the primary care teams, a lack of awareness and perhaps adherence to 
treatment guidelines, insufficient medical knowledge, and erroneous, sometimes misguided 
beliefs about patients’ capability to change their lifestyle (DE Hert et al. 2011a; De Hert et al. 
2011b). Factors common to the psychiatrist and other physicians include a tendency to 
dismiss or interpret physical symptoms as psychosomatic, lack of good quality care, 
unequipped teams, insufficient assessment, and difficulties providing consistent monitoring 
and continuity of care. Other physician-related factors relate to problems coordinating 
psychiatric and medical care. 
 
In general, probably common to all suffers of mental illness, service-provision factors as 
outlined by NICE (NICE 2014)include a lack of clarity and consensus as to where the 
responsibility of physical health lies (DE Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, 
Cohen D, Asai I, Detraux J, Gautam S, Möller HJ, Ndetei DM, Newcomer JW, Uwakwe R 
2011). The role of general practitioners in supervising healthcare for people with SMI who 
live in the community is variable. The fragmentation of medical and mental health care 
systems, lack of integration of services (poor or absent liaison links) and insufficient funds to 
resource the mental health service, limit the ability of most psychiatrists to focus beyond 
their own specialty.  Service and system changes are prevalent in industrialised countries 
because reforms in mental health have led to reduced inpatient resources leading to shorter 
and infrequent hospital admissions with less time available to focus or investigate physical 
health problems. However, it is of concern when the highest number of excess deaths in 
schizophrenia is associated with cardiovascular disease, but still people with schizophrenia 
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have low rates of surgical interventions such as stenting and bypass grafting (Laursen TM, 
Munk-Olsen T, Agerbo E 2009; Lawrence D, Holman CDJ 2003). Similarly, individuals with 
psychosis are less likely to receive cerebrovascular arteriography or prescribed 
anticoagulants following stroke (Kisely S 2009), and of elderly patients hospitalised with 
heart failure, those with mental health problems receive poorer care during hospitalisation 
and have a greater risk of death and readmission (Rathore et al. 2008). In diabetes, patients 
with co-occurring mental health conditions are less likely to receive standard levels of care 
(Frayne 2006), and there are concerns about metabolic disorders going untreated in 
patients with schizophrenia, with non-white women especially vulnerable to under-
treatment of dyslipidemia and diabetes (Nasrallah et al. 2006).  Individuals with SMI are 
more likely to miss out on routine cancer screening (Carney & Jones 2006; Woodhead et al. 
2016). Even a condition such as appendicitis has been found to present late and with more 
complications among individuals with schizophrenia and with worse outcomes from surgery 
(Cooke BK, Magas LT, Virgo KS, Feinberg B 2007).  Meta-analyses of quality of medical care 
for people with co-morbid mental illness, have concluded that the majority of studies 
demonstrate significant inequalities in receipt or uptake (Mitchell AJ 2009). Chronic health 
problems are very common in patients with bipolar disorder, and tend to be under-
recognised and sub-optimally treated (McIntyre RS et al. 2007). Most studies report on 
medical comorbidity in bipolar samples; relatively fewer studies report the reciprocal 
association. Individuals with bipolar disorder are differentially affected by several 'stress-
sensitive' medical disorders notably circulatory disorders, obesity and diabetes mellitus 
(McIntyre RS et al. 2007) with iatrogenic factors and insufficient access to primary, 
preventive and integrated healthcare systems are all contributory.   
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1.6 Conclusion  
 
Despite significant investments over the last 100 years, the mechanisms underlying the 
development and maintenance of psychosis remain unclear. While the emerging 
technologies of neuroscience and genetics have provided greater access to patients at the 
level of genes, protein, cells, and circuits, these new data have been connected only loosely 
to more clinically relevant psychopathology. People with the disorders underlying SMI 
experience substantial inequalities in many respects, with physical health outcomes 
becoming increasingly salient. Understanding relationships between the nature and 
characteristics of the mental disorders and associated health outcomes is important for 
developing interventions to address such inequalities, and the next chapter will review 




2 Literature review of mortality studies in people with severe mental 
illness 
 
2.1 Chapter outline 
 
This chapter aims to review all observational studies that have investigated predictors of 
mortality outcomes for people with schizophrenia, schizoaffective disorder and bipolar 







The specific objectives of this review were- 
 
• In the selected studies which investigate risk factors for mortality within SMI, to 
describe and compare all-cause mortality rates across SMI stratified by its three 
component conditions (schizophrenia, bipolar disorder, schizoaffective disorder) 
• In the selected studies, to summarise reports of relative mortality rates against 
comparator groups including the general population 
• To review reported predictors of mortality in people with SMI including particular 







2.3.1 Search strategy 
 
The search strategy incorporated the following databases: Embase and Ovid MEDLINE(R).  
The final search was carried out in May 2017 and is summarised in Table 2.1. Papers were 
initially selected by undertaking a search of articles on Medline. Relevant papers to SMI 
were identified by searching for key search terms on Table 2.1 which included the terms 
essential for this search including ‘schizophrenia’, ‘psychotic disorders’, ‘schizoaffective 
disorder’, ‘bipolar disorder’, ‘mood disorders’, ‘affective disorders’ and ‘depressive disorder’ 
where these overlapped with search terms for mortality. This search was supplemented 
with reviews of the bibliographies of relevant articles and from Google Scholar. SMI was 
defined and identified by a diagnosis of one of the component conditions- schizophrenia, 





Table 2:1 - Search strategy for literature review 
 
Electronic databases:  
MEDLINE – January week 1, 2003 to May week 4, 2017, EMBASE – January, 2003 to May, 2017  
Limits: Humans 
English Language Search terms only 
MeSH terms Medline:   
Search ((((Schizophrenia[Title] OR Schizoaffective[Title] OR bipolar[Title] OR psychosis[Title] OR 
"antipsychotic agents"[Title] OR "antimanic agent"[Title]OR "Serious mental illness"[Title])))) AND 
(mortality[Title] OR death[Title] OR "mortality rate"[Title] OR "SMR"[Title] OR "standa* mortality 
ratio"[Title]) 
 
Further restrictions applied-  
Search ((((Schizophrenia[Title] OR Schizoaffective[Title] OR bipolar[Title] OR psychosis[Title] OR 
"antipsychotic agents"[Title] OR "antimanic agent"[Title]OR "Serious mental illness"[Title])))) AND 
(mortality[Title] OR death[Title] OR "mortality rate"[Title] OR "SMR"[Title] OR "standa* mortality 
ratio"[Title]) Filters: published in the last 10 years 
 
Search ((((Schizophrenia[Title] OR Schizoaffective[Title] OR bipolar[Title] OR psychosis[Title] OR 
"antipsychotic agents"[Title] OR "antimanic agent"[Title]OR "Serious mental illness"[Title])))) AND 
(mortality[Title] OR death[Title] OR "mortality rate"[Title] OR "SMR"[Title] OR "standa* mortality 




2.3.2 Study selection- Inclusion and exclusion criteria 
 
Full text articles were retrieved to assess more thoroughly for inclusion for those which 
could not be excluded based on the criteria described below.   Methodological strengths 
and weaknesses of different approaches were considered when interpreting and collating 
findings. For example, studies which mentioned collecting data from clinical records were 
included as cohort studies because it was assumed that clinical information would have 
been prospectively recorded. However, if in a study, data were collected and analysed as an 
ecological study and not at individual level, the study was excluded. Figure 2.1 shows the 




Figure 2-1 - Flowchart of search results and studies included in final review 
 
Broad database searches resulting in 345 
papers identified (initial screening of 
titles/abstracts) 
   
 
 
    
 
   
 
   
 
Limited search by publication date (since year 
2003)- 224 papers 
    
 
  
Excluded: n= 121, Reasons for 
exclusion: following title and abstract 
review, studies identified as not 
assessing mortality, studies that were 
not limited to individuals with SMI as 
defined in inclusion criteria, were 
reviews and not original investigations, 
n<50 
Articles after duplicated were excluded (n=40) 
   
 
  
Papers identified from hand searching 
references + google scholar (n=11) 
Papers identified- data and information used 
within review (n= 51) 






2.3.3 Inclusion criteria  
 This literature review included peer reviewed observational research.  Studies were eligible 
for inclusion based on the following criteria:  
i) published in English,  
ii) published from 2003 onwards to provide review of papers published in the last 
13 years,  
iii) peer reviewed observational research,  
iv) one of the following study designs – cohort/ data linkage study (prospective or 
retrospective), studies involving sample recruitment and collected data from 
individuals with SMI,  
v) sample with SMI at least 50 in number. 
 
2.3.4 Exclusion criteria  
 Papers identified by searches were excluded if they were conference abstracts or reports, 
letters, case reports or case series, ecological studies, reviews or qualitative studies and 
cohort studies of SMI with a sample size below 50. However, bibliographies of reviews were 








For this review, 51 papers were identified as appropriate from the literature search. Table 
2.2 summarises core characteristics of each included study including country, sample size, 
data source, study design & inclusion criteria. Most studies (n=41, 80%) included were from 
Europe or from the United States of America with the remainder from Australia, Canada and 
Asia. A variety of data sources were used in the different studies ranging from registry based 
data, hospital records, data linkages, and insurance databases in addition to data from 
bespoke cohorts. This resulted in a wide range of sample sizes from 72 (Morgan et al.,2003) 
to over one million (Olfsen et al., 2015). All studies were observational studies with cases 
either defined as SMI or schizophrenia or bipolar or schizoaffective disorders. In some 
studies, comorbid conditions were included, such as in the manuscript reported by Davis et 
al. (2012) describing patients with diabetes and schizophrenia. All studies used ICD-10 or 







Table 2:2- Description of studies from articles reviewed: predictors of mortality among patients with SMI 
 
Study Country Sample size Data source Study design & inclusion criteria Case+/- comparator definitions 
(Aagaard et al. 2016) Denmark 
1995 (n=1,100) 
 1998 (n=1,965)  
2001 (n=2,327) 
 2004 (n=2,756)  
2007 (n=2,725) 
Danish Civil Registration 
System 
Historical prospective record linkage study of 
patients with at least one visit to a Danish 
psychiatry emergency rooms in 1995–2007. Five 
consecutive 3-year cohorts of individuals aged 
20 to <80 years included. Data from Danish Civil 
Registration System linked to Cause of Death 
Register & Central Psychiatric Research Register. 
Logistic predictor analyses for premature death 
performed. 
SMI- during at least 2 years of 
primary diagnosis as F20, F22, F25 
or F30–31 and at least four 
admissions or 50 inpatient days or 
secondary diagnosis as F1 or Z04.6 
(Bowersox et al. 2012) USA 3300 Dept. for Veteran affairs 
Veterans with SMI lost to Veterans Affairs care 
for more than 1 year were contacted by 
providers who attempted treatment 
reengagement. Fisher's Exact Tests evaluated 
associations between mortality cause and 
Veterans with SMI lost to Veterans 
Affairs care for more than 1 year 
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Study Country Sample size Data source Study design & inclusion criteria Case+/- comparator definitions 
reengagement status, and a Cox proportional 
hazard model evaluated the association 
between reengagement and survival. 
(Brown et al. 2010a) UK 370 Hospital records 
Cohort study- people with schizophrenia who 
had contact with local National Health Service 
psychiatric services between 1 January 1981 and 
31 January 1982 
Cases- ‘firm diagnosis of 
schizophrenia’ made by the 
responsible consultant; case-note 
evidence of first-rank symptoms of 
schizophrenia or persistent non-
affective delusions or auditory 
hallucinations, in the absence of 
organic brain disease; and misuse 
of alcohol or other substance. 
Comparator- general population 
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Study Country Sample size Data source Study design & inclusion criteria Case+/- comparator definitions 
(Brown et al. 2010b)  201  
Social Security 
Administration's (SSA's) Death 
Master File (DMF) was used 
Participants with SMI were recruited from six 
public and private outpatient mental health 
clinics in urban and suburban communities 
across the Baltimore metropolitan area to 
represent a broad range of patients receiving 
outpatient care. Participants with type 2 
diabetes and without SMI were recruited from 
three primary care clinics near the psychiatric 
clinics. 
Individuals with 
schizophrenia(n=201), major mood 
disorder(n=101) and persons 
without mental illness (n=99) in the 
prior year, all of whom had type 2 
diabetes, were recruited from 
September 1999 until September 
2002 
(Brown S 2012) UK 95 Hospital records Cohort study- community cohort Schizophrenia  
(Callaghan et al. 2014). USA 
Schizophrenia= 174,277, 
bipolar= 78,739 
Inpatient records were linked 
to death-certificate data 
Cohort study- Age-, sex-, and race-adjusted 
standardized mortality ratios (SMRs) for the 19 
diseases causally linked to tobacco use. 
Individuals aged 35 or older at the 
mid-point of their follow-up period, 
with ICD-9 diagnoses of 
schizophrenia and related disorders 
(Capasso et al. 2008) USA 319 
Medical records linkage 
system 
Cohort study between 1950 and 1980 were 
followed until February 2005 for a median of 
23.5 years 
Residents meeting DSM-IV-TR 
criteria for schizophrenia or 
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Study Country Sample size Data source Study design & inclusion criteria Case+/- comparator definitions 
schizoaffective disorder. 
Comparator- general US population 
(Castagnini et al. 2013) Denmark 
Bipolar= 3200, 
schizophrenia= 4576 
Danish Psychiatric Central 
Register 
Record linkage study to the oﬃcial register of 
causes of death 
All cases aged 15–64 years who 
were listed for the ﬁrst time in the 
Danish Psychiatric Register 
between 1995 and 2008 with an 
ICD-10 diagnosis of bipolar disorder 
and schizophrenia.  
(Chang et al. 2010) UK 38,066 SLaM BRC Case Register 
Cohort study- included were schizophrenia 
(F20), schizoaffective disorders (F25), and 
bipolar affective disorder (F31). Substance use 
disorders (F10 to F19), depressive episode (F32) 
and recurrent depressive disorder (F33) 
Deaths were identified by regular 
national tracing returns after 2006. 
Standardized mortality ratios 
(SMRs) were calculated for the 
period 2007 to 2009 using SLaM 
records for this period and the 
expected number of deaths from 
age-specific mortality statistics for 
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Study Country Sample size Data source Study design & inclusion criteria Case+/- comparator definitions 
the England and Wales population 
in 2008(Chang et al. 2010). 
(Crump et al. 2013). Sweden 6618 
Swedish Outpatient Registry, 
Swedish Hospital Registry, 
Swedish Pharmacy Registry 
National cohort study- followed up for physical 
comorbidities  
Bipolar disorder (ICD-10- 
F31),which was identified by any 
outpatient or in patient diagnosis 
during the preceding 2 years. All 
adults 20 years or older who had 
lived in Sweden for at least 2 years 
as of 2003 (N=6,587,036)  
(Das-Munshi et al. 
2017) 
UK 18,201 SLaM BRC Case Register 
longitudinal cohort study between 2007 and 
2014. Linked mortality data from the UK Office 
for National Statistics for the general population 
in England and Wales. Cox proportional hazards 
regression to estimate hazard ratios and a 
modified Cox regression, considering competing 
People with severe mental illness 
for five ethnic groups (white 
British, black Caribbean, black 
African, south Asian, and Irish)  
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Study Country Sample size Data source Study design & inclusion criteria Case+/- comparator definitions 
risks to derive sub-hazard ratios, for the 
association of ethnicity with all-cause and cause-
specific mortality. 
(Davis et al. 2015). Australia 1,291 
Western Australia data 
linkage system 
Longitudinal study 
Type 2 Diabetics as cases. 
Comparators from electoral roll  
(Dickerson et al. 2014) USA  517 National Death Index  
Prospective cohort study- assessed with clinical 
evaluation and blood sample from which 
antibodies to human herpes viruses and 
Toxoplasma gondii were measured 
Schizophrenia patients vs. general 
population 
(Dutta et al. 2007) UK 239 
Camberwell Case Register and 
hospital records 
longitudinal study-indirectly standardized for 
age and gender. Univariate and multivariate 
analyses were used to test potential risk factors 
for suicide 
All patients who presented for the 
first time with a DSM-IV diagnosis 
of bipolar I disorder in a defined 
area of southeast London over a 
35-year period (1965–1999), 
Mortality rates were compared 
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Study Country Sample size Data source Study design & inclusion criteria Case+/- comparator definitions 
with those of the 1991 England and 
Wales population 
(Ernst et al. 2013) Denmark 14,974 
Danish Psychiatric Research 
Register and the Danish Cause 
of Death Register  
1980- 2010 Cohort study using linkage systems 
Patients diagnosed with 
schizophrenia and representative 
sample of Danish population, 
excluding persons diagnosed with 
schizophrenia  
(Fiedorowicz et al. 
2009) 
USA 435 
Participants recruited for the 
National Institute of Mental 
Health Collaborative 
Depression Study 
Prospective cohort study of Caucasian, English-
speaking individuals knowledgeable about their 
biological parents, and were recruited between 
1978 and 1981  
comparison between participants 
with bipolar I and II disorder  
(Fiedorowicz et al. 
2014) 
USA 1,716 
Database of National Institute 
of Mental Health Genetics 
Initiative Bipolar Disorder 
Cohort design- assessed the relationship 
between the duration of the most severe 
depressive and manic episodes and time to 
Final best estimate diagnosis of 
bipolar I disorder from centres that 
due to the wording of the original 
informed consents provided 
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Study Country Sample size Data source Study design & inclusion criteria Case+/- comparator definitions 
Consortium and National 
Death Index 
vascular mortality (cardiovascular or 
cerebrovascular) 
personal identifiers to facilitate 
searching of the National Death 
Index  
(Fors et al. 2016) Sweden 255 National population register Retrospective observational study 1981-1991 
All persons with schizophrenia 
diagnosed per DSM-III-R criteria 
identified for the period 
(Hayes et al. 2012a). UK 
6880 SMI (4064, 745, 
1770- Schizophrenia, 
Schizoaffective, Bipolar) 
Case register linked to 
national mortality tracing 
This dynamic cohort consisted of individuals 
who were diagnosed with SMI during a specific 
observation period (from the 1st of January 
2007 to the 31st of December 2010, inclusive) 
and who had been assessed by a clinician using 
the Health of the Nations Outcome Scale 
(HoNOS), at least once during this observation 
period- symptoms. 
Patients were classified as having 
an SMI if, while in contact with 
Mental Health hospital services and 
they had been diagnosed with 
schizophrenia (ICD-10 code: F20), 
schizoaffective disorder (F25) or 
bipolar affective disorder (F31) 
during the observation period 
64 
 
Study Country Sample size Data source Study design & inclusion criteria Case+/- comparator definitions 
(Hayes et al. 2012b). UK 
6,880 SMI (4064, 745, 
1770- Schizophrenia, 
Schizoaffective, Bipolar) 
Case register linked to 
national mortality tracing 
Cohort study-  individuals diagnosed with SMI 
from the 1st of January 2007 to the 31st of 
December 2010 and assessed by a clinician using 
the Health of the Nations Outcome Scale 
(HoNOS), at least once during this observation 
period- for functional status. 
Patients were classified as having 
an SMI if, while in contact with 
Mental Health hospital services and 
they had been diagnosed with 
schizophrenia (ICD-10 code: F20), 
schizoaffective disorder (F25) or 
bipolar affective disorder (F31) 
during the observation period 
(Hayes et al. 2015). UK 14,754 
Case register linked to 
national mortality tracing 
Cohort study modelling the effect of clozapine 
on mortality over a 5-year period (2007-2011) 
using Cox regression 
SMI diagnosis (WHO ICD-10 codes: 
F20, F25, F31) during 2007 to 2011. 
Analyses compared individuals who 
were newly prescribed clozapine 
against those with no evidence of 
this agent being prescribed 
(excluded if already had clozapine 
in the past) 
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Study Country Sample size Data source Study design & inclusion criteria Case+/- comparator definitions 
(Hjorthøj et al. 2015). Denmark 
Schizophrenia= 41,470, 
Bipolar= 11,739 
Linked nationwide registers 
Prospective, register-based cohort study, 
treatment for substance use disorders 
(categorised into treatment for alcohol, 
cannabis, or hard drug misuse), date of death, 
primary cause of death, and education level.  
Cases included unipolar depression 
in addition to SMIs. Comparators 
from Danish civil registration 
system 
(Hoang et al. 2011) UK 373,099 discharges 
English hospital episode 
statistics and death 
registration data 
Record linkage study 
People discharged from inpatient 
care with a diagnosis of 
schizophrenia or bipolar disorder, 
followed for a year after discharge.  
(Hoang et al. 2013) UK 51,624 
English national Hospital 
Episode Statistics and death 
registrations from Oﬃce for 
National Statistics 
Prospective record linkage study 
people aged <75 years, discharged 
from inpatient care with 
schizophrenia or bipolar disorder in 
2006– 2007, and followed up for 
365 days.  
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Study Country Sample size Data source Study design & inclusion criteria Case+/- comparator definitions 
(Høye et al. 2011) Norway 1,111 
Case register of hospital 
linked to the Causes of Death 
Register of Norway 
Cohort study- Schizophrenia was defined per the 
International Classification of Diseases (ICD-
9:295, ICD-10: F20, F21and F25) 
Observed from the date of first 
admission after January 1st 1980 
until death, moving abroad or the 
end of 2006, for a total of 16129 
person years. In-hospital patients 
at January 1st 1980 were included, 
with start of follow-up the same 
day. All death certificates are 
coded by a physician per the 
current ICD- system.  
(Kim et al. 2017) 
South 
Korea 
Schizophrenia= 9,387 National Health Insurance 
Cohort study between 2002 to 2013- Poisson 
regression modelling conducted to quantify the 
effect of baseline characteristics on all-cause 
and suicide mortality risks.  
Mood disorder, or mental and 
behavioural disorder due to 
psychoactive substance use and to 
compare this with that of the 
general population included in 
addition to schizophrenia  
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Study Country Sample size Data source Study design & inclusion criteria Case+/- comparator definitions 




Mental Health Information 
System of psychiatric 
inpatient, outpatient and 
community contacts, Mental 
Health Review Board 
database of compulsory 
psychiatric treatment, 
Hospital Morbidity Data 
System; and mortality data 
Record linkage observational study- Cohort 
included patients from all community-based and 
inpatient psychiatric services 
Compulsory community treatment, 
such as community treatment 
orders 
(Kredentser et al. 2014) Canada  9,038 
De-identified administrative 
databases 
Population-based analysis was performed to 
compare age- and sex-adjusted 10-year (1999-
2008) mortality rates, overall and by specific 
cause, of decedents aged 10 years or older who 
had 1 diagnosis of schizophrenia (ICD-9-CM code 
295, ICD-10-CA codes F20, F21, F23.2, F25) over 
a 12-year period 
Includes F21, F23. Comparator is 
general population  
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Study Country Sample size Data source Study design & inclusion criteria Case+/- comparator definitions 
(Lahti et al. 2012) Finland 12,939 Helsinki Birth cohort study 
Cohort study- with 30 years follow up by using 
national databases on cardio- and 
cerebrovascular hospitalizations and mortality 
and on reimbursement entitlements and use of 
drugs for treatment of hypertension, 
dyslipidaemia, coronary heart disease and 
diabetes 
Cases limited to individuals with 
schizophrenia 
(Laursen et al. 2011) Denmark 16,079 
Danish Civil Registration 
System 
Cohort study. Patients with schizophrenia (ICD8: 
295 (exclusive 295.79), ICD10: F20) and bipolar 
disorder (ICD8: 296.39, 296.19, ICD10: F30, F31) 
and with any of the remaining psychiatric 
diagnoses registered at psychiatric contact were 
identified 
investigates and evaluates the 
impact of 19 severe chronic 
diseases on excess mortality due to 
diseases and medical conditions 
(natural death) in individuals with 
psychotic disorders  
(Laursen et al. 2014) Denmark 1,061,532 
Danish population register, 
Danish Psychiatric Central 
Register 
Prospective cohort study 
Individuals with schizophrenia or 
bipolar disorder with subjects with 
no prior psychiatric hospitalisation  
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Study Country Sample size Data source Study design & inclusion criteria Case+/- comparator definitions 
(Medici 2015) Denmark 15,334 
Danish Psychiatric Central 
Research Register, Danish 
Register of Causes of Death 
Cohort study- bipolar disorder (International 
Classification of Diseases-10: F31) 
First-ever diagnoses of bipolar 
disorder (International 
Classification of Diseases-10: F31) 
between 1995 and 2012. Age- and 
gender standardized incidence 
rates, standardized mortality ratio 
(SMR) and Kaplan-Meier survival 
estimates  
(Morden et al. 2012) USA 65,362 Veteran Affairs health system 
Matched cohort study- annual prevalence of 
diagnosed cardiovascular disease, diabetes, 
dyslipidemia, hypertension, obesity, and all-
cause and cause-specific mortality was 
compared for fiscal years 2000-2007. Mean 
years of potential life lost (YPLLs) were 
calculated annually 
65,362 patients in the Veteran 
Affairs (VA) health system with 
schizophrenia to 65,362 VA 
patients without serious mental 
illness (non-SMI) matched on age, 
service access year and location  
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Study Country Sample size Data source Study design & inclusion criteria Case+/- comparator definitions 
(Morgan et al. 2003) Ireland 72 
Hospital records and 
interviews 
Cohort study- All persons with schizophrenia, 
including both inpatients and those living in the 
community,  
Individuals with schizophrenia 
followed up 7.5 years after case 
ascertainment  
(Olfson et al. 2015) USA 1,138,853 
Medicaid program, Death 
record information was 
obtained from the National 
Death Index 
National retrospective longitudinal cohort of 
patients with schizophrenia 20 to 64 years old 
during 2001 to 2007.  
Adults with schizophrenia  
(Ösby et al. 2016) Sweden 614 035 person-years National health registers 
Population-based register study including all 
Swedish patients in adult psychiatry admitted to 
hospital with a main diagnosis of schizophrenia, 
bipolar or unipolar mood disorder in 1987–2010 
Mortality rates adjusted for age, 
sex and period were calculated 
using direct standardization 
methods with the 2010 Swedish 
population as standard. Data on all 
residents aged 15 years or older 
were used as the comparison 
group(Ösby et al. 2016)(Ösby et al. 
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Study Country Sample size Data source Study design & inclusion criteria Case+/- comparator definitions 
2016)(Ösby et al. 2016)(Ösby et al. 
2016)(Ösby et al. 2016)(Ösby et al. 
2016)(Ösby et al. 2016)(Ösby et al. 
2016)(Ösby et al. 2016)(Ösby et al. 
2016)(Ösby et al. 2016) 
(Pan et al. 2016a). Taiwan 7987 Health Insurance system Cohort study 
Cases- diagnosed with bipolar in 
2008 aged 18 years or above with 
data were available for a minimum 
of 12 months before and 36 
months after the index date and 
did not have a diagnosis of bipolar 
in the year preceding the index 
date  
(Pan et al. 2016b). Taiwan 15,254 
National Health Insurance 
Research Database 
Cohort study of newly diagnosed bipolar 
disorder 
Survival analyses were performed 
with this national cohort to 
examine the associations between 
the first-year treatment pattern 
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Study Country Sample size Data source Study design & inclusion criteria Case+/- comparator definitions 
(hospitalisation and number of 
outpatient clinic visits) and 
mortality over a follow-up period of 
3 years (2008-2011)  
(Pan et al. 2017) Taiwan 272,617 
National Health Insurance 
Research Database 
Cohort study to estimate age- and gender-
standardized mortality ratios (SMRs) were 
calculated for each of the 3-year observation 
periods. Weight gain and metabolic syndrome in 
relation to use of second-generation 
antipsychotics SGAs assessed 
Two nationwide samples of 
individuals with schizophrenia and 
bipolar disorder 





Retrospective case control study of bipolar 
disorder- 1) manic episode (n=46); 2) hypomanic 
episode (n =195); 3) subthreshold manic 
symptoms (n =1,041); and 4) no manic spectrum 
episodes (n =13,588). 
Participants with manic spectrum 
episodes were compared to those 
without such episodes for mortality 
after 26 years  
(Reininghaus et al. 
2015) 
UK 557 
Mental health services 
records 
First-episode psychosis initially identified in 2 
areas (southeast London and Nottinghamshire, 
Cohort of individuals with SMI   
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Study Country Sample size Data source Study design & inclusion criteria Case+/- comparator definitions 
United Kingdom) were traced over a 10-year 
period in the ӔSOP-10 study 
(Schoepf D, Uppal H, 
Potluri R 2014) 
UK 1418 
Local health authority 
computerized hospital activity 
analysis register 
Retrospective case–control study with up to 12-
year follow-up in general hospital admissions 
from 2000 to 2012  
Cases were individuals with 
schizophrenia. 14,180 age- and 
gender-matched hospital controls  
(Talaslahti et al. 2012) Finland 9461 Nationwide registers 
Cohort study- Patients retired because of 
schizophrenia or schizoaffective disorder also 
included. Those living abroad or in the Åland 
Islands were excluded. Mortality and causes of 
death of this sample were followed up using the 
registers for the 10-year period (1999–2008). 
Individuals with schizophrenia over 
65 years by the ﬁrst of January 
1999, with schizophrenia or 
schizoaffective disorder (ICD-8, 
ICD-9: 295, ICD-10: F20, F25) as the 
main register diagnosis during the 
period 1969–1998  
(Talaslahti et al. 2015) Finland 6,142 Nationwide registers 
Cohort study with register based follow-up for 
mortality covered 10 years between 1999 and 
2008  
Cases- individuals with 
schizophrenia aged 65years or 
above, mortality and causes of 




Study Country Sample size Data source Study design & inclusion criteria Case+/- comparator definitions 
psychosis, VLOSLP) Comparator- 
sex- and age-matched general 
Finnish population. Comparator- 
earlier onset (below 60years) 
schizophrenia patients  
(Tenback. et al. 2012) USA 7,415 Health insurer database 
Observational study examining schizophrenia 
diagnosis and mortality. Includes medication, 
antipsychotic use, type of antipsychotic, other 
medication 
Patients with schizophrenia using 
an antipsychotic (n = 7415) and a 
group of randomly chosen control 
subjects (n = 97,726)  
(Tiihonen et al. 2016) Sweden 21,492 
National Patient Register 
&MiDAS register (maintained 
by the Social Insurance 
Agency of Sweden), 
Prescribed Drug Register 
Prospective population-based cohort study of 
patients with schizophrenia aged 16–65 years of 
age  
Cumulative low, moderate, and 
high exposure to antipsychotics, 
antidepressants, and 
benzodiazepines from 2006 
through 2010. all antipsychotics 
dispensed from 2006 through 2010 
except lithium. cumulative 
exposure of antipsychotics was 
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Study Country Sample size Data source Study design & inclusion criteria Case+/- comparator definitions 
estimated by using the deﬁned 
daily dose  
(Toffol et al. 2015). Finland 826 Hospital Discharge Register 
All the individuals who were hospitalized in 
Finland because of a suicide attempt 
(International Classiﬁcation of Diseases, 10th 
Revision ICD-10 codes X600 to X840, Z728, or 
Z915) between January 1, 1996 and December 
31, 2003, and in prospective screening had been 
hospitalized due to bipolar disorder (ICD-10 
codes F30.0 to F30.9, F31.0 to F31.9) before the 
index attempt, were included in the study 
Relative risk of suicide attempts 
leading to hospitalisation, 
completed suicide, and overall 
mortality during lithium vs. no-
lithium, antipsychotic vs. no-
antipsychotic, valproic acid vs. no-
valproic acid, antidepressant vs. 
no-antidepressant and 
benzodiazepine vs. no-




Study Country Sample size Data source Study design & inclusion criteria Case+/- comparator definitions 
(Westman et al. 2013) Sweden 17 101  
Swedish Total Population 
Register Swedish Cause-of-
Death Register and the 
National Patient Register 
Cohort study with a 20-year follow-up of 
persons were diagnosed with bipolar disorder 
between 1987 and 2006. 
Bipolar diagnoses recorded 
between 1987 and 1996 were 
identified using ICD-9 (296A, C, E 
and 298B) from 1997 and ICD-10 
(F30-F31).  
(Wu et al. 2015) Taiwan 11,247 
National Health Insurance 
Research Database 
Population-based matched cohort study- Cox 
proportional hazard models to determine the 
effect of schizophrenia on macrovascular and 
microvascular complications, and all-cause 
mortality 
11 247 participants with diabetes 
and schizophrenia and 11 247 
participants with diabetes but not 
schizophrenia were enrolled 
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2.4.2 Types of studies included-Clinical records based studies 
 
Overall, 22 studies utilising clinical records as their primary data source investigated all-
cause mortality or factor mortality such as age, gender or ethnicity. The sample sizes 
(individuals with schizophrenia) varied from less than 100 individuals in one study to over a 
million individuals with schizophrenia, bipolar disorder or schizoaffective disorder. The 
strengths and the weaknesses of these studies are summarised below. 
 
Callaghan et al. 2014 investigated outcomes for age, sex, and race-adjusted standardised 
mortality ratios among 253,016 individuals with schizophrenia and bipolar disorder.  This 
study was large but its limitations included some methodological considerations in case-
ascertainment. For example, tobacco-related cancer deaths might as a result be partly 
misattributed to other causes commonly occurring such as cardiovascular problems or more 
easily apparent conditions such as bronchitis or emphysema present near the time of death. 
In addition, competing risks of death from other causes, especially those occurring earlier in 
the lifespan than tobacco- related cancers, might also play a role. The use of inpatient 
diagnoses of schizophrenia, bipolar disorder, and depression means that the study included 
only individuals who both required and received inpatient care. This will have resulted in a 
sample with relatively severe illness, and may have excluded individuals with limited access 
to care or only received outpatient care. The available administrative medical records did 
not contain any information about the presence, frequency, intensity, or duration of 
tobacco use. Mortality estimates will be biased downwards to some extent due to out-
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migration, as individuals leaving the state would be lost to follow-up but would continue to 
accrue time at risk. As the sample was restricted to individuals hospitalised with diagnosed 
psychiatric conditions, findings might be less generalisable to other psychiatric samples, 
such as those drawn from the general population or outpatient care. The study was not able 
to assess the validity of the psychiatric diagnoses by reviewing patient medical charts and, 
as a result, it is possible that such misdiagnoses biases may have affected the mortality 
estimates. 
 
Chang et al. 2010 used a case register to investigate outcomes for all-cause mortality among 
38,066 individuals with schizophrenia, schizoaffective disorder, bipolar affective disorder as 
well as depressive episode and recurrent depressive disorder. Case registers derived from 
secondary healthcare offer advantages for investigating “high penetrance” disorders where 
the chances of secondary care contact are high. Prevalence bias, however, is an issue which 
needs consideration, in that the cases known to a service within a given time are likely to be 
dominated by those with long and relapsing clinical courses - they therefore cannot be 
taken to generalise to incident cases. A further methodological challenge was that service 
data were principally (but not entirely) derived from a single catchment area whereas 
expected deaths were derived from national data. However, the local data were reflective 
of an urban city population, so retain at least some generalisability to similar populations. 
Diagnostic categories overlapped since a proportion of individuals suffer from more than 




Crump et al. 2013 investigated all-cause mortality in 6,618 individuals with bipolar disorder.  
The study’s limitations include possible confounding by disease severity or unmeasured 
factors, the fact that few individuals received monotherapy, and that precision was limited 
for specific medications. Unlike the study described by Callaghan et al. (2014), the 
availability of outpatient diagnoses is a strength because it allows the inclusion of milder, 
non-hospitalised co- morbidities. This reduces the selection effects that arise from the sole 
use of inpatient data and enables more generalisable risk estimates. In addition, individual 
data about smoking, exercise, or other direct lifestyle measurements were unavailable. 
Other substance use disorders were examined using nationwide outpatient and inpatient 
diagnoses, but incomplete ascertainment may have resulted in under-estimation of effects. 
 
Das-Munshi et al. 2017 investigated outcomes for all-cause and cause-specific mortality by 
ethnicity among 18,201 individuals with schizophrenia, schizoaffective disorders and bipolar 
disorders.  The study’s strengths include use of a large cohort from an ethnically diverse 
location to assess differences in mortality outcomes for each ethnic minority group. By 
prospectively assessing mortality and tracing emigrations out of the cohort, the possibility of 
bias through emigration was addressed. A surveillance period of up to 8 years was carried 
out enabling more comprehensive ascertainment of patients in contact with the mental 
health trust with severe mental illness. The study was not able to capture people with 
psychosis who sought private health care but numbers were expected to be small in a UK 
context. The findings are generalisable by location to other urban inner cities where ethnic 
minority communities tend to reside. The study’s limitations include the fact that diagnoses 
of severe mental illness were not based on research diagnostic criteria. Biased diagnostic 
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practices might have led to ethnic minority groups being more likely to receive a psychosis 
diagnosis that would not meet research diagnostic criteria, and thus lower recorded 
mortality risk if such misdiagnosis in ethnic minority groups meant that these individuals 
had less severe mental illness. In addition, the broad ‘south Asian’ category applied in this 
study might have masked important differences for Indian, Pakistani, and Bangladeshi 
individuals.  The study adjusted for neighbourhood-level deprivation, but did not have data 
on individual-level socio economic position. The role of mediators of premature mortality, 
particularly tobacco use, type 2 diabetes, obesity, and hypertension were not addressed. 
 
Hayes et al. 2012a investigated outcomes for all-cause mortality among 6,880 individuals 
with schizophrenia, schizoaffective and bipolar disorder.  The sample was large and inclusive 
of all individuals with SMI who had made contact with mental health services within a 
defined area over a 4-year period. The mental health service is a large provider of secondary 
mental healthcare and a near-monopoly provider for its geographic catchment, hence the 
data should be representative of individuals with SMI living in urban and suburban areas. 
The longitudinal analysis utilised complete electronic clinical records of more than six 
thousand cases, providing the statistical power to simultaneously control for a range of 
potential confounders. In the UK, it is a legal requirement for primary and secondary 
healthcare providers to keep death records up to date. Mortality tracing in the source 
records system is updated monthly and is based on national certification so that only deaths 
occurring outside the UK are likely to have been missed. However, the issue of residual 
confounding remains, in particular, for factors such as medication use that were not 
included in this analysis. Also, a reliable assessment of duration of illness was not available 
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for this cohort as well as whether it was chronic or episodic illnesses. It was not possible to 
manually code free text fields in patient records due to the large sample size and numerous 
records per individual. Consequently, symptom assessment was restricted to Health of the 
Nation Outcome Scales (HoNOS) items. The HoNOS scales were developed to measure the 
health and social functioning of people with severe mental illness(Wing JK, et al 1998). In 
the HoNOS instrument, hallucinations and delusions are combined as one item making it 
impossible to analyse these separately, and there are no HoNOS scales covering symptom 
domains such as negative or disorganisation.  Due to small numbers in some response 
categories, it was necessary to group together people who had mild through to very severe 
problems. It is possible that this grouping might have obscured associations. Furthermore, 
symptom assessment was based on the first HoNOS measurement in the observation 
period, and fluctuations in symptoms over time would not be well captured by a single 
HoNOS assessment. It is possible that mortality risk is mediated by other symptoms not 
included in this study, and the levels of disadvantage or referral bias may still influence the 
characteristics of the cohort who present to secondary care.  
 
Hayes et al. 2012b reported mortality outcomes by functional status for the same cohort 
described above among 6880 individuals with schizophrenia, schizoaffective and bipolar 
disorder. Data on adverse lifestyle choices (other than drinking problems), such as smoking, 
poor diet, and physical inactivity variables were not available, although these are more likely 
to represent mediating rather than confounding factors for associations between a mental 
disorder and mortality. ADL impairment, one of the key exposures of interest, was assessed 
using a single HoNOS item, consequently it was not possible to explore the relative 
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contributions of basic versus instrumental ADLs. In addition, cognitive function was not 
assessed in this analysis. Three quarters of patients with SMI in the cohort had received at 
least one HoNOS assessment during the observation period but there were differences 
between those with and without this assessment. Most notably, those missing the HoNOS 
assessment were older and more likely to have died during the observation period, 
differences which may have impacted on results. It should be noted that HoNOS is not a 
research assessment, and inter-rater variation may have reduced the apparent effect of the 
exposures examined. All secondary mental healthcare within the UK National Health Service 
(NHS) is provided at no cost to consumers, so the only missing mental health service 
contacts would be from individuals seeking exclusively private healthcare. However, the 
characteristics of the cohort who are known to secondary care may still be influenced by 
levels of disadvantage or referral bias. Consequently, the generalisability of both findings is 
principally to secondary care rather than primary care populations but given the high 
penetrance nature of SMI described by Chang et al., 2010, secondary contact is expected 
from most individuals. 
 
Hayes et al. 2015 investigated outcomes for premature mortality from natural causes 
among 14,754 individuals with schizophrenia, schizoaffective and bipolar disorder, 
specifically focusing on clozapine use as an exposure.  This investigation has a number of 
strengths. The sample included all individuals with SMI in contact with mental health 
services within a defined area over a 5-year period. The study drew on complete electronic 
clinical records for close to fifteen thousand cases, providing the statistical power to control 
for a range of potential confounders. Its limitations include the fact that it only examined 
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cases newly prescribed clozapine during the observation period and did not investigate 
mortality associations beyond 5 years. Despite using propensity scores to perform sensitivity 
analysis and adjustment sensitivity, confounding by indication is an important consideration 
which cannot be ruled out entirely in any observational study. A strength is that the study 
adjusted for indicators of severity of illness including diagnosis, symptoms, physical illness, 
and functional status but not an assessment of duration of psychiatric illness was not 
available.  
 
Hoang et al. 2011 investigated trends in age-standardised mortality ratios over time, 
comparing the mortality in individuals with schizophrenia or bipolar disorder with mortality 
in the general population, using data on 373,099 discharges among individuals with 
recorded diagnoses of schizophrenia or bipolar disorder.  The strengths of this study include 
its large size and the fact that it includes all records of discharges with a diagnosis of 
schizophrenia or bipolar disorder in the study period and is nationally representative for 
England. By linkage to national mortality data there is comprehensive information on 
deaths, especially in the period after discharge from hospital when the risk is thought to be 
greatest. Potential limitations include the use of information from hospital records and 
death certificates, which were not collected for research purposes. There are also caveats 
about the validity of a dichotomy between “natural” and “unnatural” categories of death, 
although the definitions of these categories from the ICD codes were standard and applied 
consistently over time. The case groups consisted of people who had been recently 
admitted to hospital with a principal diagnosis of a mental disorder during the period in 
question and, similar to the sample used by Callaghan et al. (2014) are likely to represent a 
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relatively severely affected group at a period of higher risk. The severity of the disorders in 
the case groups might have changed over the monitoring period because of changes in 
admission policy. Another limitation as described before with other observational studies is 
that residual confounding with severity of illness cannot be excluded entirely. 
 
Hoang et al. 2013 investigated outcomes for all-cause SMRs- natural/ unnatural among 
51,624 individuals with schizophrenia or bipolar disorder.  Its strengths include a large 
sample size of this study, and includes all records of discharges with a diagnosis of 
schizophrenia or bipolar disorder in the study period nationally, study characteristics aid the 
generalisability. A study limitation is the reliance on the accuracy of routinely collected data, 
which are not primarily collected for research purposes. The study only focused on 
investigating avoidable mortality risk in people who had been admitted with a diagnosis of 
schizophrenia or bipolar disorder which may have over-estimated the risk from these 
conditions as it did not include people who had not been recently admitted. Age and sex 
differences on avoidable causes of death examined but other determinants such as ethnicity 
and duration of mental illness, were not examined.  
 
Kisely et al. 2013 investigated outcomes for 2-year all-cause mortality among 2,958 
individuals with schizophrenia and affective disorder.  This included psychiatric and physical 
morbidity measured through records of individuals’ use of health services. Potential 
confounders include lack of insight or treatment adherence, social disability, types of 




Kredentser et al. 2014 investigated all-cause mortality among 9,038 individuals with 
schizophrenia.  The strengths of the study include its population-based analysis, accounting 
for the underlying general mortality rates and prevalence of diagnoses. The “cause of 
death” coding through the Manitoba government’s Department of Vital Statistics was 
limited to a single primary cause of death. If the primary cause of death is not specific or 
misleading such as “death by mental illness”, having additional coded causes of death would 
be useful. The death certificate data source also contains data from local residents only, 
which may limit generalisability of findings. In this study there was also limited ability to 
assess the various determinants of the causes of mortality often implicated in schizophrenia, 
such as smoking behaviour, weight, and comorbid illness symptoms such as blood-sugar 
levels. 
 
Olfson et al. 2015 investigated outcomes for all-cause and cause-specific mortality among 
1,138,853 individuals with schizophrenia.  The main strength of this study is the large 
sample size; however, the study had no methods of validating the accuracy of schizophrenia 
diagnoses or estimating the proportion of cases ascertained in the source Medicaid claims 
data, and there is a possibility that different results would have been obtained if privately 
insured and uninsured individuals with schizophrenia were included in the analysis. The 
authors were also not able to investigate smoking status, body mass index, and substance 
abuse. In addition, in common with all studies investigating externally caused mortality, the 
impact of stigma is difficult to quantify and it is possible that it may have contributed to 
under-reporting of suicide and inflated accidental deaths. A further limitation could come 
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from Medicaid encounter data providing incomplete coverage of individuals enrolled in 
some managed care plans. 
 
Schoepf D et al 2014 investigated general hospital mortality outcomes among 1,418 
individuals with schizophrenia, and a hospital-based control group of 14,180 control 
subjects, matching each schizophrenia case with ten randomly selected hospital controls of 
the same age and gender which increases power of study. However, there were limitations 
to note. Firstly, due to matching method, the differences of ethnicity and marital status not 
measured. Secondly, discharge records and general hospital mortality data did not permit to 
differentiate between primary diagnoses and secondary or tertiary diagnoses. The possible 
effects of diagnostic awareness may have influenced findings. The awareness bias may have 
led to systematic under- reporting of physical diseases in the schizophrenia population and a 
systematic underreporting of mental diseases in the control population. For example, 
cardiovascular diseases such as hypertension, angina, and hyperlipidaemia may have been 
underreported in the schizophrenia population compared to the control population.  
 
Davis et al. 2015 investigated outcomes for mortality among 1,291 individuals with 
schizophrenia and diabetes.  There is possibility that there is healthy participant effect as 
questionnaire data were collected; however, the study was potentially informative through 
the comprehensive assessments carried out in a large community-based, representative 




All of the remaining studies described here under clinical records study type have sample 
sizes less than 1,000, some even less than 100. They therefore contribute less substantially 
to the evidence base on the basis of statistical power, although often have advantages in 
sample selection and data availability. Brown et al. 2010a investigated 25-year mortality in 
people with schizophrenia with a particular focus on changes over time among 370 people 
with schizophrenia.  The study was limited by missing people with unrecognised 
schizophrenia and those who avoided service contact during the index year, but was 
representative of Southampton residents with schizophrenia living outside hospital and 
known to local mental health services in 1981–82. The use of a cohort recruited 25 years 
ago means their experiences may differ from that of people diagnosed more recently. 
However, ascertainment was relatively rigorous, as status was independently checked and 
loss to follow-up was low. Brown et al., 2012 investigated outcomes for natural mortality 
among 95 people with schizophrenia.   This study’s strengths include its prospective design, 
face to face assessment and completeness of follow-up. The original diagnoses of 
schizophrenia were made by consultant psychiatrists based on the standard clinical criteria-
individuals were representative of middle aged people with schizophrenia, living in the 
community in the UK making the study findings generalisable. There is, however, selection 
bias as the results are derived from people who were survivors of an initial cohort and who 
consented to interview.  
 
Morgan et al. 2003 investigated outcomes for all-cause mortality among 72 individuals with 
schizophrenia.  Its strengths include an epidemiologically complete cohort, and as such 
encompasses the totality of schizophrenia, from young, first episode cases, through a 
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majority of cases receiving care in the community, to a minority of elderly cases who 
continue to receive long-term inpatient care. There is still potential confounding factors 
such as residential mobility and socioeconomic, ethnic and geographical diversity but all 
cases were ascertained, interviewed in person and diagnosed using contemporary 
operational criteria by the same investigatory team, and the study utilised limited 
information was available on factors such as diet, smoking habits and exercise. Capasso et 
al. 2008 investigated outcomes for all-cause mortality among 319 patients with 
schizophrenia or schizoaffective disorder.  The limitations include diagnosing retrospectively 
from the unified medical record leading to inherent limitations compared with prospective 
identification. Changes in clinical practice over time in history taking and documentation 
meant certain aspects of the medical and psychiatric interview were not recorded 
consistently, particularly smoking history. Dickerson et al. 2014 investigated all-cause 
mortality among 517 individuals with schizophrenia with strengths including detailed clinical 
assessment at baseline and the inclusion of blood-based antibody markers; however, 
information was missing on factors such as obesity and physical inactivity, and on other 
potentially relevant blood- based markers such as C-reactive protein, lipid levels, and blood 
glucose.  
 
Dutta et al. 2007 investigated suicide and all-cause mortality rates among 239 individuals 
with bipolar I disorder. It is unlikely that the rating of risk factors was biased because this 
was done to create a case register and not to test specific hypotheses. However, the risk 
factors were only assessed using the specific criteria for the period until the first year after 
presentation, and data on suicide attempts during the follow-up period were not available. 
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If the recording of suicide on death certificates was more likely if the deceased was known 
to have had recent contact with psychiatric services, then this would have been a source of 
bias towards higher mortality ratios for suicide. Reininghaus et al. 2015 investigated 
outcomes for all-cause, natural-cause, unnatural cause mortality among 557 individuals with 
first-episode psychosis.  However, the limited follow-up of this cohort may have also led to 
type 1 error and there is possibility of unmeasured confounding by other factors such as 
smoking, obesity and other unhealthy lifestyle factors, medication, and access to, or quality 
of, healthcare. This includes alcohol use at baseline because if measured this would have 
enabled, as for baseline illicit drug use, to investigate its role as a risk factor. Toffol et al. 
2015 investigated all-cause and suicide mortality among 826 individuals with bipolar 
disorder. The study included only individuals with high-risk bipolar disorder who were 
hospitalised due to a suicide attempt but was nationwide from the whole Finnish 
population, and had a relatively long follow-up period. The study was only able to identify 
hospital-treated suicide attempts and the diagnosis of bipolar disorder was not based on 




2.4.3 Register based studies 
Register-based research considered in this review will be research that has been based on 
data contained in records kept by government agencies or other organisations, and where 
data can be traced to individuals which could be for the entire population or individuals with 
a particular characteristic. Overall, 24 register based studies investigated all-cause mortality. 
Study size varied from less than 100 individuals in one study to over a million of individuals. 
The study strengths and weaknesses are summarised below. 
 
Aagaard et al. 2016 investigated causes of death and mortality rates among individuals with 
severe mental illness.  The limitations of this study include that its sample was drawn from 
users of psychiatric emergency rooms in a specific Danish context and, therefore, the results 
cannot necessarily be generalised to users of other mental health-care settings. In addition, 
the number of deaths from specific causes was too small in some cohorts for reliable 
assessment of trends over time and in general. Furthermore, local categorisation practice 
differences may make the register-based clinical data quality variable. 
 
Brown et al. 2010b investigated all-cause mortality in 201 individuals with type 2 diabetes 
and SMI. Strengths include the relatively large cohort with this combination of conditions, 
who were extensively characterised at baseline and compared to a local group of individuals 
with type 2 diabetes who did not have SMI. Study limitations include the fact that causes of 
mortality were unknown, as was the extent to which mortality was attributable to diabetes. 
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Overall, the sample size and number of deaths limited the number of predictors of mortality 
that could be investigated in the multivariate logistic regression model. 
 
Castagnini et al. 2013 investigated mortality and cause of death among 7,776 individuals 
with bipolar disorder and schizophrenia.  The limitations of this study are those inherent to 
record linkage surveys which use information collected routinely from psychiatric and death 
registers. 
 
 Ernst et al. 2013 investigated trends in age of death among individuals with schizophrenia.  
The authors noted that findings may not be generalisable to countries with a different 
health system or social welfare; however, less ready access to healthcare would probably 
contribute to even greater differences between the groups of interest over time. Data on 
specific causes of death should be interpreted with caution, as the reliability of these 
estimates might vary over time and in quality. The main strengths of the study were the 
long follow-up and nationwide sample, in which data were gathered systematically and 
individuals not lost to follow-up. Primary and secondary care in Denmark is free at the point 
of access, removing a potential confounding factor compared with studies based in 
countries where free healthcare is less available.  
 
Fiedorowicz et al. 2009 investigated cardiovascular mortality risk in 288 individuals with 
bipolar I disorder and 147 individuals with bipolar II disorder. Some participants were lost to 
follow-up prior to the assessment of the primary outcome, potentially leading to bias, and 
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this loss to follow-up limited the ability to assess exposure to medications and burden of 
clinically significant affective symptomatology. It may also overestimate the burden of 
affective symptoms and perhaps medication exposure for those lost to follow-up early, 
resulting in a differential misclassification of exposure. Limited observed exposure to several 
medication classes impeded the pursuit of a more refined medication exposure assessment, 
for example of more recently marketed or less commonly prescribed medications, limited 
instead to first- generation antipsychotics, lithium and specific anti-depressants. The 
treatment exposure was not controlled and may therefore be confounded by a variety of 
factors, including severity of illness and general health-seeking behaviours. The baseline 
cardiovascular risk assessment was limited by available data, for example not including 
dyslipidaemia, body mass index, and smoking history. The primary outcome variable, 
cardiovascular mortality was observed in 33 participants, limiting statistical power.  
 
Fiedorowicz et al. 2014 investigated time to vascular mortality using Cox proportional 
hazards models in 1,716 participants with bipolar I disorder.  Limitations include potential 
misclassification of exposure, given prior findings suggestive that manic symptom burden 
may be over-estimated retrospectively, and infrequency of the outcome of interest limited 
the number of covariates that could be included in models without over-categorising. 
Furthermore, vascular risk factors, especially smoking, were under-ascertained and 
treatment variables could be included only individually in models. Taken together, this 




Fors et al. 2016 investigated mortality in 255 individuals with schizophrenia. Strengths of the 
study included the thorough search for all people with schizophrenia in a catchment area, 
the use of comparisons with matched referents from the general population (without 
schizophrenia), and the thorough process of diagnosis and re-diagnosis by a psychiatrist. The 
study was performed in a middle-sized town and its surroundings, and may therefore be 
more representative of people with schizophrenia in Sweden than a study performed in a 
larger city. Dropouts were few: 1.5% over the follow-up period of 10 years. Weaknesses of 
the study included the lack of information in the medical data sources on confounders such 
as smoking habits and alcohol/drug abuse which may have contributed to the excess 
mortality, and lack of information on glucose tolerance or other signs of metabolic 
disturbance. Another problem was the lack of control for treatment outcome and changes 
in the healthcare organisation that could have impacted how healthcare was delivered. 
  
Hjorthøj et al. 2015 investigated all-cause mortality and cause-specific mortality associated 
with substance use disorder, including alcohol and cannabis, in 41,470 individuals with 
schizophrenia and 11,739 individuals with bipolar disorder.  The limitations include 
underestimation of the associations because substance use disorders are under-diagnosed. 
Furthermore, by limiting analyses to individuals with a diagnosed substance use disorder, 
the mortality effects of drinking or drug taking that do not meet the thresholds of substance 
use disorder were not assessed. Additionally, in the primary analyses, an immortality bias 
was potentially introduced because individuals in the exposed categories, who were 
diagnosed with substance use disorder, would have survived to the point of diagnosis, 
whereas individuals without diagnosed substance use disorder could have died at any point 
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during follow up. Therefore, the mortality rate in substance users will be under-estimated 
because they were observed for a longer period. The study classified people who had 
received prescription medicines used to treat alcohol and hard-drug use disorders as having 
the disorder in question but they may have been prescribed for a non-mental health reason.  
 
Høye et al. 2011 investigated mortality ratios among 1,111 individuals with schizophrenia.  
There was minimal loss to follow-up as the Norwegian Cause of Death Register can be 
considered complete with regard to mortality. Being the only regional psychiatric hospital, 
all admitted residents should have been included, although non-admitted individuals with 
schizophrenia would not be included. This is particularly likely in the last part of the 27 year 
period because of more extensive out-patient care. Non-differential misclassification of 
diagnoses would have resulted in attenuation of the reported relationships.  
 
Kim et al. 2017 investigated outcomes for all-cause and suicide mortality rates among 9,387 
individuals with schizophrenia.  The study used ICD-10 to classify medical illnesses; however, 
inaccuracies in diagnoses could have occurred as recordings made by different individuals. 
Information was not available on several key risk factors, including education level, smoking 
status, and alcohol consumption status. The date of death was only given up to the year and 
month in the data, therefore may have led to some inaccuracies in estimating date of death. 
 
Lahti et al. 2012 investigated cardio- and cerebrovascular hospitalisations and mortality with 
reimbursement entitlements and use of drugs for treatment of hypertension, dyslipidaemia, 
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coronary heart disease and diabetes among 12,939 individuals with schizophrenia.  The 
strengths of this study include the large, population-based sample and the long follow- up 
period. The diagnoses in the Hospital Discharge Register and the Causes of Death Register 
are well validated. However, although the overall sample was large, numbers of individuals 
in specific diagnostic categories were relatively low, reducing power. Furthermore, this 
study recorded the use of medication from prescriptions filled in out-patient care, not 
covering inpatient receipt, resulting in a potential classification bias. 
 
Laursen et al. 2011 investigated hospital admission and mortality among 2,450,812 persons 
with schizophrenia and bipolar disorder. The study utilised diagnostic information in the 
Psychiatric Central Register for schizophrenia and bipolar disorder which is known to have a 
strong agreement between the psychiatric clinical diagnoses in the registers and research 
criteria diagnoses. In Denmark close to 100% of all diagnoses of schizophrenia and bipolar 
disorder are registered in the Psychiatric Central Register because the GPs in virtual 100% of 
the cases refer individuals with symptoms of schizophrenia or bipolar disorder to an in-
patient or out-patients contact to a psychiatric hospital. Individuals in outpatient treatment 
tend to have many contacts, and the number of incorrectly assigned person-years would be 
limited. The study only included younger persons under the age of 52 because the Danish 
registries did not contain complete medical information on persons born before 1955. 
Similarly, Laursen et al. 2014 investigated mortality outcomes among 1,061,532 individuals 
with schizophrenia and bipolar disorder with cardiovascular drug use.  The limitations 
include the fact that its association between psychiatric status and cardiac deaths could not 
be controlled for behavioural risk factors such as smoking, diet and physical inactivity. The 
96 
 
study measured exposure on first redemption of a medication and no estimations of 
compliance were made.  
 
Medici et al 2015 investigated age- and gender standardised mortality incidence rates, 
mortality ratios and Kaplan–Meier survival estimates among 15,334 individuals with bipolar 
disorder. A strength was the fact that age at time of diagnosis was not subject to recall bias. 
However, mortality in prevalent cases cannot be fully assessed over relatively short periods 
of time, because of an increased risk of incidence-prevalence bias, where individuals with a 
long and relapsing clinical course dominate the picture; therefore, only incident cases were 
followed.  
 
Ösby et al. 2016 investigated mortality adjusted for age, sex and time period among 
individuals with schizophrenia, bipolar or unipolar mood disorder from 1987–2010 (614,035 
person-years).  The strengths include the fact that Swedish Registers include all residents in 
the country and are considered comprehensive, with 99% of all somatic and psychiatric 
hospital discharges recorded. Swedish hospitals and government agencies are required by 
law to enter medical information to this register. All diagnoses in the national patient 
register and the Cause-of-Death Register were given by the physician treating the individual 
using an internationally accepted standard classification. Being register based, this study 
used information about clinical diagnoses from hospital admissions in Sweden, but the 
categorisation of patient groups was based on the most recent diagnoses given at the 
discharge. The diagnoses were based on in-patient diagnoses, which may have generated a 
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selective bias towards severely ill individuals; however, most individuals with schizophrenia 
and most with severe stages of bipolar and unipolar mood disorder are thought to be 
admitted to hospital in Sweden. Since medical care, including hospital care and prescribed 
medication, is heavily subsidised in Sweden, there is no bias by costs for hospital care 
leading to differences in health-seeking behaviour. The researchers did not have access to 
medical records or information on medical treatment, and lacked information on other 
factors affecting health, such as measures of socio- economic status and health behaviour.  
 
Pan et al. 2016a investigated hospital treatment, mortality and healthcare costs among 
7,987 individuals with bipolar disorder. The study strengths include whole country coverage, 
inclusion of bipolar disorder individuals diagnosed in all clinical settings, longitudinal follow-
up for consecutive 3 years, examinations of socioeconomic status at both personal and 
household levels and provision of the rarely available data on the relationship between 
socioeconomic status, outcomes of hospital treatment and mortality. By including only 
newly diagnosed individuals, the study further minimised the bias in the baseline socio-
economic status because of illness-related social decline. Similar strengths and limitations 
apply to the study reported by Pan et al. 2016b investigating mortality risk among 15,254 
individuals with bipolar disorder, and that of Pan et al. 2017 investigating age- and gender-
standardised mortality ratios among 272,617 individuals with schizophrenia and bipolar 




Talaslahti et al. 2012 investigated mortality in 9,461 individuals with schizophrenia aged 
over 65 years.  Its limitations included the fact that it was not possible to check the 
reliability of the schizophrenia diagnoses and no information was available on the living 
habits of the individuals or on the exact age at onset of the disorder. From a methodological 
point of view, because several statistical tests were performed, some possibility of chance 
findings (type I error) exists, but because of the small number of cases in some of the 
subgroup analyses, a possibility of type 2 error to detect small differences may also have 
occurred. Talaslahti et al. 2015 investigated mortality among 6,142 individuals with earlier 
onset schizophrenia with similar limitations, as well as the limited generalisability to late 
onset schizophrenia and other late life psychiatric conditions.  
 
Tenback. et al. 2012 investigated all-cause mortality among 7,415 individuals with 
schizophrenia, strengths of which included the reliability of routinely collected data from a 
health insurer with no missing data. However, no data were available on risk factors such as 
length of illness, smoking, alcohol or substance abuse, socioeconomic status, poor nutrition, 
or diminished physical activity levels. In addition the follow-up period of 3 years is limited, 
most individuals in this database will have had longer illness duration, and individuals might 
have been switched from medication because of cardiovascular risk factor such as excessive 
weight gain.  
 
Tiihonen et al. 2016 investigated all-cause and cause-specific mortality rates as a function of 
cumulative low, moderate, and high exposure to antipsychotics, antidepressants, and 
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benzodiazepines among 21,492 individuals with schizophrenia. The information was limited 
as the usage of open care health services could not be obtained from registers. The register 
data did not allow comparison of individuals with late onset schizophrenia and individuals 
with other old age psychiatric conditions.  
 
Westman et al. 2013 investigated mortality rate ratios, excess mortality, cardiovascular 
disorder and specifically cerebrovascular disease, coronary heart disease, acute myocardial 
infarction, sudden cardiac deaths and hospital admission rate ratio among 17,101 
individuals with bipolar disorder. The sample was limited to those with inpatient diagnoses, 
which may have generated a selective bias towards severely ill individuals. Authors 
additionally did not have access to medical records or information on medical treatment to 
ascertain additional variables.  
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2.4.4 Relative levels of all-cause mortality in SMI  
 
The search identified 24 studies that investigated all-cause mortality as listed in Table 2.3. 
The comparators used in most studies were from the general population except in Schoepf 
et al., 2014 where age- and gender-matched hospital controls were included and Talaslahti 
et al., 2012 and 2015 which compared early onset with late onset schizophrenia population. 
Standardised mortality ratios (i.e. comparisons of mortality risks of people with SMI with the 
age specific general population), hazard ratios, odds ratios and relative risks were used. 
 
Chang et al 2010 was the only study included in the review that included a mortality 
measure for individuals with schizoaffective disorder. Overall, the SMR for SMIs was 2.15 
but when stratified by SMI diagnosis, schizoaffective disorder had the highest SMR of 2.52 
and bipolar disorder had the lowest SMR of 1.95 (all SMRs statistically significant). As well as 
Chang et al 2010, the other study that investigated mortality in people with SMI as a whole 
found a raised SMR of 3.6 for all-cause mortality (Reininghaus et al., 2015).  
 
Eleven further studies investigated risk of death among people with schizophrenia 
specifically. The studies reporting SMRs found that mortality was significantly high among 
people with schizophrenia, apart from the study reported by Dickerson et al., 2014 where 
SMRs were not significant. Among all other studies investigating schizophrenia mortality risk 
and reporting risk ratios or hazard ratios, deaths were significantly higher compared with 
general population. In the Hoang et al 2013 study, the individuals with schizophrenia were 
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younger than 75 years, and their SMR was higher than the studies that did not have an age 
cut-off. However, the Talaslahti et al 2015 study found that SMR was higher among 
individuals with late onset schizophrenia (SMR=5.02- 95% CI 4.61- 5.46) compared to earlier 
onset schizophrenia (SMR=2.93- 95% CI 2.83- 3.03).  
 
Although reviewing change over time was not a primary aim, several studies included did 
investigate mortality measures at different time points. Pan 2017 found that the mortality 
gap for people with schizophrenia had decreased slightly, reporting an SMR of 3.40 (95% CI 
3.30–3.50) for their 2003 cohort and 3.14 (3.06–3.23) for their 2008 cohort. On the other 
hand, Hoang et al 2011 reported that the mortality hazard ratio for schizophrenia in 1999 
was 1.6 and in 2006 had increased to 2.2; the same study found hazard ratios for bipolar 
disorder in 1999 as 1.3 and in 2006 as 1.9 (Hoang et al 2011). In the Pan 2017 study, the 
mortality gap for bipolar disorder individuals remained relatively stable with only those aged 
15–44 years having an SMR rising significantly from 7.04 (6.38–7.76) to 9.10 (8.44–9.79).  
 
In relation to bipolar disorders, in all identified studies reporting mortality risk using SMRs, 
RRs and HRs, significantly high mortality risk was found among people with bipolar disorders 
compared with general population.  
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Table 2:3- All-cause mortality rates among individuals with SMI 
Author Rate/HR/OR/ SMR (95% CI) 
Study cohort (Cases Vs Controls 
(comparisons)) 
Chang et al., 2010 
SMR=2.15 (1.95-2.36)2.25 (2.01-2.51, n = 322), 2.52 (1.83-
3.39, n = 44), 1.95 (1.60-2.35, n = 108) 
 
SMI (F20, 25, & 31 combined), Schizophrenia 
(F20), Schizoaffective disorders (F25), Bipolar 
affective disorder (F31)  
Reininghaus et al., 2015 SMR=3.6, (2.6–4.9)   SMI 
Callaghan et al., 2014 HR= 2.45 (2.41–2.48) Schizophrenia 
Castagnini et al., 2013 HR= 1.3 (1.0–1.6) Schizophrenia 
Dickerson et al., 2014 SMR=2.80 (0.89- 6.38). Schizophrenia 
Ernst et al., 2013 HR= 2.05 (2.01–2.09) Schizophrenia 
Hoang et al., 2011 
HR=1.6 (1.5-1.8) in 1999  
HR=2.2 (2.0 to 2.4) in 2006  Schizophrenia 
Hoang et al., 2013 SMRs= 4.23 (3.85–4.60) Schizophrenia aged <75 years 
Kredenster et al., 2014  RR= 1.70, P < .0001 Schizophrenia  
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Author Rate/HR/OR/ SMR (95% CI) 
Study cohort (Cases Vs Controls 
(comparisons)) 
Olfsen et al., 2015 SMR= 3.7 (3.7-3.7)  Schizophrenia 
Pan et al., 2017 
SMR for 2003 cohort= 3.40 (3.30– 3.50)  
SMR for 2008 cohort= 3.14 (3.06–3.23)  Schizophrenia 
Talaslahti et al., 2015 
SMR=5.02 (4.61–5.46) in late onset  
SMR=2.93 (2.83–3.03) in earlier onset  
Late onset schizophrenia in individuals aged 
65years or above vs earlier onset (age below 
60years) 
Callaghan et al., 2014 SMR= 1.57 (1.53–1.62) Bipolar disorder 
Crump et al.,  2013 
Women- HR=2.34 (2.16-2.53)  
Men- HR=2.03 (1.85- 2.23) Bipolar disorder 
Hoang et al., 2011 
HR=1.3 (1.1 to 1.6) in 1999 and  
HR=1.9(1.6 to 2.2) in 2006 Bipolar disorder  
Hoang et al., 2013 Bipolar HR=2.60 (2.21–3.00) SMI aged <75 years  
Pan et al., 2016a HR=1.74 (1.40–2.15) 




Author Rate/HR/OR/ SMR (95% CI) 
Study cohort (Cases Vs Controls 
(comparisons)) 
Pan et al., 2017 
Aged 15–44years- SMR= 7.04(6.38–7.76) to 9.10(8.44–9.79). 
Aged 15–44 years- natural-cause-SMR= 5.65 (4.93–6.44) to 
7.16 (6.46–7.91) Bipolar disorder 






2.4.5 Relative levels of cause-specific mortality in SMI  
 
The review identified studies that calculated SMRs or HRs or mortality rate ratios as a 
measure for strength of association. Table 2.4 summarises the findings from the literature 
reporting on underlying cause of death. Overall there is a combination of natural and 
unnatural causes that are associated with mortality. Chronic physical conditions such as 
chronic obstructive pulmonary disease and malignant neoplasm were investigated as well as 
unnatural causes of death including suicide and accidental deaths. The evidence base was 
extensive for cardiovascular disease.  
 
In the study by Reininghaus et al., 2015 which found an overall SMR of 3.6, the SMR for 
natural-cause mortality was 1.7 (95% CI 1.0–2.7) and unnatural-cause mortality was 13.3 
(95% CI 8.7–20.4). Severe mental disorders are associated with elevated suicide rates. For 
example, the mortality rate due to suicide is estimated to be over 12 times greater among 
people with schizophrenia compared to the general population. In the publications 
summarised in table 2.3, a history of suicide attempts, depression, not taking medications as 
prescribed, and drug and alcohol misuse are risk factors for suicide among patients with 
schizophrenia and bipolar disorder. 
 
Two studies investigated accidental deaths among individuals with schizophrenia and found 
significantly high SMRs compared with the general population. Olfsen et al, 2015 found SMR 
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of 3.2 for accidental deaths and Talaslahti et al, 2015 found a ten-fold difference in SMRs by 
onset groups: 33.74 in those with an onset at 60 years or later group compared to 8.93 in 
those with an onset before 60 years.  
 
Six more studies investigated cancer mortality among patients with SMI and found SMRs 
were significantly higher than the general population. Das Munshi et al., 2017 found the 
cancer SMR to be 1.45 and Olfsen et al., 2015 reported an SMR of 2.4, while Kredenster et 
al., 2014 described a risk ratio of 1.45 for lung cancer mortality. Talaslahti et al., 2015 found 
an SMR of 1.75 among individuals with late onset schizophrenia aged 65 years or older while 
for individuals with earlier onset SMR was 5.05. and Castagnini et al., 2013 reported a 
hazard ratio of 1.9 for cancers. A further 11 studies investigated the SMRs for CVD, 
circulatory, stroke and cerebrovascular deaths in patients with SMI compared with the 
general population.  In 8 studies out of 11, significantly raised SMRs were found compared 
with either the general population or a specific control group, ranging from an SMR of 3.6 in 
the study by Olfsen et al., 2015 in relation to cardiovascular disease, to a hazard ratio of 
1.67 for stroke in schizophrenia reported by Lahti et al., 2012.   
 
Five studies investigated SMRs for respiratory related deaths such as pneumonia, influenza, 
chronic obstructive pulmonary disease and general respiratory illness. All of these showed 
significantly high SMRs or risk ratios among patients with SMI compared with general or 
control populations. The risk ratio reported by Kredenster et al., 2014, was 2.0 for deaths in 
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respiratory illnesses, while the SMR was 9.9 for COPD deaths in the study reported by Olfsen 
et al., 2015. 
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Table 2:4- Summary of research findings evaluating cause-specific mortality in SMI 
Author Cause of death Strength of the association with mortality (95%CI) Study cohort (Cases Vs Controls (comparisons)) 
Olfsen et al., 2015 Accidental deaths Accidental deaths SMR= 3.2 (3.1-3.2) Schizophrenia 
Talaslahti et al., 2015 Accidental deaths SMR= 33.74 (20.88–51.58) 
Late onset schizophrenia in individuals aged 
65years or above vs earlier onset (age below 
60years)  
Castagnini et al., 2013 Bipolar- natural causes Bipolar- natural causes HR= 1.5 (1.1–1.9) Schizophrenia 
Das- Munshi et al., 2017 Cancers  Cancers SMR=1·45 (1·32–1·60). SMI  
Kredenster et al., 2014 Cancers  28.6 vs. 27.3 per thousand, P = 0.42 Schizophrenia  
Olfsen et al., 2015 Cancers  
Among 6 selected cancers, lung cancer had the highest 
mortality rate (74.8 per 100,000 person-years)  
SMR= 2.4 (2.4-2.5). 
Schizophrenia 
Talaslahti et al., 2015 Cancers SMR= 1.75  
Late onset schizophrenia in individuals aged 
65years or above vs earlier onset (age below 
60years)  
Castagnini et al., 2013 Cancers Neoplastic diseases HR= 1.9 (1.1–3.2) Schizophrenia 
Kredenster et al., 2014 Lung Cancer mortality RR = 1.45, P < 0.001 Schizophrenia  
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Author Cause of death Strength of the association with mortality (95%CI) Study cohort (Cases Vs Controls (comparisons)) 
Das- Munshi et al., 2017 Cardiovascular disease cardiovascular disease SMR=2·65 (2·45–2·86) SMI  
Fiedorowicz et al., 2009 Cardiovascular disease 
Bipolar subtype no longer predicted cardiovascular 
mortality HR=1.85 (0.74–4.65), p=0.19 
Bipolar disorder  
Olfsen et al., 2015 Cardiovascular disease 
Cardiovascular disease had the highest mortality rate 
(403.2 per 100,000 person-years) 
SMR=3.6 (3.5-3.6).  
Schizophrenia 
Brown et al., 2010 Cardiovascular disease 
SMR at start=129 (27–377) to SMR at end=350 (186– 
598), P=0.053 
Schizophrenia 
Westman et al., 2013 Cerebrovascular disease MRR=2.00 (1.81- 2.22) Bipolar disorder  
Fors et al., 2016 Circulatory diseases RR= 2.2, p<0.001 Schizophrenia  
Talaslahti et al., 2015 Circulatory diseases SMR= 2.26  
Late onset schizophrenia in individuals aged 
65years or above vs earlier onset (age below 
60years)  
Kredenster et al., 2014 Circulatory illness RR = 1.64, P < .0001 Schizophrenia  
Lahti et al., 2012 Coronary heart disease HR=2.92 (1.70–5.00) Schizophrenia  
Westman et al., 2013 Coronary heart disease MRR= 1.95 (1.81- 2.09)  Bipolar disorder 
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Author Cause of death Strength of the association with mortality (95%CI) Study cohort (Cases Vs Controls (comparisons)) 
Westman et al., 2013 
Mortality from sudden Cardiac 
death, cardiac arrest/ventricular 
fibrillation 
MRR=1.85 (1.42- 2.41) Bipolar disorder  
Lahti et al., 2012 Stroke HR= 1.67 (0.53–5.26) Schizophrenia 
Kredenster et al., 2014 Injury RR = 2.35, P < 0.0001 Schizophrenia  
Olfsen et al., 2015 influenza and pneumonia SMR= 7.0 (6.7-7.4) Schizophrenia 
Olfsen et al., 2015 
Chronic obstructive pulmonary 
disease 
SMR= 9.9 (9.6-10.2)  Schizophrenia 
Das- Munshi et al., 2017 Respiratory diseases SMR= 3·38 (3·04–3·74) SMI  
Talaslahti et al., 2015 Respiratory diseases SMR= 6.18  
Late onset schizophrenia in individuals aged 
65years or above vs earlier onset (age below 
60years)  
Kredenster et al., 2014 Respiratory disease RR = 2.00, P < .0001  Schizophrenia  
Crump et al., 2013 Suicide 
Female HR=10.37 (7.36-14.60)  
Male HR=8.09 (5.98-10.95) 
Bipolar disorder 
Høye et al., 2011 Suicide SMRs=17.0 (12.8- 22.4)  Schizophrenia 
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Author Cause of death Strength of the association with mortality (95%CI) Study cohort (Cases Vs Controls (comparisons)) 
Olfsen et al., 2015 Suicide  Suicide SMR=3.9 (3.8-4.1)  Schizophrenia 
Westman et al., 2013 Suicide, homicides and accidents MRR=9.66 (8.99 to 10.37) Bipolar disorder 
Das- Munshi et al., 2017 Suicides Age-and-sex-standardised SMR=7·65 (6·43–9·04) SMI   





2.4.6 Demographic factors as predictors of mortality in SMI 
 
Age and gender have been extensively investigated and did not appear to present 
controversy in terms of outcomes. As listed in Table 2.5, the studies shortlisted for this 
review confirm that mortality in SMI is greater for males and a steady increase in mortality 
associated with increasing age as described in Koola et al., 2012, Fors et al., 2016 and Brown 
et al, 2010 except one study which showed risk ratio was 3.26 compared with females 
(Dickerson et al., 2014). Two studies investigated the association between ethnicity and 
mortality among patients with SMI and found no significant association with non-Caucasian 







Table 2:5- Summary of findings from literature examining demographic factors as a predictor of mortality 
 
Author Risk factor Strength of the association with mortality (95% CI) Study cohort (Cases Vs Controls (comparisons)) 
Brown et al., 2010 Age One year increase in age: OR= 1.13 (1.07-1.18) Mortality among patients with SMI with co-morbid diabetes 
Brown et al., 2012 Age Age at onset-HR 1.08 (1.02-1.13) Schizophrenia 
Fors et al., 2016 Age 
Age 45-64 years, HR=4.12, p<0.001, >65 years HR= 23.7, 
p<0.001 (reference group age 18-44 years) 
Schizophrenia  
Koola et al., 2012  Age Older ages (35–55 years versus <35 years)- HR=2.3, p=0.01 Cannabis users vs non-users with psychotic disorders 
Tenback et al., 2012 Age Age per one year increase- HR= 1.06, (95% CI, 1.04–1.08) Schizophrenia  
Brown et al., 2010 Ethnicity 
Non-Caucasian ethnicity vs Caucasian ethnicity- OR= 1.98 
(0.97- 4.00) 
Mortality among patients with SMI with co-morbid diabetes 
Dickerson et al., 2014 Ethnicity 1.59 (0.64 – 4.82) for Caucasian ethnicity Mortality among patients with SMI with co-morbid diabetes 
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Author Risk factor Strength of the association with mortality (95% CI) Study cohort (Cases Vs Controls (comparisons)) 
Dickerson et al., 2014 Gender RR= 3.26 (1.45–7.98), for females Schizophrenia 
Aagaard et al., 2016 Gender OR= 1.5 (1.0-2.1) P= .031 for males Schizophrenia and substance use 
Brown et al., 2010 Gender Male: 0R= 1.95 (95% CI 0.97- 3.90) Mortality among patients with SMI with co-morbid diabetes 
Davis et al., 2015 Gender Male HR= 1.52 (1.29–1.78) Schizophrenia  






2.4.7 Lifestyle, socioeconomic/ social environmental factors and mortality in SMI 
 
Table 2.6 lists the findings from literature examining lifestyle, socioeconomic/ social 
environmental factors as predictors of mortality in cohorts with SMI. Within the papers 
included in this review the following factors were assessed- body mass index, cigarette 
smoking, education, employment, family support, household income, occupational and 
recreational activities, social relationships, standard of living conditions and urbanisation. 
One study examining the association between higher body mass index and mortality among 
individuals with schizophrenia found a 3% increase in hazard in each one-unit increase in 
BMI (Davis et al., 2015). The authors explain that the increase in BMI is partly due to 
unmonitored antipsychotic treatment, which can lead to weight gain. Significant weight gain 
is one of the main reasons individuals do not want to take prescription medication. Weight 
gain in this population also poses a significant risk of lipid abnormalities and cardiovascular 
complications. 
 
Smoking was identified as adversely associated with mortality in six of these studies. All 
studies reporting this exposure found clear associations between risk of smoking and 
mortality among individuals with SMI. A risk ratio of 4.67 in Dickerson et al., 2014 among 
individuals with schizophrenia. SMRs of 2.45 and 1.57 was reported for individuals with 
schizophrenia and bipolar disorder, respectively, in Callaghan et al., 2014.   The odds of a 
current smoker with SMI and co-morbid diabetes dying was found to be double that of a 
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person who is diabetic and is currently not smoking (Brown et al., 2010b). Even among all 
individuals with schizophrenia not known to have diabetes or other specific co-morbid 
conditions, the hazard ratio for mortality is 2.5 times higher for current smokers compared 
to individuals who not current smokers (Brown et al., 2012).    
 
Years of education (Dickerson et al., 2014) and qualifications (Reininghaus et al., 2015) were 
both not statistically associated with mortality. Reininghaus et al., 2015 also reported that 
there was no statistically significant association with unemployment.  
 
Bowersox et al., 2012 found that lack of re-engagement was associated with increased non-
injury death (odds ratio 1.64), with increased cancer-related mortality (odds ratio 4.76) and 
with an average of 97.4 fewer days of life. Family involvement at first contact was found to 
be significantly protective with a risk ratio of 0.09 (Reininghaus et al., 2015).  One study 
investigated household income and deaths among SMI patients and found that the SMR was 
6.47 among females and 5.51 for males with SMI among low income families compared with 
those not from low income households (Pan YJ et al., 2016). Factors such as family support 
(Reininghaus et al., 2015) and social relationships (Hayes et al., 2012b) have not been found 
to have strong associations with mortality, although urbanisation was associated with 




None of the studies in this review provided a comprehensive suite of factors. Findings on 
the different predictors have been mainly derived from studies using different 




Table 2:6- Summary of findings from literature examining lifestyle, socioeconomic/ social environmental factors as a predictor of mortality 
 
Author Risk factor Strength of the association with mortality (95% CI) 
Study cohort (Cases Vs Controls 
(comparisons)) 
Davis et al., 2015 Body Mass Index Increase of 1 kg/m2 Hazard ratio= 1.03 (1.01–1.04),  Schizophrenia  
Brown et al., 2010b Cigarette smoking 
Current smoker vs not current smoker: OR= 2.06 (1.01- 
4.20) 
Mortality among patients with SMI with co-
morbid diabetes 
Brown et al., 2012 Cigarette smoking 
Current smoker vs not current smoker: HR 2.53 (1.01-
6.34) 
Schizophrenia 
Callaghan et al., 2014 Cigarette smoking 
Mortality estimates for conditions causally related to 
tobacco vs conditions not causally related to tobacco 
smoking: Schizophrenia SMR= 2.45 (2.41- 2.48), Bipolar 
SMR= 1.57 (1.53- 1.62)  
General population vs SMI 
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Author Risk factor Strength of the association with mortality (95% CI) 
Study cohort (Cases Vs Controls 
(comparisons)) 
Davis et al., 2015 Cigarette smoking 
Current smoker vs never or ex-smoker HR=1.98 (1.59–
2.47) 
Schizophrenia  
Dickerson et al., 2014 Cigarette smoking Cigarette smoker vs non-smoker: RR= 4.66, P =0 .0029 Schizophrenia  
Dickerson et al., 2014 Education Year of education: RR= 0.89 (0.78 – 1.03) Schizophrenia 
Reininghaus et al., 2015 Education No qualifications: 1.32 (0.69–2.53) SMI 
Reininghaus et al., 2015 Employment Unemployment: 0.70 (0.37–1.33) SMI 
Reininghaus et al., 2015 Family support 
Family involved in first contact with health services: RR= 
0.09, (95% CI 0.01–0.69) 
 First-episode psychosis  
Pan Y-J 2016 Household income 
SMR for low-income males=5.51 (3.21- 8.81) 
SMR for low-income females=6.47 (2.96, 12.28) 




Author Risk factor Strength of the association with mortality (95% CI) 
Study cohort (Cases Vs Controls 
(comparisons)) 
Hayes et al., 2012b 
Occupational and 
recreational activities 
HR for Significant problem: 0.9 (0.6–1.3) SMI patients aged 15 years and over 
Hayes et al., 2012b Social relationships HR for Significant problem: 0.9 (0.6–1.3) SMI patients aged 15 years and over 
Hayes et al., 2012b 
Standard of living 
condition 
Significant problem: HR= 1.1(0.8–1.6) SMI patients aged 15 years and over 
Fors et al., 2016 Urbanisation 
Living in the city than among those living in less 




2.4.8 Physical co-morbidities 
 
Table 2.7 provides a summary of findings from studies which investigated physical co-
morbidities as predictors of mortality in people with SMI. In general, having a comorbidity 
was associated with an increased risk of mortality.  
 
Five of the studies reviewed had assessed circulatory conditions. Davis et al., 2015, reported 
that an increase of 10 mm Hg systolic blood pressure was associated with a decreased 
hazard ratio for mortality of 0.92 (0.88–0.96), although an increase of 5 mm Hg to diastolic 
blood pressure was associated with an increased hazard ratio of 1.07 (1.03–1.12). Lahti et 
al., 2012 found that hospital admission with Coronary heart disease was associated with 
higher mortality. We et al., 2015 found an increased risk of mortality with macrovascular 
complications for individuals who had diabetes and schizophrenia which was statistically 
significant but not statistically significant with microvascular complications. Schoef et al., 
2014 reported that the odds of suffering from an ischaemic stroke was three times higher 
among individuals with schizophrenia. 
 
Findings for respiratory conditions were obtained from two studies. Schoepf et al., 2014 
found for individuals with schizophrenia that the odds of being diagnosed with bronchitis 
(2.6 times higher), chronic obstructive pulmonary disease (COPD) (2.8 times higher) and 
pneumonia (3.0 times higher). Dickerson et al., 2013 also found a raised risk ratio for 




Cancer findings included reports from Pan et al., 2016a for individuals with bipolar disorder 
a significantly raised hazard ratio of 2.14. Kredenster et al., 2014 did not report a significant 
association with risk ratio of 1.05 (p-value of 0.42).   
 
Digestive conditions were reported by Schoef et al., 2014 with a 10-fold increase of having 
alcoholic liver disease associated with general hospital mortality among individuals with 
schizophrenia. Other conditions assessed included diabetes as well as dermatological, 
genitourinary, haematological, immunological, musculoskeletal, neurological and renal 
conditions. Five studies included diabetes with statistically significant increased hazards 
ratios of 1.61 (Pan e al., 2016a) and 1.33 (Davis et al., 2014). The findings for dermatological 
conditions was not statistically significant (Dickerson et al., 2014). Risks were higher for 
genitourinary conditions (p-value 0.002) and haematological conditions (p-value 0.085). 
Schoef et al., 2014 also found increased odds of iron deficiency anaemia, a haematological 
condition (p<0.05). One study found evidence for raised risk of musculoskeletal conditions 
with risk ratios of 3.24 95% CI 1.18- 7.71) (Dickerson et al., 2013). The same study found no 
association with neurological conditions 2.04 (95%CI 0.83- 4.59). Renal disease has been 
significantly associated with schizophrenia- four time more renal failure (Schoef et al., 2014) 




Table 2:7- Summary of findings on physical co-morbidities as predictors of mortality in SMI 
 
Author Risk factor Strength of the association with mortality (95% CI) 
Study cohort (Cases Vs Controls 
(comparisons)) 
Schoepf et al., 2014 Alcoholic liver disease OR = 10.3, (3.3–32.1), p< 0.001 Schizophrenia general hospital mortality 
Schoepf et al., 2014 bronchitis OR = 2.6, (1.2–5.3), p<0.05 Schizophrenia  
Pan et al., 2016a cancer HR=2.14 (1.74–2.63) Bipolar disorder 
Davis et al., 2015 CHD: cardiovascular disease 
SBP (increase of 10 mm Hg) HR= 0.92 (0.88–0.96),  
DBP (increase of 5 mm Hg) HR= 1.07 (1.03–1.12) Schizophrenia  
Lahti et al., 2012 
CHD: coronary heart disease 
hospitalisation HR= 1.65 (1.03–2.57) Schizophrenia  
Schoepf et al., 2014 COPD OR = 2.8, (1.7–4.7) Schizophrenia  
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Author Risk factor Strength of the association with mortality (95% CI) 
Study cohort (Cases Vs Controls 
(comparisons)) 
Wu et al., 2015 CVD: complications 
Macrovascular complications- HR- 1.49, (1.32–1.68), 
Microvascular complications- HR- 1.05, (0.91–1.21) Diabetes & schizophrenia  
Kredentser et al., 2014 Cancer RR= 1.05 (p=0.4247)  
Dickerson et al., 2014 Dermatologic RR= 0.53 (0.03–2.49 Schizophrenia 
Pan et al., 2016a Diabetes mellitus HR=1.61 (1.38–1.89) Bipolar disorder 
Brown et al., 2010 Diabetes: Duration of diabetes 0R= 1.05 (1.01-1.10) SMI with co-morbid diabetes 
Brown et al., 2010 
Diabetes: Hospitalised for diabetes-
related condition OR: 5.44 (1.94- 15.2) SMI with co-morbid diabetes 
Schoepf et al., 2014 Diabetes: Type 1 diabetes mellitus  OR = 3.8, (1.5–10.1) Schizophrenia  
Davis et al., 2014 Diabetes: Type 2 diabetes mellitus HR= 1.33 (1.12–1.57) Schizophrenia  
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Author Risk factor Strength of the association with mortality (95% CI) 
Study cohort (Cases Vs Controls 
(comparisons)) 
Dickerson et al., 2014 Genitourinary disease RR = 4.35, P = 0.002 Schizophrenia  
Dickerson et al., 2014 Haematological RR = 3.46, P=0.085 Schizophrenia  
Dickerson et al., 2014 immunologic disease RR = 3.14, P = 0.044 Schizophrenia  
Dickerson et al., 2014 
Infections: level of antibodies to Epstein–
Barr virus and to Herpes Simplex virus 
type 1 
Epstein–Barr virus RR = 1.22, P = 0.0041  
Herpes Simplex virus type 1 RR = 1.19, P = 0.030;  Schizophrenia  
Schoepf et al., 2014 Infections: pneumonia OR = 3.0, 1.6–5.6, p<0.001 Schizophrenia  
Schoepf et al., 2014 iron-deﬁciency anaemia OR = 2.8, (1.1–7.3), p<0.05 Schizophrenia  
Schoepf et al., 2014 ischaemic stroke OR = 3.3 (1.2–8.8), p<0.05 Schizophrenia  
Pan et al., 2016a 
Number of outpatient clinic visits within 
the first year of bipolar diagnosis HR=1.74, (1.40- 2.15). Bipolar disorder 
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Author Risk factor Strength of the association with mortality (95% CI) 
Study cohort (Cases Vs Controls 
(comparisons)) 
Dickerson et al., 2013 Musculoskeletal RR= 3.24 (1.18–7.71) Schizophrenia 
Dickerson et al., 2013 Neurological RR= 2.04 (0.83–4.59) Schizophrenia 
Schoepf et al., 2014 Parkinsonism OR= 7.5 (3.2–17.4), p<0.001 Schizophrenia  
Pan et al., 2016b Renal disease HR=1.65, (1.36–2.00) Bipolar disorder  
Schoepf et al., 2014 Renal disease: Non-speciﬁc renal failure OR=4.7 (2.0–11.0), p<0.001 Schizophrenia  




2.4.9 Psychiatric factors including co-morbidities 
 
Factors that can be best grouped as ‘psychiatric’ have been summarised in Table 2.8. these 
include presence of lifetime manic spectrum episodes, cognitive function, depression and 
substance use including alcohol). Eleven studies included in this review had findings of 
relevance to substance misuse, alcohol, cannabis abuse. These studies indicate that, in 
general, a dual diagnosis of substance use disorder and SMI significantly increases mortality. 
Hjorthøj et al., 2015 study found that the standard mortality ratios were higher for 
individuals with schizophrenia (SMR= 8.46) was higher than that for individuals with bipolar 
disorder (SMR= 6.47). In other studies that have included hazard ratios for substance use 
disorders, the figures ranged from 1.74 (Pan et al., 2016b) to 6.81 (Dutta et al., 2007). The 
“non-substance use but psychiatric” factors investigated and included here are cognitive 
score, community treatment order, depression, remission, lifetime manic spectrum 
episodes, psychiatric hospitalisation as well as a comparison within SMI between bipolar 
and schizophrenia.  One study of this review reported a protective effect from cognitive 
function among individuals with (Dickerson et al., 2014). Co-morbid depression is a 
significant risk factor for mortality among individuals with bipolar disorder with hazard ratio 
of 1.16 (p=0.02) (Fiedorowicz et al., 2014). 
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Table 2:8- Summary of findings from literature examining psychiatric factors including co-morbidities as a predictor of mortality 
 
Author Risk factor Strength of the association with mortality (95% CI) Study cohort (Cases Vs Controls (comparisons)) 
Ramsey et al., 2013 
Lifetime manic spectrum 
episodes 
OR=1.42 (1.18- 1.70) 
 Bipolar with manic spectrum episodes  
Dickerson et al., 2014 Cognitive function RR = 0.96, P =0 .013 Schizophrenia  
Fiedorowicz et al., 2014 Depression HR= 1.16 (1.02-1.33), p = 0.02 Bipolar I disorder  
Aagaard et al., 2016 
Drug and/or alcohol use- 
Substance use disorder RR= 0.93 (0.42–2.08) Schizophrenia 
Dickerson et al., 2014 Drug/alcohol abuse RR= 6.61 (1.33–32.77) SMI 
Reininghaus et al., 2015 
Illicit drug use- Substance use 
disorder RR= 2.31, (1.06–5.03)  SMI  
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Author Risk factor Strength of the association with mortality (95% CI) Study cohort (Cases Vs Controls (comparisons)) 
Dutta et al., 2007 
Alcohol abuse- Substance use 
disorder HR 6·81, (1·69–27·36), p=0·007  Bipolar I disorder  
Aagaard et al., 2016 Substance use disorder OR= 1.8 (1.5- 2.2). Schizophrenia and substance use 
Hjorthøj et al., 2015 Substance use disorder SMR = 8·46 (8·14–8·79) Schizophrenia 
Hjorthøj et al., 2015 Substance use disorder SMR= 6·47 (5·87–7·06)  Bipolar disorder 
Hjorthøj et al., 2015 
Substance use disorder- 
alcohol, cannabis, hard drugs, 
combined 
Alcohol- HR 1·52, (1·40–1·65); cannabis, 1·24, (1·04–1·48); 
hard drugs HR= 1·78, (1·56–2·04), Schizophrenia  
Hjorthøj et al., 2015 
Substance use disorder- 
alcohol & hard drugs 
HR= 1·52 (1·27–1·81) & 
HR= 1·89 (1·34–2·66) Bipolar disorder  




2.4.10 Medication use 
 
Six studies included in this review have investigated the effect of medication on deaths 
among individuals with SMI.  The medications include cardiovascular medication such as 
lipid lowering agents, antihypertensive or diabetes medication, and psychiatric medication 
such as antidepressants, antipsychotics and specific medications including benzodiazepines, 
clozapine, lithium and other mood stabilizers.  Table 2.9 provides a summary of findings 
from literature examining medication use as a predictor of mortality. The review identified 
two studies that specifically investigated medication for physical illness- lipid lowering 
medication and antihypertensive medication. Six other studies listed in the table presented 
outcomes for antidepressants, antipsychotic medication including clozapine, 
benzodiazepines, lithium and mood stabilizers. Lipid lowering medications were found to be 
associated with lower mortality risk in SMI (Lahti et al., 2012). In terms of mood stabilizers, 
Morgan et al., 2003 reported that lithium users with SMI had better survival while Tenback 
et al., 2012 found an association between mood stabilizers and increased risk of death.  
Tiihonen et al., 2016 found that moderate antidepressant exposure was associated with 
lower mortality. Similarly, clozapine was associated with lower mortality in Hayes et al., 
2015. However, Tenback et al., 2012 found that receipt of first-generation antipsychotics 
was associated with higher mortality, and Tiihonen et al., 2016, found that treatment with 





Table 2:9- Summary of findings from literature examining medication use as a predictor of mortality 
 
Author Risk factor Strength of the association with mortality (95% CI) 
Study cohort (Cases Vs Controls 
(comparisons)) 
Lahti et al., 2012 Lipid lowering medication use OR= 0.47, (0.27–0.80) Schizophrenia  
Lahti et al., 2012 Antihypertensive  HR= 0.37 (0.22–0.61). Schizophrenia  
Lahti et al., 2012 Diabetes medication  HR= 1.52 (0.93–2.51) Schizophrenia 
Tiihonen et al., 2016 
Antidepressant- moderate 
exposure & high exposure 
HR=0.85, (0.73–0.98) &  
HR=0.71, (0.59–0.86).  
Schizophrenia 
Tenback et al., 2012 
Antipsychotics- first 
generation 
HR= 2.36, (1.38–4.04) Schizophrenia  
Tiihonen et al., 2016 
Antipsychotics moderate 
exposure & high exposure 
HR=0.59 (0.49–0.70) & 




Author Risk factor Strength of the association with mortality (95% CI) 
Study cohort (Cases Vs Controls 
(comparisons)) 
HR=0.75 (0.63–0.89). 
Tiihonen et al., 2016 Benzodiazepines HR= 1.74 (1.50–2.03) Schizophrenia 
Hayes et al., 2015 Clozapine HR= 0.4 (0.2-0.7), p =0 .001 Schizophrenia 
Morgan et al., 2003 Lithium 
Univariate RR=0.39 (0.17-0.93), p=0.03,  
HR=0.37 (0.16-0.88), p=0.02 .  
Schizophrenia, including both inpatients and 
those living in the community 





2.4.11 Symptom profiles and other features of the mental disorder  
 
Few studies were found to have investigated associations between symptoms and mortality 
in SMI. Table 2.10 provides a summary of findings from literature examining presenting 
broader features of mental disorders as predictors of mortality. Impairment of activities of 
daily living, depressed mood, hallucinations and delusions and overactive–aggressive 
behaviour has been investigated through extracting data from brief Health of the Nation 
Outcome Scales (HoNOS) on individual patient records. There have also been investigations 
of manic/hypomanic symptomatology, and deterioration from pre-morbid level of 
functioning up to a year after onset in the studies included in this review.  Hayes et al., 
2012b, reported that significant ADL impairment was associated with higher mortality in 
SMI including schizophrenia specifically. Another study by the same group (Hayes et al., 
2012a) found that hallucinations and delusions and depressed mood had no effect on 
mortality in SMI. One study found that deterioration from pre-morbid level of functioning 
up to a year after the onset of bipolar conditions was significantly associated with higher 
mortality (Dutta et al., 2007).  Fiedorowicz et al., 2009, investigated the association between 
manic/hypomanic symptomatology measured by affective symptom burden (the proportion 
of time with clinically significant manic/hypomanic or depressive symptoms) and 
cardiovascular mortality and found that there is high mortality due to CVD among bipolar 




Table 2:10- Summary of findings from literature examining presenting symptoms as a predictor of mortality 
 
Author Risk factor Strength of the association with mortality (95% CI) Study cohort (Cases Vs Controls (comparisons)) 
Hayes et al., 2012b  ADL significant impairment  HR=1.9 (1.3–2.8) p=0.001 
All SMI cases (schizophrenia, schizoaffective and 
bipolar disorder) aged≥15 years 
Hayes et al., 2012b  ADL significant impairment  HR= 1.8 (1.2– 2.9) Schizophrenia 
Hayes et al., 2012b  ADL significant impairment  HR= 3.2 (1.1– 9.5) Schizoaffective disorder  
Hayes et al., 2012b  ADL significant impairment  HR= 2.0 (0.8– 4.9) Bipolar affective disorder  
Hayes et al., 2012a  
Depressed mood- sub-
clinical & severe 
HR= 1.2 (0.9–1.7), p=0.174 &  
HR= 0.9 (0.6 –1.3), p=0.534 
SMI cases (schizophrenia, schizoaffective and 
bipolar disorder) aged≥15 years 
Dutta et al., 2007 
deterioration from pre-
morbid level of functioning 
up to a year after onset 
HR= 5·20 (1·24–21·89), p=0·024 Bipolar I disorder  
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Author Risk factor Strength of the association with mortality (95% CI) Study cohort (Cases Vs Controls (comparisons)) 
Hayes et al., 2012a  
Hallucinations and 
delusions- subclinical & 
severe 
HR=1.1 (0.7–1.6), p=0.773& 
HR= 1.0 (0.7–1.6), p=0.990 
SMI cases (schizophrenia, schizoaffective and 
bipolar disorder) aged≥15 years 
Fiedorowicz et al., 2009 
Manic/hypomanic 
symptomatology  
HR=1.30 (1.09–1.55), p<0.01  Bipolar disorder  
Hayes et al., 2012a  
Overactive–aggressive 
behaviour- subclinical & 
severe 
HR= 0.8 (0.6–1.2), p=0.333& 
HR= 1.1 (0.8- 1.6), p=0.604 
SMI cases (schizophrenia, schizoaffective and 




2.5 Strengths and limitations of the review 
 
Various large data sources including case registers from the United Kingdom and 
Scandinavia were used in the studies included.  Other studies were mainly carried out in 
developed ‘Western’ countries such as the USA, Finland, Denmark and Sweden; however, 
the review also included studies from South Korea and Taiwan. Sample sizes of the 
individual studies varied from less than 100 to over 1,000,000. The studies with larger 
sample size tended to obtain data from civil registers, a health register or an insurance 
database. The SMI population may, however, not be homogenous.  For example, some 
studies included had data from community samples, inpatients only as well as utilised a 
broad range of data sources including Veteran registers, general hospital records and 
psychiatric hospital records leading to heterogeneity.  
 
In terms of defining SMI, most studies used ICD criteria.  Some of the older publications 
used ICD-8 or ICD-9 classification systems while recent cohorts have used ICD-10 
classifications; few have used DSM-III-R or DSM-IV criteria. In terms of SMI cohort 
identification those studies used ICD have used schizophrenia (ICD-10 code: F20.x), 
schizoaffective disorder (F25.x) or bipolar affective disorder (F31.x).  Some studies included 
F21.x and F23.x and I did not exclude them from the review as long as F20.x, F25.x or F31.x 
was included.  Regarding all-cause mortality and cause specific mortalities, the search 
criteria only obtained the studies with predictors of SMI deaths and I did not carry out an 
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extensive search to review SMRs of all studies published to find out all-cause mortality or 
cause specific mortality SMRs.  In terms of predictors, certain outcomes were extensively 
studied including demographics such as age and gender, alcohol and substance misuse, 
physical comorbidities such as diabetes.   
 
Reflecting on the studies based on clinical records, as described above, the sample size 
varied considerably between studies. The logistical demands of ascertaining 
epidemiologically complete and accurate datasets has been challenging. Those studies with 
smaller sample size had reduced statistical power but were generally able to use 
supplementary data collection options to improve completeness. However, for the larger 
longitudinal studies, without technologically advanced mechanisms to extract the required 
data from structured fields or free text, utility has failed to reach full potential. The 
individual study designs introduced specific errors. In particular, for the ones using clinical 
records, mortality risk estimates are sensitive to the age composition of the study 
population and the length of follow-up.  
 
Reflecting on studies based on registers, they have tended to be large, population-based 
and can include long follow-up. Completeness of data and consistency in information quality 
available further add to strengths. Several researchers have highlighted the risk of 
confounding or selection bias due to the non-randomised study design. In the absence of 
rigorous experimental methodology, it is not possible to be certain that the findings of an 
observational study are as indicative of a causal relationship as would be the case for 
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findings from a well-designed randomised controlled trial. Therefore, the majority of the 
findings described here have to be viewed as hypothesis-generating and different study 






2.6 Conclusion   
 
This review of literature revealed several important issues. To begin with, there is consistent 
evidence that all-cause mortality for individuals with schizophrenia and bipolar disorder is 
higher than that observed in the general population. While it is true that the research field 
may need to move towards designing and evaluating interventions to improve this situation, 
it is also evident that the distribution of mortality risk in SMI remains poorly understood. 
Although there has been considerable previous research that has investigated factors that 
characterise and predict mortality, previous studies have been limited by investigating 
relatively few factors in the same study, mostly due to the unavailability of diverse 
contextual information. This means that findings on predictors of mortality in SMI have 
been mainly derived from studies using different methodologies and samples. In addition, 
studies have often been limited in the number of potential confounders investigated, which 
raises queries about unobserved confounding. Furthermore, although there have been 
some large cohort studies, generalisability of findings has been difficult to conclude beyond 
the populations that were examined, due samples focusing on specific population groups. 
This is particularly true if only inpatients are assessed or if insurance claims data is utilised. 
Therefore, it remains unclear whether key patient factors such as gender, ethnicity, social 




The evidence identified and reviewed does not sufficiently clarify whether there are any 
clinical subgroups of individuals with SMI who are at higher risk of mortality, or whether the 
raised risk applies equally to all individuals with SMI. There is a need for large cohort studies 
that are designed with minimal introductions of chance, bias, confounding and reverse 
causality and are generalisable to the population seen by secondary mental health care, 
which in the United Kingdom provides the majority of mental health care to individuals with 
SMI (NICE 2014). The studies need to be able to measure simultaneously a diverse number 
of possible predictors and outcomes in the same sample of patients as well as a range of 
possible confounders, thus improving the robustness of findings. Large studies are also 
needed to provide sufficient power to detect an association with rare outcomes such as 




3 Rationale for the thesis 
 
The South London and Maudsley (SLaM) hospital has used electronic records 
comprehensively since 2006 across all its services. The Clinical Record Interactive Search 
(CRIS) is a system developed to enable researchers to search and retrieve anonymised 
electronic health records efficiently. CRIS currently contains records for over 400,000 service 
users and allows the generation of bespoke research databases drawn from a 
pseudonymised copy of SLaM’s EHR, including over 3.5 million de-identified documents in 
common word processor formats. Since its development, CRIS data have been substantially 
enhanced through external linkages and natural language processing. This provides unique 
opportunity to marry the benefits of clinical records based studies with those of the registry 
type studies, typically noted from the Scandinavian countries from the review in chapter 2, 
which are generally based on diagnoses and data derived from financial transactions in the 
health service, welfare services and other domains of public sector. In essence, the potential 
for a unique contribution from CRIS is embedded in the novelty of the methods where very 
large data can be automatically collected from medical records including correspondence 
between psychiatric services and general practitioners on to quantitative databases. 
However, CRIS has the possibility to go beyond diagnoses, and explore for example 
individual symptoms or traits, as described in later chapters. The more specific rationale for 





1. As a first consideration, although it is recognised that natural and unnatural causes 
of death are responsible for premature mortality, there has been only limited 
evidence on the contribution of different more specific causes. In particular, while 
the life-expectancy gap has been described and widely cited (Chang CK, et al 2011), it 
is not clear how different causes of death account for this. Life expectancy is a 
product both of risk factors for mortality and of the age groups at which these 
deaths manifest. Thus, a disorder causing deaths in young adulthood will be 
responsible for many more years of life lost than a disorder of similar prevalence 
which primarily affects people in old age. In reviewing causes of death in SMI, I was 
not able to identify any previous piece of research which had evaluated this.  
 
2. Medical comorbidity is an important factor in accounting for the lost life expectancy 
in SMI (Bahorik AL, et al 2017). Hospitalised medical conditions are likely to be 
particularly important because of their severity and sometimes life-threatening 
nature. However, in the course of my appraisal of the literature, I was not able to 
find any comprehensive description of acute care hospitalisation (i.e. inpatient 
episodes excluding mental healthcare) in people with SMI. While there has been 
more targeted research on individual comorbid conditions- some examples include  
diabetes (Brown C et al, 2010) and other cardiovascular risk factors (Ösby et al. 
2016), I felt that it was important to generate at least some information on the most 
common reasons for hospitalisation across all physical healthcare diagnostic groups 
(as well as their relative frequency in people with SMI compared to the general 




3. Finally, as concluded from the review described in Chapter 2, evidence remains 
limited on characteristics of people with SMI who are most at risk of adverse health 
outcomes – namely mortality. Most of the research in this area has focused on other 
health conditions, lifestyle factors such as smoking and substance use, and 
medications, as well as differences between diagnostic groups. This has largely been 
driven by data which happen to be available in the large administrative or healthcare 
databases used for mortality research in SMI. In this respect, I sought to take 
advantage of ongoing work in the mental healthcare database to develop more 
detailed clinical profiles using natural language processing. More specifically, I 
sought to investigate whether particular symptom profiles in SMI were associated 
with mortality and acute care hospitalisation, using mental healthcare 







The overarching aim of this thesis was to use a novel approach with detailed electronic 
clinical health records in a “proof of concept” for the use of natural language programming 
for data gathering in the investigation of adverse outcomes among individuals with severe 
mental illness. I used recent mortality and morbidity data for individuals with SMI and 
sought to answer the following questions: 
 
• What are the relative contributions of major disease groups to the gap in life 
expectancy between individuals with SMI and the general population (chapter 6)? 
• What are the most common reasons for admission to non-psychiatric hospitals by 
individuals with SMI and what are the relative frequencies of these admissions 
compared to the general population (chapter 7)? 
• As a proof of principle for ascertaining meaningful symptom profiles from routine 
mental health record text fields, what is the prospective association between the 
number of recorded negative symptoms and mental healthcare outcomes 
(admission, duration of admission, and readmission) among individuals with 
schizophrenia (chapter 8)? 
• What is the association with mortality and hospitalisation for each of six symptom 
dimensions (positive, negative, manic, disorganisation, catatonic and depressive) 
extracted from the clinical records of individuals with SMI (chapter 9)? 





5.1 Chapter outline 
 
In this chapter, I describe the study setting, main data source, main data extraction 
methods, study variables extracted from data sources and brief overview of statistical 
methods. The brief overview of the main statistical analyses will be described in more detail 
in individual analyses chapters.  Data used in the analyses described in Chapters 6, 7, 8 and 9 
were derived from the Clinical Record Interactive Search (CRIS) data resource, developed 
within the NIHR Mental Health Biomedical Research Centre and Dementia Unit (BRC/U), 
which allows researchers to search and retrieve de-identified clinical data sourced from the 
South London and Maudsley electronic health records. In this chapter, I have included a 
description of the operational model of the CRIS interactive search tool and natural 
language processing developments that have been instrumental to data described in this 
thesis. CRIS is a dynamic database, which updates against source files every 24 hours.  At the 
time of writing, it contains more than 280,000 cases.    
 
Some contents of this chapter have contributed to the following publication: 
Jackson RG, Patel R, Jayatilleke N, Kolliakou A, Ball M, Gorrell G, Roberts A, Dobson RJ, 
Stewart R. Natural language processing to extract symptoms of severe mental illness from 
clinical text: the Clinical Record Interactive Search Comprehensive Data Extraction (CRIS-
CODE) project. BMJ Open. 2017 Jan 17;7(1):e012012. doi: 10.1136/bmjopen-2016-012012. 
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5.2 Setting  
 
The South London and Maudsley NHS Foundation Trust (SLaM) is a mental health care Trust 
in London, which provides near-monopoly secondary mental healthcare for a geographic 
catchment of four London boroughs – Lambeth, Southwark, Lewisham and Croydon and a 
source population of over 1.2 million people (Stewart et al, 2009).  It is believed to be the 
largest unit mental health care provider in Europe and provides a broad range of mental 





5.3 Data sources 
 
Electronic Health Records and the Patient Journey System 
All clinical notes at SLaM have been in the form of Electronic Health Records (EHRs) since 
2006, using the ‘Patient Journey System’ (PJS) which was developed to integrate EHRs 
across all services in SLaM. Some SLaM services used EHRs before that time and legacy data 
were imported at roll-out. The Patient Journey System as the name suggests has enabled a 
patient’s journey within the mental health service to be recorded and shared across 
multidisciplinary teams. PJS contains a comprehensive record of patient’s demographics, 
contact information, referrals, transfers, detailed clinical assessments, care plans, 
medication, clinical activity and reviews in a combination of structured fields (such as dates 
and drop down menus) and unstructured free-text (e.g. case notes and correspondence) 
(Stewart et al. 2009). EHR-derived databases have the potential for revolutionising clinical 
research opportunities as they contain unprecedented large volumes of diverse real-world 
data and enable research to be carried out not only with source records but also with 
linkages to other data sources as described below.  
 
Clinical Record Interactive Search 
From 2006 onwards, electronic clinical records have been used comprehensively across all 
SLaM services, and in 2008, the Clinical Record Interactive Search (CRIS) system supported 
by SLaM’s NIHR Biomedical Research Centre (BRC) for Mental Health was developed to 
enable researchers to search and retrieve anonymised electronic health records efficiently. 
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CRIS currently contains records for over 280,000 service users and allows the generation of 
bespoke research databases drawn from a pseudonymised copy of SLaM’s EHR, including 
over 3.5 million de-identified documents in common word processor formats. Since its 
development, CRIS data have been substantially enhanced through external linkages and 
natural language processing (Perera G, Broadbent M, Callard F, Chang CK, Downs J, Dutta R, 
Fernandes A, Hayes RD, Henderson M, Jackson R, Jewell A, Kadra G, Little R, Pritchard M, 
Shetty H, Tulloch A 2016), as will be described.   
 
There is a security model for CRIS which has been developed and continues to be managed 
by an Oversight Committee. The committee includes membership from two mental health 
service users, a SLaM Research and Development Office representative, a Caldicott 
Guardian representative for the Trust, a Child and Adolescent Mental Health representative, 
the CRIS academic lead and CRIS manager. All potential CRIS projects are considered at this 
meeting following online application. Scientific robustness and patient confidentiality are of 
critical importance for a project to be approved and for the researcher to access CRIS within 
the SLaM firewall (Fernandes et al. 2013).  
 
CRIS de-identifies PJS records not only by removing or condensing identifier fields (e.g. date 
of birth truncated to year and month), but also by identifying, marking and masking patient 
identifiers in text with ZZZZZZ (and carer identifiers with QQQQQQ), thus permitting the use 
of clinical data for research purposes within an overarching research governance 
framework.  The algorithm used for de-identification has been evaluated and has achieved 
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98.8% masking of personal identifiers and 97.6% of all personal identifiers in text fields 
(Fernandes et al. 2013).  
 
Data are therefore available in CRIS from both structured and unstructured fields from PJS. 
Structured data include information that is recorded as dates and in drop-down menu fields 
whilst unstructured data refer to free-text fields. Incorporating a daily update against its 
source files, CRIS provides up to date longitudinal information at individual patient level 
(Perera et al. 2016). The longitudinal nature of the data allows for factors to be measured at 




5.4 Data extraction from CRIS 
 
5.4.1 Natural language Processing 
 
Natural language processing (NLP) techniques can be used for extracting knowledge from 
unstructured text data and have been developed in CRIS because most information of value 
in mental healthcare tends to be recorded as text. Of the many NLP techniques, information 
extraction has been used to convert unstructured text into structured data tables that can 
be used in database assembly – for example, ascertaining mentions of medications in text so 
that samples can be extracted on the basis of medication mentions and/or variables 
generated within samples to this effect. The technique can reduce time required by 
researchers to unlock information held in clinical notes, and represents the only way to 
achieve this when sample sizes move beyond what can be manually coded. In order to 
implement NLP processes within the local system (i.e. CRIS) a core NLP infrastructure is 
required. General Architecture for Text Engineering (GATE) provides this infrastructure and 
enables a text-mining capability within CRIS. GATE is a widely used suite of open source 
software for text engineering that includes a workbench for developing applications, tools 
for distributing those applications on different computer hardware architectures, a quality 
assurance suite and facilities. The GATE suite also includes tools for text-mining workﬂow, 
distributed processing and visualisation. A variety of text processing tools and document 
formats may be plugged into this architecture, with individual tools being chained together 
into processing ‘pipelines’, and documents processed in series through these pipelines. Two 
distinct shallow language processing methodologies have been adopted for CRIS 
development, in collaboration with University of Shefﬁeld Department of Computer Science. 
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The ﬁrst may be described as rule-based pattern matching of key concepts. Sentences are 
ﬁrst processed to ﬁnd and create annotations based on simple surface linguistic information 
(such as words, sentences, etc.). This step is then followed by the process of ﬁnding 
concept-speciﬁc keywords, which are used to recognise likely sentences of importance to 
the task followed by a set of patterns speciﬁc to the text-mining task are run over the 
previously generated annotations to create a ﬁnal annotation containing all the information 
required in a readily extractable format. Given the complex nature of the topic in hand, the 
approach requires text-processing algorithms to be built manually by GATE users with 
language engineering skills, working closely with clinical and research staff. 
 
More recently, local developments took place at the SLaM BRC with the development of 
TextHunter which is an NLP information extraction suite implemented jointly by SLaM and 
the Institute of Psychiatry, Psychology & Neuroscience at King’s College London. TextHunter 
has been described in technical detail (Jackson et al, 2014), but in summary its principal 
purpose is to provide a user-friendly interface to accomplish three tasks required to extract 
concepts from free text: first, to find instances of a concept in a database of documents; 
second, to provide an efficient interface to allow human annotators to label a portion of the 
instances in order to develop a gold standard and training set; and third, to attempt to 
construct an appropriate statistical language model of the concept in order to generate 
structured data more widely. The TextHunter program typically provided the opportunity to 
annotate constructs to the following categories: (1) positive (coding text implying that the 
construct is present); (2) negative (coding text stating that the construct is absent); and (3) 
irrelevant text. TextHunter functionality also includes platforms for inter-annotator 
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agreement testing, and the creation of gold standard and test annotation sets. Whether 
rules-based or machine-learning approaches are used, separate training and test data sets 
are constructed. Symptom definitions that were developed from initial annotation 
guidelines are shown in the appendix 1. 
 
Two key metrics are traditionally used in NLP for evaluating the information extraction 
application performance in the test data sets, at the level of the individual text annotation.  
Precision, broadly equivalent to positive predictive value in psychometrics, is the proportion 
of application ‘hits’ which are found to identify the genuine construct.  Recall is the 
proportion of instances of the genuine construct which are identiﬁed by the application (i.e. 
equivalent to sensitivity). For precision and recall testing, a baseline level of performance of 
the application and later stage level measuring performance after post-processing have 
been helpful to monitor because advancements inevitably lead to a trade-off between the 
two. However, in the type of NLP applied in clinical records, suboptimal recall at an 
instance-level can sometimes be accepted as a price to pay for maximising precision 
because the longitudinal nature of EHR data means that there are generally multiple 
opportunities for an NLP application to capture a piece of information (e.g. if an NLP 
algorithm missed a symptom being stated as present in one sentence, it might well be 
picked up later in the document or record). Clearly this depends to an extent on the use to 




The most common approaches in TextHunter and GATE applied to CRIS have used a “bag-of-
words” feature which includes identifying keywords, surrounding word tokens and part-of-
speech tags in conjunction with knowledge engineering features to build a Support Vector 
Machine (SVM) sentence classifier. SVM is a machine learning technique where the 
intention is to represent instances of text as vectors in high dimensional space. With a 
training set of instances labelled as indicative of a desired class, the SVM implementation 
generates a hyperplane which can in turn be used to classify unseen instances pertaining to 
the described class in the training set. SVMs have been used in CRIS where the assertion to 
be extracted is simple and restricted to a concise set of clinical language. In these cases, the 
specific NLP task is defined as a sentence classification problem, with a classifiable instance 
as a sentence containing (for example) a symptom keyword, or the general constructs of a 
symptom domain. In addition to the keywords, clinically relevant modifier terms are also 
defined for some concepts, to produce sub-classifications of symptoms where appropriate 
(Table 5-1). If a modifier term is detected within 8 words of a keyword, the modifier is 
deemed to be a possible relation. Further specifications have been applied so that modifiers 
can be ‘mandatory’ (meaning a modifier is required to be present for the definition of an 
instance to be met), or ‘optional’ (meaning only the keyword needs to be present for an 
instance definition to be met).  
 
Considering NLP used to define symptoms (a key consideration for this thesis) and regarding 
potential biases that might result from missing synonyms outside of the selected keywords, 
these have not been considered to be a significant problem because the intended end-point 
was to identify clinician-assigned constructs, rather than attempt to classify descriptions of 
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experiences. In addition, keywords that are standard methods of symptom documentation 





Table 5:1- Examples of natural language processing constructs applied in CRIS 
(Abstracted from (Jackson et al. 2017)) 
Modification 
type 
Keyword Modifier Example of a ‘positive’ annotation 
Mandatory Speech pov* There was some poverty of speech and content of 
thought.  
Optional hallucinat* Audit* For past 1 week has been having auditory command 
hallucinations telling him to kill himself and also suicidal 
ideation. 
None Rapport  When she was last seen at her CPA on XXXXX by 
Specialist Registrar Dr XXXXX,  ZZZZZ  presented as well 






A key task in CRIS development, which underlies a significant component of this thesis, has 
been to create data on a range of symptoms of mental disorders in order to ‘unlock’ this 
information and render it available for research use – e.g. being able to characterise a 
patient over a given time period on the basis of the mental health symptoms recorded 
during that period. In terms of the symptoms prioritised for inclusion, firstly, the potential 
salience of symptoms for research applications was considered. The Positive and Negative 
Symptoms Scale (PANSS) (Kay et al. 1987) and Young Mania Rating Scale (Lukasiewicz et al. 
2013) were also used as templates for guidance in this respect. Secondly, the language used 
in routine clinical records was taken into consideration in choosing symptoms, focusing 
particularly on those which were likely to be recorded in the most consistent and tractable 
language, based on the experience of the clinicians within the group. Thirdly, it was decided 
a priori to extract sufficient numbers of symptom types to generate scales for further 
evaluation within the following domains: i) positive symptoms; ii) negative symptoms; iii) 
disorganisation symptoms; iv) manic symptoms; v) catatonic symptoms; vi) depressive 
symptoms (Table 5-2). The first four of these followed the findings of Demjaha and 
colleagues (Demjaha et al. 2009) at an early stage, who had found that factor analysis gave 
rise to a five-factor solution of manic, reality distortion, negative, depressive and 
disorganisation symptom dimensions. The scores of identified dimensions were 
differentially associated with specific variables. The manic dimension had the highest 
number of significant associations (strong correlations were observed with shorter duration 
of untreated psychosis, acute mode of onset and compulsory admission). Adding 
dimensional scores to diagnostic categories significantly increased the amount of variability 
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explained in predicting these variables; the reverse was also true but to a lesser extent. The 
study concluded that categorical and dimensional representations of psychosis are 
complementary and suggested using both could be a promising strategy in conceptualising 
psychotic illnesses. Depressive symptoms were looked at later. Catatonic symptoms were 
further added to improve consistency with the study of Cuesta and colleagues (Cuesta & 
Peralta 2001), and as a symptom group of interest which is often not adequately captured in 
dimensional studies because of its relative rarity in recruited clinical samples. Depressive 
symptoms were ascertained at a later stage of development, driven by a particular research 




Table 5:2- Symptom groupings with “key terms” applied for CRIS natural language 
processing  
 
Domain Key terms (symptoms) 
Positive 
Agitation, aggression, arousal, hostility, delusions, hallucinations, 
paranoia, persecution 
Negative 
Blunted or flat affect, emotional withdrawal, social withdrawal, abstract 
thinking, poor rapport, apathy, poverty of speech, poverty of thought 
Disorganisation 
Circumstantial speech, reduced coherence, formal thought disorder, 
thought block, tangential speech, derailment, flight of ideas 
Manic 
Elevated mood, disturbed sleep, insomnia, pressured speech, irritability, 
elation, grandiosity 
Catatonic 
Mannerism, rigidity, posturing, perseverance, stupor, waxy flexibility, 
immobility, echolalia, mutism, catalepsy, echopraxia 
Depressive  
Anergia, anhedonia, loss of appetite, poor concentration, low energy, 
guilt, helplessness, hopelessness, poor motivation, psychomotor 






5.4.2 Personal contributions to application development and annotation of SMI 
symptom concepts 
 
The development of NLP applications ascertaining symptoms of psychotic and affective 
disorders was a substantial task carried out as a team rather than by individuals. Having 
secured my studentship around the commencement of this initiative, it was envisaged that I 
would assist with the development and lead on specific analyses which exploited the new 
data in relation to physical health and mental health service use outcomes. This thesis 
therefore describes the development work to which I contributed and the analyses which I 
led. As will be discussed in later chapters, my involvement in the development work assisted 
a great deal in interpreting findings derived from it. 
 
My key contribution was participating with colleagues in drawing up a list of potential 
symptoms of interest and in providing manual annotations of text from clinical records as 
training data for the algorithms. I provided input to developments to produce annotation 
guidelines to ensure consistent, high quality gold standard and training data, and annotation 
guidelines were developed by the team based around internal, iterative discussions. 
Developments to applications created and data extracted relevant to this thesis were 
carried out by a team of individuals including myself. Within the team, Richard Jackson, an 
informatician and fellow PhD student, led on TextHunter software development. Other 
team members undertook leading the annotations for the symptom domains as follows: 
positive symptoms were developed by myself; negative symptoms by Professor Robert 
Stewart (Consultant Psychiatrist and my Primary Supervisor); disorganisation symptoms 
shared between myself, Professor Robert Stewart and Dr Rashmi Patel (Clinical Research 
160 
 
Fellow and Senior Trainee Psychiatrist); manic symptoms by Dr Rashmi Patel; and catatonic 
symptoms by Dr Anna Kolliakou (Post-doctoral Research Associate). Subsequent to the main 
period of work on this, a range of depressive symptom NLP algorithms were developed by 
Professor Robert Stewart, assisted by Jyoti Jyoti and Dr David Chandran (Informaticians), 
and were incorporated in later research papers.  
 
To optimise the performance of the language models for the SMI cohort, the training corpus 
was enriched by selecting any text occurrence in CRIS (irrespective of the document type), 
relating to a patient who had received an SMI diagnosis, defined as schizophrenia (ICD-10 
code F20.x), schizoaffective disorder (F25.x) or bipolar disorder (F31.x). This diagnosis 
information was drawn from structured fields in the source EHR, which are completed by 
clinicians during the normal course of care by means of selecting an appropriate ICD-10 
code. These codes were supplemented by a separate NLP application which returns 
searchable text strings associated with diagnostic statements in text fields. In UK NHS 
mental health Trusts, recording of diagnosis is effectively mandatory, but recorded 
diagnoses themselves have no financial implications for Trusts (e.g. are not used for any 
billing purposes).  
 
When I carried out annotations, a relevant instance was defined as a mention of a symptom 
observed in a patient, without a grammatical negation which is where a term contradicting 
some or all of the meaning of an affirmative (positive) sentence was found. Independent 
sets of gold standard data were also created for each symptom to assess the performance 
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of each model. These were derived in the same manner as the training data which meant 
that annotations were carried out in a similar way for both sets of data. For both training 
and gold standard data, a relevant instance of a symptom was labelled as ‘positive’, (such as 
‘the patient had poverty of speech’) whereas irrelevant or negation instances (such as 
‘today I examined the patient for poverty of speech…’ or ‘the patient did not have poverty 
of speech’) were combined into a ‘negative’ category to create a binary classification 
problem. Once the agreed number of annotations were completed, the informatics team 
members were made aware. They would then use the training data to carry out a 10-fold 
cross validation to estimate the optimal SVM model parameters using the features provided 
by TextHunter. An instance was considered correctly classified if the sentence containing 
the human label of ‘positive’ or ‘negative’ and symptom type matched the model generated 
label and symptom type. Sub-classifications based upon any optional modifiers that were 
present (e.g. modality of hallucination) were not evaluated in this work. Finally, the 
optimised models were validated against the gold standard data. Arbitrarily, the gold 
standard for each concept was to contain a minimum of 100 ‘positive’ mentions, to derive 
precision and recall measures for the ‘positive’ class. The findings were relayed to me (for 
positive symptoms and the specific disorganisation symptoms I annotated) as well as a 
sample of output from the initial prototype. I then used these outputs to stimulate 
discussion about requirements and to provide a basis for multiple iterations of development 
until performance requirements were met with senior colleagues.  For several symptoms, at 




5.5 Data extraction from CRIS Linkages 
 
CRIS has been linked to other local or national databases, such as Lambeth DataNet (local 
Primary Care), Hospital Episode Statistics, the Department of Education National Pupil 
Database, the national Cancer Registry and national mortality data. In this thesis, two data 
linkages were used: i) linkage between CRIS and the Office for National Statistics (ONS) 
mortality data, which includes information available on individuals’ death certificates, 
including recorded cause of death; and ii) Hospital Episode Statistics where admissions data 
are compiled centrally for all Trusts in England, both acute and mental health services.   
 
5.5.1 Mortality data 
 
CRIS contains a limited level of mortality information for deceased individuals such as date 
of death (Perera et al. 2016).  As used in chapter 6 and 9, to obtain more detail, anonymised 
BRC IDs are linked to the ONS death register using SLaM’s Clinical Data Linkage Service 
(CDLS). The CDLS send identifiers (CRIS ID, first name, last name, date of birth, gender, 
postcode and NHS number) to NHS Digital, who in turn request the mortality data from the 
ONS, and then return the mortality data to CDLS via a secure file transfer protocol. The CDLS 
is responsible for linking, extracting and storing the data in accordance with the SLaM ICT 




5.5.2 Hospital Episode Statistics (HES) 
 
HES data are compiled centrally for all secondary care Trusts in England, both acute and 
mental health services. These data include statistical abstracts of records of all inpatient 
episodes, as well as outpatient and emergency care, and within the time CRIS has been 
operational were held initially by the Health and Social Care Information Centre (HSCIC) and 
then by NHS Digital. CRIS identiﬁers were compiled by CDLS, and transferred to HSCIC using 
an NHS-approved secure ﬁle transfer protocol. HSCIC then added the CRIS identifier to all 
HES records that match CRIS records and extracted all other HES records for residents within 
the four catchment boroughs served by SLaM- Lambeth, Southwark, Lewisham and Croydon 
(in chapter 7- the comparison group). HSCIC destroyed patient identiﬁers leaving only the 
CRIS ID and HES extract ID. As with other linked data sets, the CRIS-HES data were 
transferred back to CDLS to be held and provided to researchers in a fully anonymised 
format – i.e. replacing the CRIS identifier with a project-specific anonym. This means that 
HES episodes will refer to any hospitalisation in England for individuals on CRIS (in chapters 




5.5.3 Personal contributions to data extraction 
 
Following discussions with supervisors, I prepared data collection templates that would then 
stimulate discussion with the clinical informaticians in the CRIS team who prepare the SQL 
query for data extraction. While the data extraction process was completed in collaboration 
with the clinical informaticians, I provided detailed instructions on the selection parameters, 
specifying individual variables, coding and time frames for measuring exposures and 
outcomes. Furthermore, I worked closely with clinical informatics colleagues to ensure most 
recent updates to applications developed were used for data extraction. Following 
extraction, I conducted all the data analyses and (with input from my supervisors and co-




5.5.4 Study variables extracted from data sources 
 
The analyses described in Chapters 6,7,8 and 9, primarily include individuals who had 
received a SMI diagnosis (the cohort in chapter 8 was only individuals with schizophrenia), 
who were aged 15 years or over at first diagnosis, and who were active to SLaM clinical 
services during the observation period. Each chapter defines the specific observation 
periods for each investigation.  ‘Active to SLaM services’ was defined as having an open 
team episode in PJS: in other words, an on-going contact between the patient and a team 
within the service.  SMI was defined as any previous receipt of a schizophrenia (ICD-10 code: 
F20.x), schizoaffective disorder (F25.x) or bipolar disorder (F31.x) diagnosis. All three 
conditions represent clinically significant psychiatric syndromes, relatively unlikely to be 
treated without hospitalisation at some point in a lifetime.  Thus, they have a high 
‘penetration’ to secondary mental healthcare records. Diagnostic data were derived from 
diagnostic structured fields within CRIS supplemented by the NLP diagnostic algorithms. For 
individuals identified as having received a SMI diagnosis, their first diagnosis was used 
throughout the time frame. This means that a second diagnosis or multiple diagnoses at 
multiple visits was not considered which meant a consistent approach was followed but 
accuracy of information may be lowered.  However, diagnostic categories are expected to 
overlap since a proportion of individuals will suffer from more than one mental disorder 
(Chang et al. 2010). More specifically, Chang et al 2010, utilising CRIS as its data source 
found that of the sample, 1,680 (5.3%) had two diagnoses of interest before the end of 
2009, 121 (0.4%) had three diagnoses and six (0.02%) had four diagnoses. In this study, the 
most common combinations of diagnoses applied on different occasions in the same 
individual were schizophrenia and schizoaffective disorders (n = 421). Only individuals with 
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at least one diagnosis of schizophrenia, schizoaffective disorder or bipolar disorder were 
included, based on assigned ICD-10 classification. Other psychotic conditions, for example, 
F21-Schizotypal disorder, F23-Acute and transient psychotic disorders or F29-Unspecified 
nonorganic psychosis, have more variation in duration and severity (World Health 
Organization 2010), making any estimates less reliable as well as not reflective of SMI. 
 
5.5.5 Main exposures and outcomes  
Main exposures and outcomes for each analysis are described in relevant chapters. In this 
chapter, I have described the covariates that were included in each of the analyses.  
 
Age  
Age was derived from a truncated version of the patient’s date of birth (truncated to year 
and month to avoid identification), which is a structured field in PJS and was calculated at a 
defined time point as specified in each analysis chapter. inclusion age ranges for the 
different chapters varied and will be described for each analysis.  
 
Gender 
Gender was derived from a structured field in CRIS and classified as either male or female. 





Ethnicity was extracted from CRIS.  In SLaM records, ethnicity is classified according to 
standard census codes and was available as one of the following and pragmatically 
condensed into groups- White (British, Irish, any White background),Black (African, 
Caribbean, any Black background), Asian (Indian, Chinese, any Asian background)and Mixed/ 
unknown/ missing.  
 
Relationship status   
Relationship status was derived from structured fields and has a total of eight categories- 
cohabitating, married, in civil partnership, single, divorced, separated, widowed, unknown. 
 
Employment status   
Employment status was derived from a structured field. It contained sixteen categories, 
which were employed; other employment status; paid employment; part-time employment; 
self-employed; full-time student; full-time student school age; not known; not applicable; 












Other relevant data recorded & 
available at assessment & 
subsequent appointments 
SLaM referral, assessment and 
diagnosis 
Outcome data 
SLaM not referred/ private healthcare 
Incomplete assessment 
Under-diagnosis 
Unrecorded/ incomplete data fields 
NLP deficiency- recall, precision 
Variability of contact & its record on text 
Lost to follow up 
 
Migration from catchment + use of private 
provision (SLaM outcomes) 
Migration from England (from HES) 
Migration from United Kingdom (from 
mortality) 
Key clinical event Potential opportunities to introduce 
error 
Figure 5-1- Data Journey and potential opportunities for introduction of errors 
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Data linkages to mortality and hospitalisation 
Using nationally available data sources such as Office for National Statistics mortality data as 
well as Hospital Episode Statistics meant that mortality data and hospital admission data are 
as comprehensive as possible. Completeness is good for both these data sources as there is 
a legal requirement to record every death while the hospitalisation data have an 
administrative function and are linked to payments to hospitals. The linkage to a national 
data source also meant that loss to follow up is very limited unlike that described in other 
studies (Fiedorowicz et al. 2009). There are limitations associated with the linked data and 
these include the quality of cause of death information on death certificates, and the quality 
of discharge diagnosis data on HES. There are potentially some limitations on coverage. For 
example, mortality data on Office for National Statistics are only ascertained in the UK and 
HES data are only collected in England covering a large geographical distribution (figure 
10.1). Therefore, this needs to be borne in mind when interpreting findings on different 
ethnic/nationality groups. For example, my data source would not have picked up a death in 
an individual who had returned permanently to the Caribbean or South Asia.  
 
Dealing with deficiencies in diagnostic distinctions  
In chapter 1, I referred to literature citing the need for a more dimensional approach 
because SMI as a cluster may have more validity than its specific component diagnoses. As 
discussed, this was a key justification for developing measures of symptom dimensions. This 
is also pertinent to considering clinician variability (figure 10.1) in diagnoses entered onto 
the EHR, codes on death certificates, and codes on discharge diagnoses, combined with the 
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need to conform to ICD-10 classification. It is likely that there will be more agreement on 
broader than narrower diagnostic groupings, hence the approach taken in my thesis. 
However, embedding more broader groupings that are relatively heterogeneous categories 
means the more nuanced effects defining the specific component diagnoses will be 
overlooked.  
 
Use of NLP to improve characterisation  
The problem of sub-diagnosing SMI supports the aim to improve characterisation through 
NLP. This approach undoubtedly has helped to extract data from unstructured fields on 
large samples which would otherwise not have been feasible. Information extraction 
processes focusing on free text which would include correspondence maximises the 
generalisability of the approach, as letters to primary care physicians, which accounted for a 
large portion of the correspondence text, are unlikely to vary substantially between mental 
health services with respect to the language used to describe the symptoms of interest.  
 
The key metrics traditionally used in NLP for evaluating the information extraction 
application performance in the test data sets, at the level of the individual text annotation 
are precision and recall. These are, respectively, the proportion of application ‘hits’ which 
are found to identify the genuine construct and the proportion of instances of the genuine 
construct which are identiﬁed by the application. Preference to maximise precision over 
recall impacts the latter thereby introducing error. Error can also vary by symptom as some 




It is possible to search the patient's entire record but it was not possible to delineate the 
timing or duration of individual symptoms, or whether they were primary (for example, a 
direct consequence of illness) or secondary (for example, side effects of treatment) as this is 
not routinely documented. However, for the former at least, by setting end points to 
observation periods and start dates for follow up, it has been possible to measure temporal 
relationships. In this thesis, the extent to which individual symptoms could be considered as 
having equal weight in a composite score was not explored. The application of NLP to 
clinical records is clearly unlikely to identify symptoms as accurately as a direct assessment 
using a specialised psychopathological rating scale, and consistency of assessment and 
recording is likely to be lower in clinical staff than trained interviewers. Underestimation of 
symptoms may have occurred for several reasons. First, because a minimum length of 
treatment was not specified in the inclusion criteria, relatively new patients with sparse 
documentation may not have much symptoms information in their record. Second, aims to 
improve precision over recall in the models may have reduced the probability of detection. 
Third, the list of symptoms used was not comprehensive and may have missed some aspects 
of psychosis presentation – either because of different symptoms which were missed, or 
because of target symptoms which were described in non-standard language (for example, 
‘hearing voices’, rather than ‘auditory hallucination’). A final consideration regarding 
symptoms data is that the appearance of a given term in the record depends on the 
perceived salience of that term in routine clinical practice. A symptom which is known to 
reflect an individual’s state of health (e.g. sleep disturbance, grandiosity, paranoia) may be 
frequently monitored and thus recorded, whereas others may be less noticeable and less 
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likely to be recorded. This may in turn depend on other factors. For example, even though 
schizophrenia and bipolar disorder are recognised to be overlapping entities, the presence 
of a particular diagnosis may well influence the symptoms a clinician particularly looks for 
and chooses to record; likewise, there may be influences arising from a patient’s social class 





5.6 Statistical analysis 
In chapter 6, I describe in more detail the use of life tables to estimate life expectancy. For 
estimations, I used Chiang’s abridged life-table method (CL 1984) on Microsoft Excel 
software and data available from the Office for National statistics which included the 
England & Wales population estimates. Death rates in the SMI cohort for each major 
primary cause category were sequentially replaced with England and Wales gender- and 
age-specific rates for that cause of death, obtained from UK Office of National Statistics. 
  
In chapter 7, using STATA 12 and Microsoft Excel software, age- and sex-standardised 
admission ratios (SARs) were calculated for the two years of the observation period for the 
cohort with SMI. SARs were calculated first for diagnoses grouped at the highest level 
(letter) ICD-10 codes relating predominantly to the body system affected or type of disorder 
Analyses were also carried for more specific three-character diagnostic codes, describing 
those accounting for at least 1% of all hospitalisations in the SMI cohort.  
 
In chapter 8, I used STATA 11 software, to describe the distribution of negative symptoms, 
and to investigate the associations between the clinical outcomes and the presence of 
negative symptoms, using binary logistic regression; and symptom scale scores, using 
ordinal logistic regression. Associations between negative symptomatology and hospital 
admission and readmission were analysed using logistic regression, while those with length 
of inpatient stay were analysed using linear regression. For the analyses with hospitalisation 
outcomes in/following 2011. Secondary analyses were undertaken to investigate and 
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compare the relationships of individual negative symptoms of the CRIS- Negative Symptom 
Scale with risk of readmission and length of stay using binary logistic and linear regression, 
respectively. 
 
In chapter 9, using STATA 13 for the analyses on of mortality as an outcome within the 
cohort, univariate and multivariate analyses were carried out for the effect of specific 
symptom domains of SMI on all-cause mortality, using Cox regression with the adjustment 
for age, gender, ethnicity, employment status and marital status as potential confounders.  
For the analyses on of hospitalisation outcomes, univariate and multivariate linear 
regressions were applied individually for hospital admissions by symptom domains.  
 
Details for the specific analyses are available here: Chapter 6 section 6.3.3 and 6.3.4; 
Chapter 7 section 7.3.4; Chapter 8 section 8.3.4 and Chapter 9 section 9.2.3. 
 
The following four chapters which describe the results are based on published/ in 
submission papers. I have altered the wording to indicate my personal role in the papers 
and have added explanatory summaries. Within Methods sections where some information 
repeated itself from chapter to chapter, example- data sources, I have excluded the 




6 Contributions of specific causes of death to lost life expectancy in 
severe mental illness 
 
6.1 Chapter outline 
 
This chapter investigates the major disease groups that contribute to the gap in life 
expectancy between individuals with severe mental illness and the general population. 
Given the life expectancy gap between people with severe mental illness and the general 
population persists and may even be widening (Lawrence D, et al 2013), this chapter aims to 
estimate contributions of specific causes of death to the gap. 
 
The chapter has been published in the following peer-reviewed paper-  
Jayatilleke N, Hayes RD, Dutta R, Shetty H, Hotopf M, Chang CK, Stewart R. Contributions of 
specific causes of death to lost life expectancy in severe mental illness. European Psychiatry. 
2017 Mar 17;43:109-115. 
 
 
Personal contributions to publication- Using concepts discussed with supervisors, I designed 
the study approach. I had full access to all the data in the study and took responsibility for 
data integrity, accuracy of the data analysis, interpretation of data, drafting and critical 
revisions of the manuscript. 
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6.2 Research question 
 
The life expectancy gap between people with severe mental illness (SMI) and the general 
population persists and may even be widening. This analysis aimed to estimate 







Premature death among people with mental disorders is an international concern (Chesney, 
E, Goodwin, GM, Fazel 2014). Individuals with severe mental illness (SMI), including 
schizophrenia, schizoaffective disorder and bipolar disorder, experience particularly higher 
all-cause mortality and lower life expectancy (Laursen TM, Munk-Olsen T, Nordentoft M 
2007; Chang CK, Hayes RD, Perera G, Broadbent MT, Fernandes AC, Lee WE, Hotopf M 
2011). This is an important indicator for policy development to improve on current health 
inequality; however, contributions of individual causes of death to the life expectancy gap 
remain unclear, limiting the evidence. Previous research has suggested excesses of both 
natural and unnatural causes of death, and that the excess of natural causes may cross 
several mental disorder groups (Hoang et al. 2011). Nevertheless, standardised mortality 
ratios cannot be translated into the more important construct of life expectancy which 
accounts for the age of death as well as the absolute risk. Specifically, life expectancy as a 
measure adds value because it is a demographic index which is a feature of overall mortality 
emphasizing the impact of deaths occurring in younger age groups. It can thus be claimed to 
have considerably more ‘meaning’ for a population as an indicator of disadvantage, 
compared to a relative risk or hazard of mortality over a defined period of time. Life 
expectancy as a measure is obtained from estimates from the age-specific mortality of a 
specific cohort over a given period of time using the life table method and is calculated from 
the accumulated person-years contributed by the entire cohort divided by the total 




The substantial disadvantage in life expectancy experienced by people with SMI represents 
a major health inequality. Recent studies have shown how the impact of chronic illness 
varies between people with SMI and the general population. For example, the relative risk 
of Type 2 diabetes is elevated in younger populations of SMI compared to general 
population. In one study, most associations persisted despite adjustment for anti-psychotic 
prescriptions, and ethnic minority groups also had a higher prevalence of Type 2 diabetes in 
the presence of severe mental illness (Das-Munshi et al. 2016). On a similar note, the 
prevalence of multi-morbidity (which often encompasses combinations of mental and 
physical illnesses) is recognised to increase with higher deprivation (Barnett et al. 2012). 
Further, in people with SMI, prevalence of obesity, metabolic syndrome, diabetes mellitus, 
symptoms of cardiovascular disease, and respiratory disease all exceed those in the general 
population at least two-fold, and HIV prevalence may be increased as much as eight-fold 
(Scott & Happell 2011). This increased prevalence of chronic disease may be largely 
responsible for a five-fold increased risk of death (Scott & Happell 2011). 
 
An analysis was strongly warranted to add clarity to this ‘survival gap’, particularly as 
interventions have been proposed which focus on individual pathways without clear 
evidence on the contribution of those pathways to the overall outcome. This chapter is a 
descriptive analysis aiming to explain the above. Using data from a large clinical cohort, I 
estimated the contribution of the major groups of causes of death to shortened life 
expectancy in people with SMI, delineating to what extent this gap could conceivably be 






6.4.1 Data sources and cohort 
 
The South London and Maudsley NHS Foundation Trust (SLaM) is one of Europe’s largest 
secondary mental healthcare providers, serving a single geographic catchment of 
approximately 1.36 million residents in four southeast London boroughs. In 2006, fully 
electronic health records were implemented across all SLaM services, and, in 2008, the 
Clinical Record Interactive Search (CRIS) system, supported by the National Institute of 
Health Research (NIHR) Biomedical Research Centre for Mental Health at SLaM, was 
developed to allow search and retrieval of anonymised but complete medical records within 
a robust patient-led governance framework (Perera G, Broadbent M, Callard F, Chang CK, 
Downs J, Dutta R, Fernandes A, Hayes RD, Henderson M, Jackson R, Jewell A, Kadra G, Little 
R, Pritchard M, Shetty H, Tulloch A 2016; Fernandes AC, Cloete D, Broadbent MT, Hayes RD, 
Chang CK, Jackson RG, Roberts A, Tsang J, Soncul M, Liebscher J, Stewart R 2013). Using 
CRIS, individuals who had a primary diagnosis of SMI (schizophrenia, ICD-10 coded F20; 
schizoaffective disorder, F25, or bipolar affective disorder, F31) and had at least one active 
contact with SLaM during the period between 1st Jan 2007 and 31st Dec 2012 were 
included in this analysis. Recorded primary diagnoses in structured fields of the record were 
supplemented by a natural language processing application developed using Generalised 
Architecture for Text Engineering (GATE) software to identify diagnostic statements in open 
text fields (e.g. correspondence and clinical notes) (Fernandes AC, Cloete D, Broadbent MT, 
Hayes RD, Chang CK, Jackson RG, Roberts A, Tsang J, Soncul M, Liebscher J, Stewart R 2013; 





Date and primary cause of death for study subjects in the same period (i.e. 2007-2012 
inclusive) were retrieved from a CRIS linkage to death certifications, held by the UK Office of 
National Statistics which is updated regularly (Lopez-Morinigo JD,et al 2014), by NHS 
numbers through an anonymised process. The basic demographic information- gender 
(binary variable), date of birth and date of death were used to calculate age at death 
stratified by 5 year age bands (categorical variable). Cause of death was also a categorical 
variable where deaths due to Circulatory (I00-I99), Cancer (C00-D48), Respiratory (J00-J99), 
Digestive (K00-K93), Suicide (X60-X84, Y10-Y34), Other external (V01-Y98) and All other 
causes were distinct categories. 
 
The same data source (i.e. UK Office of National Statistics), but this time via online data files, 
was used to obtain age-, gender, and cause-specific mortality for England & Wales 




6.4.3 Analysis: baseline life expectancy at birth 
 
Using Microsoft Excel software, life expectancy at birth was estimated using Chiang’s 
abridged life-table method (Chiang CL 1984). In brief, the accumulated person-years were 
calculated by gender based on age- and gender-specific mortality experienced by a specified 
male / female cohort in five-year age bands, and then divided by the total number of male / 
female cohort subjects at baseline. Because of the dynamic nature of the cohort during the 
six-year follow-up period (2007-2012), the number of deaths observed was weighted by the 
average at-risk period of each age and gender band. The life expectancy at birth for the 
England & Wales population using 2010 data was also estimated for the purpose of 
validation using Chiang’s abridged method (Chiang CL 1984; Office for National Statistics 
2012). Since SMI diagnoses are relatively unlikely to be given to people under the age of 15 
years, mortality rates up to that age were assumed to be equal to those in the general 
population of England & Wales in 2010. The 95% confidence interval were found by 




6.4.4 Analysis: re-calculated life expectancies by equalising mortality rates 
 
The aim was to estimate the improvements in life expectancy which might be achieved if 
people with SMI experienced the same age- and gender-specific mortality rates for 
particular causes of death as those in the general population. For this a life expectancy 
simulation was used to examine the contribution of major causes of mortality to the 
reduced life expectancy in people with SMI. Death rates in the SMI cohort for each major 
primary cause category were sequentially replaced with England and Wales gender- and 
age-specific rates for that cause of death, obtained from UK Office of National Statistics 
(Office for National Statistics 2012). The expected numbers of deaths in each five-year age 
band were then re-calculated using these national gender- and age-specific rates. These re-
estimations were carried out for cause-of-death categories by the order of number of 
deaths observed in the SMI study cohort: i) circulatory diseases, ii) cancer, iii) respiratory 
diseases, iv) digestive diseases, v) suicide, vi) deaths due to other (non-suicide) external 
causes, and vii) all remaining causes of death. In this study, in accordance with the ICD-10 
manual, external causes comprised mortality involving injury, poisoning and certain other 
external causes. Causes of death in this broad group of scenarios include examples such as 
“accidental poisoning by amphetamine” (X41) or “driver of car injured in non-collision 
transport accident” (V48.5). Here, the underlying cause is classified according to the 
circumstances of the fatal injury, rather than the nature of the injury which is coded 
separately. Of note, this means that direct alcohol related mortality is considered under 
external causes. Where there was a reverse association identified for any cause-of-death 
category (i.e. a lower life expectancy for SMI subjects following equalisation of a specific 
cause-of-death category to general population), its contribution to loss of life expectancy 
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was set at zero. The percentage of person-year contribution to the life expectancy gap for 
each category of death was then calculated accordingly. In a sensitivity analysis, the 
adjustment for cancer was re-applied taking into account reference to cancer anywhere on 
the death certificate (i.e. rather than just as the primary cause of death). Finally, I carried 
out an additional stratification by affective (bipolar/schizoaffective) and non-affective 
(schizophrenia) SMI diagnosis in order to compare cause of death contributions between 





Calculated by Chiang’s method, the life expectancy at birth for the England and Wales 
population in 2010 was 78.5 (95% CI 78.1-78.8) years for males and 82.4 (95% CI 82.1-82.7) 
years for females: identical to values previously reported by the UK ONS (Office for National 
Statistics n.d.). In the SLaM cohort, there were 1,558 deaths during the observation period 
among 19,106 subjects with SMI (816 deaths among 10,414 males and 742 deaths among 
8,692 females)- table 6-1 shows the cohort characteristics. The life expectancy at birth in 
people with SMI was estimated to be 67.9 years (95% CI 67.1-68.6) for men and 72.2 years 
(95% CI 71.5-72.8) for women – i.e. reduced by 10.6 years for men and 10.2 years for 
women. The template abridged life table that was used for life expectancy calculations 





Table 6:1: Demographic characteristics of study population and general population (n= 
18,974 with 1,488 deaths) 












































Employment status  
Unemployed-  

























White (British, Irish, any 
White background)- 
Black (African, 
Caribbean, any Black 
background)- 
Asian (Indian, Chinese, 















In the SLaM cohort, the median (interquartile range) ages of death by cause among females 
were as follows: cardiovascular diseases 73.6 years (62.5-82.6); cancer 67.7 years (55.1-
77.6), respiratory conditions 77.3 years (68.1-85.3), digestive conditions 57.7 years (50.4-
76.1), deaths due to suicide 45.8 years (28.5-56.6), deaths due to unnatural causes 52.3 
years (37.4-64.9), and all other causes 75.4 years (51.6-84.8). Among males, median ages of 
death by cause were: cardiovascular diseases 65.4 years (55.5-74.7), cancer 69.9 (60.9-76.6), 
respiratory conditions 70.6 years (61.3-78.7), digestive conditions 54.8 (43.8-65.9), deaths 
due to suicide 39.5 years (30.6-48.8), deaths due to unnatural causes 43.3 years (32.1-54.5) 
and all other causes 56.5 years (41.7-75.0). Summarised in Table 6 1, the leading cause of 
death in people with SMI was circulatory diseases, followed by cancer, respiratory disease, 
gastrointestinal disorders, suicide, and other external causes. 
 
Figures 6.1 and 6.2 display the improvements to life expectancy by gender when major 
cause of death categories were replaced with England and Wales 2010 population rates. The 
incremental changes to hypothetical life expectancy of men with SMI from the baseline 67.9 
years were: 69.7 years by equalising circulatory disease death rates to those in the general 
population, 69.7 years (i.e. no change) by further equalising cancer mortality, 71.4 years 
equalising respiratory disease, 72.3 years equalising gastrointestinal diseases, 73.6 years 
equalising suicide, 74.5 years equalising all other external causes, and finally attaining the 
national level of 78.5 years by equalising all remaining causes. The corresponding changes to 
the life expectancy for women with SMI from the baseline 72.2 years were: 74.4 years 
(circulatory diseases), 75.2 years (cancer), 76.6 years (respiratory diseases), 77.7 years 
(gastrointestinal diseases), 79.1 years (suicide), 79.8 years (other external causes), and 82.4 
years (all remaining causes). These increments are expressed in terms of life years gained 
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and as proportions of the life expectancy gap in Table 6.1. Among ‘all remaining causes of 
death’, of note, infectious diseases (A00-B99) contributed 1.12 years to the life expectancy 





Figure 6-1- Estimated contributions of different causes of death to the loss of life expectancy 







Figure 6-2- Estimated contributions of different causes of death to the loss of life expectancy 




Table 6:2- Number of deaths by primary cause in people with SMI and the hypothetical change in life expectancy following equalisation of 
these to England and Wales cause-specific mortality rates in 2010 
 
Gender 
Primary cause of death (ICD-10 
code) 
Number of deaths during 2007-
2012 (% of all deaths) 
Life expectancy improvement in years by 
equalising causes of death with those in 
general population 
Percentage contribution to the 
overall life-expectancy gap  
Males Circulatory (I00-I99) 195 (23.9) 1.82 17.4 
Cancer (C00-D48) 110 (13.5) -0.02* -- 
Respiratory (J00-J99) 132 (16.2) 1.73 16.5 
Digestive (K00-K93) 55 (6.7) 0.92 8.8 
Suicide (X60-X84,Y10-Y34) 55 (6.7) 1.40 13.4 
Other external (V01-Y98) 57 (7.0) 0.84 8.0 
All other causes 212 (26.0) 3.76 35.9 
Females  Circulatory (I00-I99) 205 (27.6) 2.24 22.0 
Cancer (C00-D48) 148 (19.9) 0.83 8.1 
Respiratory (J00-J99) 114 (15.4) 1.40 13.7 




Primary cause of death (ICD-10 
code) 
Number of deaths during 2007-
2012 (% of all deaths) 
Life expectancy improvement in years by 
equalising causes of death with those in 
general population 
Percentage contribution to the 
overall life-expectancy gap  
Suicide (X60-X84,Y10-Y34) 33 (4.4) 1.39 13.6 
Other external (V01-Y98) 28 (3.8) 0.74 7.2 
All other causes 174 (23.4) 2.60 25.5 
* Replaced by zero in consecutive calculations 
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Of all cancer mortality in women with SMI, the commonest cause in the sample was breast 
cancer (n=179) with a mean age at death of 67.7 years, followed by lung cancer (n=110) 
with a mean age at death of 71.7 years. For males, the commonest cancer-causing death 
was lung cancer (n=128) with mean age at death of 70.9 years followed by prostate cancer 
(n=101) with mean age at death of 78.0 years. A sensitivity analysis was carried out to 
address the issue of cancer as an underlying but not primary cause of death, equalising 
mortality rates where cancer was recorded anywhere on the death certificate. In summary 
the findings were not changed substantially, with the adjustment resulting in a 0.06 year 
reduction of life expectancy among males with SMI and an improvement of life expectancy 
for females by 0.22. 
 
I then stratified the cohort by affective and non-affective subgroups, and Table 6.2 
compares the contributions of the different causes of death to the life expectancy gap. For 
women, cancer and other causes were noted to contribute more in those with non-affective 
than affective disorders, while suicide, respiratory and digestive disorders contributed more 
in those with affective disorders. In men, respiratory disorders contributed more in non-
affective disorders and other causes more in affective disorders. Other proportional 
contributions were similar between affective and non-affective groups. 
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Table 6:3- Contributions of individual causes of death to loss of life expectancy in SMI: stratification by affective vs. non-affective diagnoses. 
  
Primary cause of death 
 
Life expectancy improvement in years by equalising individual causes of death with those in general 












Circulatory (I00-I99) 1.00 (13.5) 1.03 (15.0) 2.25 (25.0) 2.29 (26.3) 
Cancer (C00-D48) 0 (0) 0 (0) 0.23 (2.6) 1.22 (14.0) 
Respiratory (J00-J99) 1.16 (15.7) 1.50 (21.9) 1.49 (16.5) 1.02 (11.7) 
Digestive (K00-K93) 0.66 (8.9) 0.67 (9.8) 1.08 (12.0) 0.53 (6.1) 
Suicide (X60-X84,Y10-Y34) 1.13 (15.3) 0.95 (13.9) 1.70 (18.9) 0.70 (8.0) 
Other external (V01-Y98) 0.40 (5.4) 0.50 (7.3) 0.50 (5.5) 0.75 (8.6) 





In a large cohort of people with SMI who had received routine mental healthcare, the 
contributions were investigated of different grouped causes of death to the reduced life 
expectancy, which itself is already well-recognised (Chang CK, Hayes RD, Perera G, 
Broadbent MT, Fernandes AC, Lee WE, Hotopf M 2011). The aim was to estimate the 
improvements in life expectancy which might be achieved if people with SMI could 
experience the same age- and gender-specific mortality rates for particular causes of death 
as those in the general population. The main finding was that the gap in life expectancy was 
accounted for by a wide range of recorded causes of death, rather than just one or two 
predominating ones. In addition, there was moderate variation in the pattern of 
contribution between men and women, and between people with affective and non-
affective SMI diagnoses.  
 
When assessing the specific contribution from each cause of death to life expectancy, it was 
difficult to identify a single group or two. As single groups of causes, circulatory and 
respiratory were highest in males and females, followed by cancer, digestive disorders, 
external causes and suicide; however, a tail of less common individual causes of death still 
contributed to 35.9% and 25.5% of the life expectancy gap for men and women respectively: 
greater contributions than cardiovascular disease and illustrating the high levels of 
heterogeneity in factors underlying mortality inequalities. 
 
Considering the national context, in the general population during 2012, the last year of this 
analysis period, there were 499,331 deaths registered in England and Wales (Office for 
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National Statistics 2013). Age-standardised mortality rates in 2012 were 6,191 deaths per 
million population for males and 4,510 deaths per million population for females. In 2012, 
cancer was the most common cause of death (29% of all deaths registered) followed by 
circulatory diseases, such as heart disease and strokes (28% of all deaths registered). Of 
note, since 2002 death rates from cancer in the general population have fallen by 14% for 
males and 10% for females, and between 2002 and 2012, the male and female age-
standardised death rates for circulatory diseases fell by 44% for males and by 43% for 
females (Office for National Statistics 2013).  
 
As stated, life expectancy is a more meaningful construct than standardised mortality for 
public health, as it takes into account not only the level of mortality but also the age of 
death. Disorders affecting mortality at younger age therefore have a higher impact on life 
expectancy, even if overall associated mortality rates are similar or even lower than those of 
later-life disorders. Estimated life expectancies for male and female cohort members in this 
analysis were comparable to those previously reported from the CRIS database (Chang CK, 
Hayes RD, Perera G, Broadbent MT, Fernandes AC, Lee WE, Hotopf M 2011). Both are 
substantially lower than the life expectancy at birth for men and women in the England & 
Wales population in 2010. The importance of ‘natural’ causes (i.e. rather than suicide or 
violence) accounting for the mortality gap is also widely recognised. For example, from 
databases covering the state of Western Australia, in a population of 292,585 people in 
contact with mental health services, 77.7% of excess deaths were found to be accounted for 
by physical conditions, of which cardiovascular illnesses contributed 29.9% and cancers 
contributed 13.5%, compared to 13.9% of excess deaths caused by suicide (Lawrence D, 
Hancock KJ 2013). In that study, excess mortality by cause was defined as the difference 
196 
 
between the observed number of deaths (the total person-years in the cohort of mental 
health service users) and the expected number of deaths in the cohort (by major cause of 
death using cause-specific death rates by age group, sex, and time period) (Lawrence D, 
Hancock KJ 2013). Kessing et al (2015) also found that 74% of life years lost after age 15 was 
due to natural causes among men with SMI, and 80% in women (Kessing LV, Vradi E, 
McIntyre RS 2015). In this cohort, natural causes accounted for 78% and 77% of deaths 
respectively. Suicide clearly remains an important adverse outcome in SMI with a 5% 
lifetime risk estimated for people with schizophrenia (Palmer BA, Pankratz VS 2005), and 
accounted for 1.4 life years lost for both genders in this sample: contributing 13.4% of life-
years lost in men and 13.6% in women. Of note, this contribution in women was stronger for 
those with affective compared to non-affective SMI diagnoses, but this diagnostic difference 
was not evident in men.  
 
The findings revealed a relatively minor contribution of deaths from cancers, especially for 
men with SMI and women with affective SMI diagnoses. Other studies have also shown 
increase in mortality due to cardiovascular diseases and infectious diseases in SMI; however, 
unlike in this study, also indicated up to 1.4 to 2.0 fold increases in deaths from cancer 
(Nordentoft M, et al 2013). One potential explanation is simply that cancer deaths happen 
later than other causes, resulting in less impact on life expectancy among people with SMI, 
particularly if competing causes of death supervene – e.g. if a person at high risk of cancer 
dies from cardiovascular disease at an earlier age before the cancer has time to develop. 
From literature searches, it was clear that this study remains unique in its methodology 
emphasising the impact of mortality patterns for each major cause of death category, rather 
than comparing summed risks as applied elsewhere. This study additionally provides an 
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overview of all cancer-associated deaths in people with SMI in the given time period, 
supplementing previous findings of similar patterns in presentation / diagnosis of cancer to 
those in the general population (Chang C-K, et al., 2014). Although 13% of deaths for this 
cohort were due to cancer, the third leading cause of death, there was no improvement to 
life expectancy at birth among men when England and Wales cancer mortality rates were 
substituted. I considered the possibility that cancer was a potential underlying cause of 
death but not always considered or recorded as the primary cause in death certificates (e.g. 
because of deaths from respiratory disease in people with advanced cancer). However, 
there was minimal alteration in findings when mortality rates were substituted where 
cancer was recorded anywhere on the death certificate. The younger age of deaths from 
breast cancer could therefore explain the greater impact on life expectancy among females, 
particularly those with non-affective disorders. The finding for cardiovascular disease 
accounting for a higher proportion of life expectancy in women was similar to those of 
another study findings with higher contributions from cardiovascular disease to excess 
deaths in female compared to male patients with mental disorders (35.2% and 26.2%, 
respectively) (Lawrence D, Hancock KJ 2013). 
 
Despite the well-recognised importance of deaths from natural causes in SMI, investigations 
and suggested interventions have tended to focus on specific causes of death such as 
cardiovascular disease, even though comparable morbidity has been reported in other 
systems (Partti K et al 2015). The findings confirm that this is likely to be over-simplistic and 
that a range of recorded causes potentially underlie the gap in premature mortality. The 
widening mortality gap between people with and without SMI is primarily accounted for by 
progressively improving survival rates in the general population which are not being 
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experienced by people with SMI, rather than by rising absolute mortality in SMI (Hoang et 
al. 2011). Furthermore, risk factors for mortality have high prevalence in people with SMI 
include smoking, alcohol, illicit drug use, poor diet and lack of exercise (De Leon J 2005; 
Lawrence D, Mitrou F 2009; Osborn DPJ, Nazareth I 2007; Kendrick T 1996; Davidson S, Judd 
F, Jolley D, Hocking B, Thompson S 2001). These are potentially implicated in a number of 
causes of death and their associations with mortality have been found to be stronger than 
expected in SMI (Davidson S, Judd F, Jolley D, Hocking B, Thompson S 2001). Excess 
mortality and morbidity associated with mental illness are recognised as multifaceted 
problems which are complicated to unpick (Lawrence D, Hancock KJ 2013). Higher levels of 
substance use, for example, have been well documented in people with mental disorders, 
including tobacco, alcohol, and illegal drugs, as well as a higher prevalence of unhealthy 
lifestyles, including poorer diets and less exercise (Lawrence D, Hancock KJ 2013). These 
findings suggest that higher incidence of illnesses associated with lifestyle risk factors might 
reduce life expectancy, supported by the fact that the majority of excess deaths in people 
with mental disorders are due to physical health conditions. It is likely that reducing 
mortality rates in the general population from common physical health conditions, such as 
heart disease, respiratory disease, and some cancers have not been experienced by 
individuals with severe mental illness to the same extent (Lawrence D, Hancock KJ 2013). 
General health promotion activities are therefore most likely to have an impact on life 
expectancy, including improvements in the availability and accessibility of prevention and 
risk management services, as well as addressing inequalities in treatment receipt where life-
threatening conditions are present (Wu S-I et al 2013). It is also clearly important to 
consider side effects of some psychotropic medications, such as the weight gain and 
hyperlipidaemia which affect a high proportion of patients during initiation or maintenance 
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of antipsychotic treatment (Kendrick T 1996). Improving the availability and accessibility of 
prevention and risk management services could be an important means to minimise the 
mortality gap, but broader attention is also needed to address profound socio-economic 
inequalities which is more common in people with mental illness (Muntaner C, Eaton WW, 
Miech R 2004). Socio-economic inequalities are also associated with health risk behaviours 
(Muntaner C, Eaton WW, Miech R 2004); however, studies that adjusted for socioeconomic 
status still found significantly worse morbidity and mortality for people with mental illness, 
suggesting that social deprivation and disadvantage are not the sole determinants of poor 
health outcomes in these populations (Lawrence D, Hancock KJ 2013; Lawrence & Kisely 
2010; Lawrence D, Jablensky AV, Holman CDJ 2000). Socio-economic inequalities are also 
associated with reduced access to healthcare and it is important to promote equality of 
access to good quality healthcare and evidence-based interventions for life-threatening 
conditions once these have developed, as a generalised deficiency in quality of healthcare 
might also underlie a heterogeneous group of conditions underlying loss of life expectancy.  
 
Strengths of this study include the large sample size and linkage to nationwide mortality, 
with up to six years of follow up. This study adds to the literature by estimating the 
hypothetical contribution of each major cause of death to its current life expectancy 
compared to England and Wales which provides a fuller picture of the mortality gap than a 
comparison of absolute rates alone. Furthermore, this study also stratified the cohort into 
diagnostic subgroups within SMI. The generalisability of this analysis needs to be further 
evaluated, as the findings clearly refer to people with these mental disorders who had made 
contact with secondary mental health services within the specified time period. However, 
secondary healthcare setting is unlikely to bias findings to a large extent as SMIs by nature 
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are disorders where most cases will have received secondary care input. This is because in 
accordance with NICE clinical guidance individuals should be assessed by a psychiatrist or a 
specialist in psychosis and treated quickly if at risk of developing psychosis or have a first 
episode of psychosis (NICE 2014). The limitations of this study include its inclusion criteria, 
as its focus was on people who had received an SMI diagnosis (schizophrenia, 
schizoaffective disorder or bipolar disorder) whether or not they had other mental health 
diagnoses as well. I did not seek to investigate other conditions such as substance use 
disorders (F10-F19) and depressive disorders (F32- F33), although it is important to 
emphasise that they were not specifically excluded – i.e. comorbidity was allowable in the 
sample. The non-inclusion of pure (non-comorbid) substance use disorders may explain the 
slightly smaller gap between life expectancy observed in this study compared to a previous 
analysis (Chang CK, Hayes RD, Perera G, Broadbent MT, Fernandes AC, Lee WE, Hotopf M 
2011); however, even without this group of individuals the overall gap in life expectancy 
remains extensive showing a very apparent need among those suffering from SMI. Although 
SLaM is a major academic as well as clinical centre, mental disorders defined from its 
records are likely to be broadly generalisable to other UK urban and suburban settings. An 
important consideration in drawing inferences from these findings concerns the 
assumptions underlying the analysis strategy, particular given it is a descriptive analysis and 
not hypothesis testing. These presupposed independent processes and did not take into 
account the potential for interactions between causes of death or competing risks of death 
(e.g. that equalising cancer mortality might have less impact than expected on life 
expectancy because of persisting cardiovascular diseases). The estimated contributions to 
the life expectancy gap therefore need to be viewed cautiously, although the principal 




This study was carried out to improve understanding of premature mortality which has been 
a long-lasting problem among people with severe mental illness and described as “… at 
worst, a form of lethal discrimination” (Thornicroft G 2013). While we agree with the other 
opinion in this area that the time has come to shift efforts towards interventions to improve 
survival, we believe that observational data remain deficient as an evidence base and in 
need of improvement. In particular, the findings suggest that prioritised interventions 
should be those which demonstrably have an impact on multiple causes of death, since 
addressing a single cause will only have a small effect on overall life expectancy. In addition 
to receiving optimum mental healthcare, it is thus imperative that people with SMI should 
receive a package of care to help improve lifestyle, diet, and proper medication 
management. It is also important to bear in mind current thinking on achieving health 
improvements through reducing health inequalities and minimising the impact of socio-
economic status on health advantages (Phelan JC, Link BG 2010). Failure to appreciate these 





6.7 Summary of findings from chapter 
 
Overall, natural causes (i.e. discounting suicide and other external causes) accounted for 
79.2% (female) and 78.6% (male) lost life-years respectively. Deaths from circulatory 
disorders accounted for more life-years lost in women than men (22.0% versus 17.4%, 
respectively), as did deaths from cancer (8.1% versus no contribution), but the contribution 
from respiratory disorders was lower (13.7% versus 16.5%). More similar contributions were 
found for digestive disorders (9.9% and 8.8%), suicide (13.6% and 13.4%), and other external 
causes (7.2% and 8.0%). Loss of life expectancy in people with SMI is accounted for by a 




7 Acute general hospital admissions in people with severe mental 
illness 
 
7.1 Chapter outline 
 
This chapter investigates the commonly recorded reasons for acute care hospitalisation in 
people with severe mental illness. Given that severe mental illness is associated with worse 
general health, reasons for admissions to general hospitals have received little investigation. 
This chapter aims to compare frequencies of non-psychiatric hospital admission by major 
diagnostic categories between people with SMI and the general population. 
 
The paper reporting this chapter is currently under peer review  
Jayatilleke N, Hayes RD, Chang CK, Stewart R. Acute general hospital admissions in people 
with severe mental illness. [In submission]. 
 
Personal contributions to publication- Using concepts discussed with supervisors, I designed 
the study approach. I had full access to all the data in the study and took responsibility for 
data integrity, accuracy of the data analysis, interpretation of data, drafting and critical 
revisions of the manuscript. 
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7.2 Research question 
 
Severe mental illness is associated with worse general health, but reasons for admissions to 
general hospitals have received little investigation. This study aims to compare frequencies 
of non-psychiatric hospital admission by major diagnostic categories between people with 






There is growing awareness of the adverse physical health experienced by people living with 
severe mental illness (SMI, which includes schizophrenia, schizoaffective disorder, and 
bipolar disorder). Specifically, people with SMI experience more medical comorbidities than 
the general population (Leucht et al. 2007; DE Hert et al. 2011), resulting in substantially 
higher mortality and shortened life expectancy (Chang CK, Hayes RD, Perera G, Broadbent 
MT, Fernandes AC, Lee WE, Hotopf M 2011; Lawrence D, Hancock KJ 2013). Nearly half of 
people with any mental disorder have comorbid medical problems such as diabetes, 
pulmonary disease or heart disease, and a further 35% have undiagnosed medical 
conditions, implying that only a small proportion are free of comorbidities (Zolnierek et al. 
2009; Miller et al. 2006). As reviewed previously (Miller et al. 2006), this is particularly an 
issue for individuals with SMI, with the risk for diabetes being doubled for individuals with 
schizophrenia and trebled for individuals with bipolar disorder. Similarly, cardiovascular 
disease is increased 2-3 fold in prevalence, with particular impact on younger adults. 
Individuals with SMI are also at increased risk of pneumonia and need for mechanical 
ventilation, and higher risk of emphysema after controlling for smoking. In all, around 20% 
of people with SMI (Miller et al. 2006), bearing in mind there is high levels of under-
reporting among individuals with SMI (Dorning, H. et al 2015), have been found to have a 
medical problem. Some of these conditions themselves may impact the mental condition by 
exacerbating signs and symptoms, response to psychotropic drugs, life expectancy and 




People with SMI are thus known to be at high risk of a number of physical illnesses which 
cover multiple disease categories and body systems (Jones DR, Macias C, Barreira PJ, Fisher 
WH, Hargreaves WA 2004). However, there is no consensus on how to treat or prevent 
physical disease in this group (Mitchell AJ, Delaffon V 2012). In the UK, most people with 
SMI live in community accommodation and receive public universal healthcare in the same 
centres used by the general population (Health and Social Care Information Centre 2013). 
Levels of and reasons for the use of acute care (i.e. general hospital/secondary physical 
healthcare) services have not been adequately characterised for people with SMI, despite 
the importance of this information for primary care and other community preventative 
services, as well as acute care providers. Using a large linked database of mental health and 
acute care records, I sought to carry out a descriptive analysis of the commonly recorded 






7.4.1 Sample and outcomes 
 
The study setting has already been described in chapter 5-sections 5.2, 5.3 and in chapter 6- 
section 6.4. Cohort members were defined on the basis of a diagnosis of schizophrenia (ICD-
10 code: F20.X), schizoaffective disorder (F25.X) or bipolar affective disorder (F31.X) 
recorded by SLaM on or before the 31st of December 2006 and on the basis of at least one 
contact with SLaM during 2007 or 2008. Diagnoses recorded in CRIS are based on the 10th 
edition of the World Health Organization International Classification of Diseases (ICD-10) 
and were extracted both from those recorded in structured drop-down menus within the 
source electronic health record or extracted from free text fields using bespoke software 
(Perera G, Broadbent M, Callard F, Chang CK, Downs J, Dutta R, Fernandes A, Hayes RD, 
Henderson M, Jackson R, Jewell A, Kadra G, Little R, Pritchard M, Shetty H, Tulloch A 2016). 
Non-psychiatric hospitalisations were investigated over an observation period from 1st 
January 2009 to 31st December 2010 inclusive, using a data linkage between CRIS and 
Hospital Episode Statistics (HES) (Perera G, Broadbent M, Callard F, Chang CK, Downs J, 
Dutta R, Fernandes A, Hayes RD, Henderson M, Jackson R, Jewell A, Kadra G, Little R, 
Pritchard M, Shetty H, Tulloch A 2016). 
 
In the United Kingdom, HES data are compiled for all healthcare providers in England (both 
acute and mental health services), including statistical abstracts of records of all inpatient 
episodes, as well as outpatient and emergency care. A dataset was compiled and 
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standardised morbidity statistics calculated for people with mental disorders on the CRIS 
database in reference to the catchment general population living in Lambeth, Southwark, 
Lewisham and Croydon. Individuals who were under the age of 20 at start of the 
observation period or when they were firstly diagnosed as SMI during the period were 
excluded from analysis, and admissions to any mental health inpatient unit were excluded 
as outcomes. 
 
Three-character ICD-10 codes for listed discharge diagnoses were extracted for each 
hospitalisation. A hospitalisation was defined as having at least one HES episode and 
contiguous episodes were combined where necessary into single hospitalisations. Age in the 
analysis was defined at the date of admission for physical illness where this occurred or at 




7.4.2 Diagnosis groupings and data management 
 
The grouping of admission diagnoses was carried out in line roughly with the chapters of the 
International Statistical Classification of Diseases and Related Health Problems, 10th revision 
(ICD-10), either by type of conditions (for example, cancers grouped together) or by organ 
affected, such as conditions of the eye (World Health Organization 2010). 
 
For this study, data were obtained for the SMI cohort and comparator population using the 
CRIS-HES linkage. The age and gender profile for the SMI cohort was obtained on 1st January 
2010 as the mid-point of the observation period for hospitalisations, and the age (in five 
year age bands) and gender profile of the comparator population was obtained from the 
2011 UK census as this was the nearest to the observation period. Discharge diagnoses (one 
per hospitalisation; primary diagnosis if multiple) were obtained for the SMI cohort in 2009 
and 2010. This study measures how much more likely or less likely a person with SMI is to 
be admitted to a general hospital compared to someone of the same age and gender living 
in the local area. Age and gender were accounted for through indirect standardisation and 
the generation of standardised admission ratios (SARs). An additional stratification was 





7.4.3 Statistical analysis 
 
Age- and sex-standardised admission ratios (SARs) were calculated for the two years of the 
observation period (2009–2010) for the cohort with SMI using Stata 12. Using the observed 
number of specific admissions as the numerator, the denominator was the expected 
number of admissions in the same period of time, estimated using the age- and gender-
specific admissions rates in 2009 and 2010 for SLaM’s catchment area. SARs were calculated 
first for diagnoses grouped at the highest level (letter) ICD-10 codes: these relate 
predominantly to the body system affected or type of disorder, and were grouped/split as 
follows: i) splitting urinary (N00-N39) from other (N40+) genitourinary conditions; ii) 
combining neoplasms (all C codes and D00-D48) and separating these from blood disorders 
(D50+); iii) combining injuries and external causes (all S codes and T00-T14) and separating 
these from poisoning (T15+); iv) combining infections (all A and B codes). Analyses were 
finally carried for more specific three-character diagnostic codes, describing those 
accounting for at least 1% of all hospitalisations in the SMI cohort. I then excluded repeat 
admissions for the same ICD-10 three-character code for the disease groups and re-






The SLaM SMI cohort consisted of 10,049 males and 8,331 females at the mid-point of the 
follow up period on 1st January 2010. The mean age of this cohort was 53.47 years. There 
were 8,622 admissions among individuals with a diagnosis of schizophrenia, schizoaffective 
disorder, or bipolar disorder who were observed from 1st January 2009 to 31st December 
2010- 48.2% of these were admissions in males. In the comparison population (residents of 
the SLaM catchment areas) the total number of admissions was 501,158 among the 1.36 
million population estimated from 2011 Census data (930,500 were aged 20 or over and 
included in the standard population). Table 7.1 displays numbers of hospitalisations by 
general chapters of ICD-10 codes in SMI cohort, crude admission rate in comparator 
population and age- and sex-standardised admission ratios in the cohort. The top five 
primary causes for hospitalisation were urinary conditions (ICD-10 codes: N00-N39), 
digestive conditions (K00-K93), unclassified symptoms (R00-R99), neoplasms (C00-D48) and 
respiratory conditions (J00- J99). SARs were raised for all of these apart from that for 
neoplasms where admissions were lower in the cohort. People with SMI also had higher 
risks of admission than the general population for poisoning and external causes, injury, 
mental and behavioural disorders, endocrine/metabolic conditions, blood disorders, 
nervous disorders, skin disorders and infections, as well as ‘Z-codes’ (another non-specific 
causes). Only neoplasms, musculoskeletal disorders, pregnancy-related disorders, and eye 
disorders showed significantly lower SARs. Figure showing-crude admission rates/ 1,000 




Table 7:1- Age- and gender-standardised admission ratios (SARs) for hospitalisations in 
2009-10 in people with severe mental illness (N of all admissions = 8,622), compared to the 
source population 
 
Primary cause of admission (ICD-10 codes) 
Number of 
hospitalisations 
in the SMI 
cohort 
Crude admission 
rate in source 
population per 
1,000 persons SAR (95% CI) 
Genitourinary system: urinary conditions (N00-N39) 1,886 84.4 1.60 (1.53- 1.67) 
Digestive system (K00-K93) 974 58.9 1.51 (1.41- 1.60) 
Symptoms, signs and findings, not elsewhere classified 
(R00-R99) 
898 41.2 1.91 (1.79- 2.04) 
Neoplasms (C00-D48) 632 69.7 0.66 (0.61- 0.71) 
Respiratory system (J00-J99) 511 16.6 2.57 (2.35- 2.80) 
Factors influencing health status and contact with 
health services (Z00-Z99) 
453 31.0 1.72 (1.57- 1.89) 
Circulatory system (I00-I99) 444 29.5 1.08 (0.98- 1.18) 
Poisoning and other external causes (T15-T98) 368 6.2 5.03 (4.53- 5.57) 
Injury (S00-T14) 352 14.6 2.52 (2.27- 2.80) 
Mental and behavioural disorders (F00-F99) 299 0.9 30.3 (27.0- 34.0)  
Musculoskeletal system  (M00-M99) 280 27.7 0.77 (0.69- 0.87) 
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Primary cause of admission (ICD-10 codes) 
Number of 
hospitalisations 
in the SMI 
cohort 
Crude admission 
rate in source 
population per 
1,000 persons SAR (95% CI) 
Endocrine and metabolic diseases (E00-E90) 277 7.5 3.07 (2.72- 3.45) 
Pregnancy related (O00-O99) 256 72.4 0.84 (0.74- 0.95) 
Blood disorders (D50-D89) 236 10.6 2.13 (1.87- 2.42) 
Nervous system (G00-G99) 176 7.8 1.94 (1.66- 2.25) 
Genitourinary system: pelvis, genitals and breasts (N40-
N99) 
165 18.6 0.98 (0.83- 1.14) 
Eye conditions (H00-H59) 162 17.1 0.61 (0.52- 0.72) 
Skin conditions (L00-L99) 159 10.1 1.54 (1.31- 1.80) 
Infectious diseases (A00-B99) 78 3.8 2.06 (1.63- 2.58) 
Ear conditions (H60-H95) 10 1.2 0.77 (0.37- 1.42) 
Congenital abnormalities (Q00-Q99) 6 1.1 0.67 (0.25- 1.46) 
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Table 7.2 reveals re-calculated age- and sex-standardised admission ratios for the SMI 
cohort, excluding repeat admissions (defined as primary discharge diagnoses falling within 
the same grouped codes in the 2-year follow-up period). Here, the five most common 
reasons for admission, using general chapters of ICD-10 codes, were digestive, unclassified 
symptoms, respiratory conditions, ‘Z-codes’ and circulatory disorders. While the rankings 
were different from Table 7.1 in terms of the frequency of hospitalisations for SMI, the 
direction and significance of the SARs remained. Ratios of all admissions (Table 7.1) to 
admissions without including repeat admissions (Table 7.2) in people with SMI were highest 
for urinary conditions, neoplasms and blood disorders, indicating high numbers of repeat 




Table 7:2- Age- and gender-standardised admission ratios (SARs) for people with severe 
mental illness excluding repeat hospitalisations (N of subjects with admissions = 5,377) 
 
Primary cause of admission (ICD-10 codes) 
Number of SMI 
subjects admitted 
(ratio of all 
admissions to 
unique 
admissions) SARs (95% CI) 
Digestive system (K00-K93) 780 (1.25) 1.37 (1.28- 1.47) 
Symptoms, signs and findings, not elsewhere classified (R00-R99) 752 (1.19) 1.78 (1.65- 1.91) 
Respiratory system (J00-J99) 409 (1.25) 2.55 (2.30- 2.80) 
Factors influencing health status and contact with health services (Z00-
Z99) 
378 (1.20) 
1.73 (1.55- 1.91) 
Circulatory system (I00-I99) 347 (1.28) 1.06 (0.95- 1.18) 
Injury (S00-T14) 331 (1.06) 2.52 (2.26- 2.81) 
Mental and behavioural conditions (F00-F99) 299 (1.00) 30.3 (27.0- 34.0) 
Poisoning and other external causes (T15-T98) 275 (1.34) 4.59 (4.07- 5.17) 
Genitourinary system: urinary conditions (N00-N39) 257 (7.34) 1.67 (1.47- 1.89) 
Musculoskeletal system (M00-M99) 237 (1.18) 0.80 (0.70- 0.91) 
Pregnancy related (O00-O99) 217 (1.18) 0.80 (0.70- 0.92) 
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Primary cause of admission (ICD-10 codes) 
Number of SMI 
subjects admitted 
(ratio of all 
admissions to 
unique 
admissions) SARs (95% CI) 
Endocrine and metabolic diseases (E00-E90) 205 (1.35) 3.49 (3.02- 4.00) 
Neoplasms (C00-D48) 202 (3.13) 0.70 (0.60- 0.80) 
Genitourinary system: pelvis, genitals and breasts (N40-N99) 140 (1.18) 0.92 (0.78- 1.09) 
Skin conditions (L00-L99) 138 (1.15) 1.53 (1.29- 1.81) 
Nervous system (G00-G99) 126 (1.40) 1.82 (1.51- 2.16) 
Eye conditions (H00-H59) 120 (1.35) 0.62 (0.52- 0.74) 
Blood disorders (D50-D89) 83 (2.84) 1.41 (1.12- 1.74) 
Infectious diseases (A00-B99) 65 (1.20) 1.91 (1.48- 2.44) 
Ear conditions (H60-H95) 10 (1.00) 0.82 (0.39- 1.50) 





Table 7.3 displays the three-character ICD-10 diagnoses which accounted for at least 1% of 
all primary discharge diagnoses, and indicates that a few conditions accounted for multiple 
hospitalisation instances in the SMI cohort. The most common was chronic renal failure 
(N18) accounting for 18.5% of all admissions, but this was substantially less common as a 
cause of any admission (i.e. when repeat admissions were excluded), as the 1,592 
hospitalisations occurred in only 22 individuals. Dental caries, other disorders of the urinary 
system, pneumonia, sickle cell disorders, type 2 diabetes mellitus, and chronic obstructive 
pulmonary disease were other common specific disorder diagnoses with SARs raised, in 
addition to non-specific diagnoses such as throat/chest pain, abdominal/pelvic pain, the Z04 
code, and alcohol-related presentation. Apart from alcohol-related presentations (F10), all 
SARs remained statistically significant when repeat admissions were excluded. ‘Other 
cataract’ was the only one of these hospitalisation diagnoses which was less common in SMI 
than in the source population, and breast cancer the only diagnosis showing no statistically 
significant difference in admission rates. Considering ratios of all admissions to unique 
admissions in SMI (i.e. column 3 divided by column 5 in Table 7.3), the highest values were 
found for chronic renal failure (72.4), sickle cell disorders (7.6), breast cancer (5.7), and 




Table 7:3- Age- and gender-standardised admission ratios (SARs) for three-character ICD 
code diagnoses contributing to at least 1% of all hospitalisations in 2009-10 among 
individuals with SMI in Southeast London 
 
ICD-10 






(% of total) 
 
Standardised 
admission ratio  
(95% CI) Number  SAR 
N18 Chronic renal failure 
1,592 




Examination and observation for 
other reasons 264 (3.1) 6.66 (5.88-7.51) 211 
5.60 (4.87-
6.41) 




Other disorders of urinary 
system 173 (2.0) 2.65 (2.27-3.07) 137 
2.55 (2.14-
3.01) 





unspecified 144 (1.7) 3.33 (2.81-3.92) 126 
3.26 (2.72-
3.88) 
C50 Malignant neoplasm of breast 120 (1.4) 0.87 (0.72-1.04) 21 
0.95 (0.59-
1.45) 












(% of total) 
 
Standardised 
admission ratio  
(95% CI) Number  SAR 
D57 Sickle-cell disorders 114 (1.3) 9.04 (7.45-10.9) 15 
4.83 (2.70-
7.97) 




Mental and behavioural 




Other chronic obstructive 
pulmonary disease 88 (1.0) 1.85 (1.48-2.28) 62 
2.18 (1.67-
2.79) 








7.6 Discussion  
 
In this study, I sought to draw a profile of the recorded reasons for non-psychiatric hospital 
admissions in people with SMI. In terms of overall numbers of hospital admissions in SMI, 
the leading diagnostic groups represented urinary, digestive, neoplastic, respiratory and 
circulatory conditions. For all of these groups of conditions apart from circulatory disease, 
admission rates were significantly different to those from the general population with SARs 
higher than expected for urinary, digestive and respiratory conditions and lower than 
expected for neoplasms. Hospitalisations with non-specific diagnostic categories (ICD-10 R 
and Z codes) were also common and higher than in the general population as were those 
due to injuries, poisonings and other external causes, and those categorised as due to 
mental disorder. All of these observations held true when repeat admissions were excluded. 
 
This investigation of non-psychiatric hospitalisations is, to my knowledge and based on 
literature reviewed, novel for SMI and was made possible because of data linkages 
negotiated and set up with CRIS over a long period. Other studies of hospitalisations have 
tended to focus either on mental healthcare specifically or all hospitalisations more 
generally (Jacobs et al. 2015; Kisely et al. 2015). In this study, considering individual 
diagnoses, clearly a number of these hospitalisations outside mental health services 
attracted a primary diagnosis of a mental or behavioural condition, with alcohol-related 
disorders accounting for around a third of instances and the most common specific three-
digit diagnosis. The role of harmful drinking as a cause of hospitalisations requires further 
more detailed evaluation in SMI but is likely to encompass a range of factors including 
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admissions for intoxication or alcohol poisoning, inpatient detoxification episodes and 
potentially other health consequences assigned as alcohol-related in the recording of the 
primary diagnosis. Other hospitalisations due to direct impacts of underlying mental 
disorders are likely to include injuries, poisonings and other external causes arising 
secondary to self-harm and/or violence from others. Relationships between mental disorder 
and violence have been discussed extensively. A mental health policy paper that reviewed 
relevant literature concluded that SMI in itself does not cause an individual to be violent and 
instead it is the socio-demographic and socio-economic factors that lead to violence; the 
review also concluded that individuals with SMI are more likely to be victims of violence 
than perpetrators (Stuart H 2003). Substance misuse is clearly an important risk factor for 
perpetration and experience of violent behaviour both with and without co-occurring SMI 
(Stuart H 2003) and strategies to reduce this comorbidity may have potential benefits on a 
wide range of outcomes. 
 
It is also interesting that hospitalisations assigned miscellaneous diagnostic codes occurred 
more often than expected in the SMI cohort. These might reflect clinically unexplainable 
symptoms or admissions precipitated by breakdowns in care arrangements and/or social 
support rather than secondary to a defined physical disorder. A recent project found that a 
small number of specialist mental health hospitals frequently used the ICD-10 code R69.x 
(“unknown diagnosis”) as the primary diagnosis for people with a previous SMI diagnosis 
(White J, Gutacker N, Jacobs R 2014); however, I did not identify any literature to suggest 
that this was common practice within non-psychiatric settings. Clinically unexplainable 
symptoms underlying non-specific codes are possibly supported by the higher frequencies 
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of throat/chest pain and abdominal/pelvic pain. However, it should be borne in mind that 
pain in the throat and chest might have been caused by cardiac disease and it is well 
established that people with SMI have excess cardiovascular mortality (Leucht et al. 2007), 
suggesting a potential need for higher scrutiny of these symptoms, which might be complex 
to interpret when comorbid with mental disorders. Oesophageal reflux symptoms have 
been found to occur more frequently among people with a range of mental disorders, not 
just SMI, potentially indicating a reduced threshold for or distorted perception of symptoms 
(Avidan B, Sonnenberg A, Giblovich H 2001), although it is also important to bear in mind 
reflux associated with use of psychotropic drugs with sedative and/or anticholinergic 
actions, as well as an indirect effects of adverse lifestyle factors such as alcohol and 
substance misuse (Avidan B, Sonnenberg A, Giblovich H 2001). 
 
Chronic renal failure predominated as a diagnosis for all admissions over the 2-year follow-
up period, but this was accounted for by many admissions in a small number of individuals, 
most likely representing inpatient dialysis episodes and/or admissions for complications of 
renal disease. The fact that people with SMI had both higher than expected total numbers 
of admissions with chronic renal failure and were more likely to have at least one admission 
with this condition, indicates a higher prevalence and/or severity of renal disease in this 
population. Other studies have also shown that in people with chronic renal disease, co-
occurring SMI can lead to an increased risk of experiencing another hospitalisation, 
particularly emergency admissions (McPherson et al. 2014). This may be accounted for by a 
higher burden of underlying risk factors such as hypertension and diabetes, although the 
role of medications such as lithium needs further evaluation, as does the possibility of 
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reverse causation through long-term renal problems leading to the development of 
psychotic illness (Tzeng et al. 2015; Fanton & Mcintyre 2011). 
 
While the findings above are in line with published literature, the association I found with 
higher than expected sickle cell related hospitalisations is possibly the first of its kind. Sickle 
cell disease mainly affects people of African, Caribbean, Middle Eastern, Eastern 
Mediterranean and Asian origin and the high SARs in this cohort are concerning, given the 
ethnic profile of the comparator local general population (around 25% black and black 
British residents). I could not identify any supporting literature beyond a handful of case 
reviews of psychosis among individuals with sickle cell, thus indicating the need for further 
research. Another novel finding is that cataract-related hospitalisations were less common 
which might reflect a lack of access to health services, as literature did not highlight any 
mental disorder profiles which would confer protection. However, coding issues need to be 
considered further, as high number of “other cataracts” (ICD-10 code: H26) were identified. 
Studies elsewhere have identified that surgery for cataracts is more likely to happen as an 
inpatient for individuals with SMI than as a day case where discharge is on the same day 
(Dorning, H. Davies, A. Blunt 2015); therefore more rather than fewer cataract-related 
hospitalisations would have been expected.  
 
There were also collections of associated diagnoses potentially indicative of social 
deprivation and lack of health service access. These included dental caries, chest infections 
and chronic obstructive pulmonary disease, with smoking also a potential underlying factor. 
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Dental caries, also known as tooth decay, is one of the two most common diseases that 
affect oral health, and people with SMI have been found to have over three times the odds 
of edentulousness than the general population (Kisely S, Quek LH, Pais J, Lalloo R, Johnson 
NW 2011). The reasons for higher susceptibility to oral disease include smoking, amotivation 
syndromes, worse oral hygiene, generalised anxiety or a specific fear of dental examinations 
and procedures, costs of dental care, difficulty in accessing healthcare facilities and side 
effects of psychotropic drugs such as xerostomia (Kisely S, Quek LH, Pais J, Lalloo R, Johnson 
NW 2011). However, one study revealed that poor oral hygiene and reduced access to 
dental care were most important in determining the sub-optimal oral health of individuals 
with SMI (Matevosyan 2010). Higher hospitalisations with pneumonia, organism 
unspecified, may also arise from self-neglect and impaired ability to recognise worsening of 
symptoms. In this respect, a lack of prompt detection and appropriate prevention of 
pneumonia have previously been found to increase the risk of poor outcomes including 
hospitalisation in schizophrenia (Yi-Hua C 2011). Poor treatment outcomes could also reflect 
misinterpretations of patients’ complaints as psychosomatic, resulting in delayed 
recognition (Schoepf & Uppal 2014). Self-neglect and its impact is an important 
consideration; however, the term “self-neglect” has been loosely applied, and deﬁnitions 
have not yet been established or validated, despite some attempts to clarify its contribution 
to vulnerability (Lamkin J, Nguyen PT, Coverdale JH 2016). Non-specific coding may also be 
an indication that individuals with SMI may need more advocacy in order to gain equitable 
access to appropriate care and support, and this might involve assistance in articulating 




This study had several strengths, including the large SMI cohort and its naturalistic data on 
people receiving mental and physical healthcare in an urban/suburban neighbourhood. The 
outcome investigated was derived from a data source used in all national hospitals and was 
available for the whole of England. It should therefore have covered the vast majority of 
hospitalisations experienced both by the SMI cohort and the catchment population. The 
data linkage also provided the opportunity to separate out admissions only to non-
psychiatric hospitals which, as mentioned, have received surprisingly little previous 
investigation. However, there are also limitations which need to be borne in mind. The 
study provides a descriptive analysis and not inferential statistics. The study was not able to 
distinguish balanced positive/negative effects at different points on the causal pathway; for 
example, breast cancer could conceivably be more common in SMI but inpatient healthcare 
less often sought/received. Furthermore, the study was restricted to assessing 
hospitalisations and did not attempt to investigate primary care outcomes or use of 
outpatient services. The study only investigated admissions to acute hospitals and there 
may of course have been individuals seen in mental health units for some physical illnesses. 
Finally, although the cohort is likely to be representative of people with SMI living in urban 
and suburban settings, there may be some unique features; for example, the prominence of 
sickle cell disease as a reason for hospitalisation may simply reflect the different ethnic 
compositions between the catchment general population and study cohort with SMI. 
 
Non-psychiatric hospitalisation is an important outcome for a number of reasons. First, and 
most importantly, preventable admissions are likely to be occurring which are not in the 
best interest of the patient. Second, preventable hospitalisations cost money that could be 
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utilised differently for the benefit of the individual with SMI and the public purse. This study 
highlights that there is a range of disease groups (e.g. digestive and respiratory conditions), 
specific disorders (e.g. sickle cell disease and chronic renal failure) and associated scenarios 
(e.g. self-neglect and alcohol abuse) that are important for policy development. Future 
research could helpfully focus on identifying and evaluating appropriate models for 
delivering more effective care, particularly for the conditions where standardized admission 
ratios were higher than expected. However, investigation is also warranted where 
admissions were lower than that of the general population, to ensure that unmet needs are 
not being missed, given the recognized vulnerability of people living with SMI. 
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7.7 Chapter summary 
 
The commonest five high-level categories of discharge diagnosis in the SMI cohort were 
urinary conditions, digestive conditions, unclassified symptoms, neoplasms, and respiratory 
conditions. SARs were raised for all of these apart from neoplasms which were lower than 
expected. Hospitalisations were also higher than expected for poisoning and external 
causes, injury, mental/behavioural disorders, endocrine/metabolic conditions, blood 
disorders, nervous disorders, skin disorders and infections, as well as non-specific (‘Z’) 
codes. The five commonest specific ICD-10 diagnoses were chronic renal failure (N18), a 
non-specific code (Z04), dental caries (K02), other disorders of the urinary system (N39) and 




8 Negative symptoms in schizophrenia: a study in a large clinical 
sample of patients using a novel automated method 
 
8.1 Chapter outline 
 
This chapter investigates the relationship between negative symptoms identified in the 
clinical records of a large sample of patients with schizophrenia using natural language 
processing and clinical outcomes. 
 
The chapter is based on the following peer-reviewed paper-  
Patel R*, Jayatilleke N*,  Broadbent M, Chang CK, Foskett N, Gorrell G, Hayes RD, Jackson R, 
Johnston C, Shetty H, Roberts A, McGuire P, Stewart R. Negative symptoms in schizophrenia: 
a study in a large clinical sample of patients using a novel automated method. BMJ Open. 
2015 Sep 7;5(9):e007619. 
* contributed equally 
 
Personal contributions to publication- Advice on study concept and design were sought 
from senior authors listed above.  I had full access to all the data in the study and undertook 
the checks for data integrity and accuracy of analyses carried out by my co-author (Patel R). 
I took lead on drafting the manuscript and undertaking the critical revisions following co-
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author feedback including referencing. My co-author (Patel R) led on the submission process 
to the publishing journal. 
I have subsequently re-analysed all major findings with ethnicity as a covariate included in 
the dataset independently.  
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8.2 Research question 
 
To identify negative symptoms in the clinical records of a large sample of patients with 









Negative symptoms, which include amotivation, a flattening of emotional responses, a 
reduction in speech and activity, and social withdrawal, contribute to much of the disability 
associated with schizophrenia (Foussias et al. 2011; Hunter & Barry 2012). These symptoms 
are also associated with poor psychosocial functioning and a reduced likelihood of remission 
(Jager et al. 2009; Ucok et al. 2011; Moller et al. 2000; Dominguez et al. 2010; McGurk et al. 
2000; Kirkpatrick et al. 2006). The aetiology and pathophysiology of negative symptoms are 
unknown, and there are no effective treatments (Arango et al. 2013; Fusar-Poli P, 
Papanastasiou E 2014). With age, the presence of negative symptoms and its associated 
factors may change. There is suggestion that negative symptoms do not dominate the 
clinical picture in later life but do have association with positive symptom scores, lower 
cognitive scores and fewer confidantes (Cohen CI, et al 2013). 
 
A number of rating scales have been developed to assess negative symptoms (Blanchard JJ, 
et al. 2011; Kirkpatrick B, et al. 2011; Kay et al. 1987). However, these are relatively detailed, 
require a trained rater, and are not routinely applied in clinical practice. As a result, current 
knowledge of negative symptoms is derived from studies in relatively small samples of 
patients, who may have been selected for inclusion because they had particularly severe 
symptoms. The findings from these samples may not therefore be representative of 




Clinical information is increasingly recorded electronically, facilitating access of rich clinical 
data, including presence or absence of symptoms (Patel R, Lloyd T 2015), from routine 
medical records. In the present study, a novel information extraction tool to identify 
negative symptomatology in a large body of electronic records collected from individuals 
with schizophrenia was used (Gorrell G, Jackson R, Roberts A 2013; Cunningham H, Tablan 
V, Roberts A 2013; Patel R, Jayatilleke N 2014). The relationships between negative 
symptoms and clinical outcomes were then examined. The hypothesis was tested that 
negative symptoms are associated with poor clinical outcome in patients with 
schizophrenia, as indexed by the frequency and duration of hospital admissions. A 
supplementary analysis was performed with age stratification on the association between 





8.4.1 Inclusion criteria, outcomes, analysis 
 
Three samples were identified for analysis and extracted from CRIS:  
 
I. Sample A (n=7678): patients with schizophrenia (International Classification of 
Diseases (ICD)-10 F20.XX) aged 16 years and over who had used SLaM services 
during 2011. This sample was used to investigate: (1) the relationship between 
negative symptoms, documented at any point in the electronic health record, and 
demographic and other clinical measures (described below); (2) the relationship 
between negative symptoms documented prior to 1 January 2011 and the risk of 
hospital admission during 2011. This year was chosen for analysis because it 
maximised the duration of time over which text would be available for measurement 
development, while allowing at least 12 months follow-up in all instances. 
 
II. Sample B (n=1612): the subset of patients from sample A who had been discharged 
from SLaM inpatient care during 2011. This sample was used to investigate the 
relationship between negative symptoms documented prior to 2011 and the risk of 




III. Sample C (n=1609): the subset of patients from sample A who received SLaM 
inpatient care during 2011. This sample was used to investigate the relationship 
between negative symptoms documented prior to 2011 and the length of the first 




8.4.2  Measurement development 
 
Natural language processing (NLP) information extraction allows structured information to 
be obtained from unstructured text records. NLP to detect statements in the 
correspondence fields of clinical records to determine references to pre-specified negative 
symptoms was carried out. Full details of the NLP method are described in a previous paper 
(Jackson et al. 2013) and are outlined in chapter 5. In summary, a putative training data set 
was selected which contained broad dictionary terms relevant to the negative symptoms of 
interest (described below). A detailed review of the training data set was undertaken by two 
psychiatrists to identify and annotate key phrases within the records that were either 
relevant or irrelevant for keywords related to each symptom. Inter-rater reliability was 
tested between the two annotators resulting in percentage agreement of 93.0% (Cohen's κ 
0.85). This training data set annotated by professionals was the gold standard used to 
construct an application (CRIS Negative Symptoms Scale, CRIS-NSS) using a hybrid 
classification model consisting of a support vector machine (SVM) learning algorithm (Li et 
al. 2009) and rule-based text matching, using the Generalised Architecture for Text 
Engineering (GATE) software package (Cunningham et al 2013). Following the same 
approach as the development of the training dataset, a gold standard data set was 
developed (Jackson et al. 2017). The SVM algorithm was applied using a ‘bag-of-words’ 
approach to take into account the context of negative symptoms within the sentence in 
which they were documented, thereby allowing ascertainment of negative symptoms 
experienced specifically by the patient as well as distinguishing between positive instances 
and negated instances (Jackson et al. 2013). Once developed, CRIS-NSS was subsequently 
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used to determine the presence of negative symptoms within the clinical sample. The 
accuracy of CRIS-NSS was evaluated using precision and recall statistics which were 
generated through internal fivefold cross-validation (Li et al. 2009): precision, representing 
the proportion of text instances identified by the tool which were found to be correct in 
terms of identifying the negative symptom of interest (equivalent to positive predictive 
value); and recall, measuring the proportion of text instances recording a given negative 
symptoms which were correctly identified as such by the tool (equivalent to sensitivity). 
 
All symptoms were extracted in the same way using similar Natural Language Processing 
steps with applications developed for 10 items: poor motivation, blunted or flattened affect, 
poor eye contact, emotional withdrawal, poor rapport, social withdrawal, poverty of speech, 
mutism, apathy and concrete thinking. Symptom definitions that were developed from 
initial annotation guidelines are shown in the appendix 1. Each of these symptoms was 
defined as a binary variable on the basis of being present at any point in the record within 
the defined time period, and a composite scale (range 0–10) was constructed by summing 
these variables, followed by Cronbach α score calculation (a measure of inter-correlation 
between individual scale items) to estimate its internal consistency. A threshold score of at 
least 2 (i.e. two or more negative symptoms documented) was applied a priori to determine 
the presence or absence of negative symptoms for analysis as a binary variable, as well as 
treating the scale score as an ordinal variable. Further technical details of the criteria for 
ascertaining the negative symptoms in the CRIS-NSS application are described elsewhere 
(Jackson et al. 2013).  
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8.4.3 Clinical outcome measures and covariates 
 
The following clinical and demographic variables were obtained as covariates from the data 
set: date of birth, gender and ethnicity were extracted in addition to employment, marital 
status and ethnicity nearest to 1st January 2011. Date of birth was used to calculate age on 
1st January 2011 and managed as a continuous variable. Ethnicity classifications were- 
“White”, “Black”, “Asian”, “mixed, unknown and others”. Marital status was classified as 
being “single”, “in a relationship (cohabiting, married or civil partnership)”, “separated”, 
“not disclosed or unknown”. Employment was classified as “employed”, “unemployed” or 
“unknown”.  Using structured data derived from the Health of the Nation Outcome Scale 
(HoNOS)(Wing JK, Beevor AS 1998), routinely completed in SLaM patients, the following 
subscales (scored 0–4) were used as covariates: activities of daily living (ADL) impairment, 
problems with relationships (social impairment), presence of hallucinations or delusions (a 
measure of positive symptoms) and depressive symptoms. For all of these HoNOS subscales, 
binary variables were defined on the basis of a score of 2 or more indicating the presence of 
each construct at levels judged to be clinically significant. In cases with multiple data points, 
all covariates were defined as those recorded closest to 1 January 2011. The date of 
admission and date of discharge were used to calculate duration of stay in days. 
Readmission was considered as a subsequent admission within the 12 months following 





8.4.4 Statistical analysis 
 
STATA (V.11) software was used. Estimates of prevalence of negative symptoms by 
demographic factors were obtained as the proportion of patients within each group with 
two or more negative symptoms. After describing the distribution of negative symptoms 
and the psychometric properties of the CRIS-NSS, further analyses were performed to 
investigate the associations between the clinical outcomes described above and (1) the 
presence of negative symptoms, using binary logistic regression; and (2) CRIS-NSS scores, 
using ordinal logistic regression. Reference groups for categorical variables were generally 
defined as the most prevalent category, apart from age group where 20-29 years group, the 
youngest group of sufficient size was assigned as the reference. Associations between 
negative symptomatology and hospital admission and readmission were analysed using 
logistic regression, while those with length of inpatient stay were analysed using linear 
regression—again, estimating associations with both the binary and ordinal CRIS-NSS 
exposure. For the analyses with hospitalisation outcomes in/following 2011, CRIS-NSS was 
generated restricting information extraction to electronic health records prior to 2011. 
Where data were missing on individual covariates (in 2362 participants), this was indicated 
in the regression models as a separate category, supplemented by sensitivity analyses 
performed on the sample with complete data on all covariates to check the consistency of 
findings (appendix 4- table 2). For the supplementary analysis, the previous analyses were 
repeated within the subgroups of those aged under the age of 40 years and those over the 
age of 40 years and including an interaction term of age under or over 40 and binary CRIS-
NSS exposure. Finally, secondary analyses were undertaken to investigate and compare the 
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relationships of individual CRIS-NSS symptoms with risk of readmission and length of stay 




8.5  Results 
 
8.5.1 Performance of CRIS-NSS 
 
Table 8.1 illustrates results from fivefold cross-validation of the CRIS-NSS tool. Precision 
coefficients ranged between 0.80 (poverty of speech) and 0.99 (mute) and recall between 
0.62 (poor motivation) and 0.97 (apathy). For the composite 10-point scale, the Cronbach α 





Table 8:1- Performance of Clinical Record Interactive Search Negative Symptoms Scale 






Prevalence (%) in patients with schizophrenia receiving care 
during 2011  
Poor motivation 0.87/0.62 30.5 
Blunted or flattened 
affect 
0.93/0.83 27.4 
Poor eye contact 0.95/0.79 26.0 
Emotional withdrawal 0.85/0.74 23.5 
Poor rapport 0.91/0.77 16.3 
Social withdrawal 0.94/0.96 12.7 
Poverty of speech 0.80/0.73 12.4 
Mute 0.99/0.94 8.1 
Apathy 0.88/0.97 7.7 




8.5.2 Prevalence and distribution of negative symptoms 
 
Of the 7678 patients with schizophrenia, 3149 (41.0%) had at least two negative symptoms 
documented. Table 8.1 displays prevalence for each of the symptoms classified by the tool. 
The most frequently recorded symptoms were poor motivation (30.5%), blunted or 
flattened affect (27.4%), poor eye contact (26.0%) and emotional withdrawal (23.5%). The 
prevalence by number of symptoms were as follows: one symptom 14.6%, two symptoms 
12.7%, three symptoms 9.3%, four symptoms 6.4%, five symptoms 5.0%, six or more 
symptoms 7.6%. 
 
Table 8.2 shows prevalence of two or more negative symptoms and binary logistic 
regression analyses for factor associated with this category. The prevalence of two or more 
symptoms was highest for age 20-29 years group (52.0%); 45.3% of males had two or 
symptoms compared to 34.7% females; 44.6% of individuals who were single had two or 
more symptoms compared to 31.6% of individuals married or cohabiting and 33.4% of 
individuals who divorced or separated had two or more symptoms. Patients who were 
employed were less likely to have negative symptoms (39.6%) compared with those 
unemployed (47.9%), and prevalence were higher in Black (48.2%) and Asian (38.7%) 
compared to White (31.0%) ethnic groups. When adjusted for other factors, two or more 
negative symptoms were also significantly associated with ADL impairment (p -value<.001) 
but not social impairment (p-value= 0.24). After adjustments, presence of delusions/ 
hallucinations (p-value=0.001) and depression (<0.001) were significantly associated with 
having two or more symptoms. 
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Table 8:2- Binary logistic regression analysis of factors associated with negative symptoms in patients with schizophrenia (n=7678) 
 
Factor Group  
Number 
in sample 
Prevalence of two 
or more negative 
symptoms (%) 
Association with two or 
more negative 
symptoms: Unadjusted 
OR (95% CI) 
P 
value 
Association with two or 
more negative symptoms: 





16–19 203 27.6 0.35 (0.25 to 0.49) <0.001 0.52 (0.37 to 0.73) <0.001 




30–39 1775 47.0 0.82 (0.71 to 0.94) 0.006 1.04 (0.89 to 1.21) 0.612 
40–49 1983 42.6 0.69 (0.60 to 0.79) <0.001 0.96 (0.82 to 1.11) 0.615 
50–59 1137 37.2 0.55 (0.47 to 0.64) <0.001 0.93 (0.83 to 1.10) 0.397 
60–69 654 29.1 0.38 (0.31 to 0.46) <0.001 0.68 (0.55 to 0.84) <0.001 
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Factor Group  
Number 
in sample 
Prevalence of two 
or more negative 
symptoms (%) 
Association with two or 
more negative 
symptoms: Unadjusted 
OR (95% CI) 
P 
value 
Association with two or 
more negative symptoms: 




70+ 589 18.0 0.20 (0.16 to 0.26) <0.001 0.45 (0.36 to 0.57) <0.001 
Gender 




Female 3084 34.7 0.64 (0.59 to 0.71) <0.001 0.75 (0.68 to 0.83) <0.001 
Marital status (most 
recent) 




Married/cohabiting 785 31.6 0.57 (0.49 to 0.67) <0.001 0.75 (0.64 to 0.89) 0.001 
Divorced/separated 776 33.4 0.62 (0.53 to 0.73) <0.001 0.76 (0.65 to 0.90) 0.001 
Widowed 208 21.2 0.33 (0.24 to 0.47) <0.001 0.75 (0.54 to 1.03) 0.079 
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Factor Group  
Number 
in sample 
Prevalence of two 
or more negative 
symptoms (%) 
Association with two or 
more negative 
symptoms: Unadjusted 
OR (95% CI) 
P 
value 
Association with two or 
more negative symptoms: 




Employment (most recent) 




Employed 341 39.6 0.71 (0.57 to 0.89) 0.003 0.72 (0.58 to 0.91) 0.006 
In education 311 39.6 0.71 (0.56 to 0.90) 0.004 0.84 (0.65 to 1.07) 0.152 
Retired 7 14.3 0.18 (0.02 to 1.51) 0.114 0.68 (0.14 to 3.19) 0.627 
Ethnicity 
White (British, Irish, any 
white background) 
3396 31.0 Reference   Reference   
 
Black (African, Caribbean, 
any Black background) 
3321 48.2 2.07 (1.88- 2.29)  1.80 (1.61- 2.00) <0.001 
246 
 
Factor Group  
Number 
in sample 
Prevalence of two 
or more negative 
symptoms (%) 
Association with two or 
more negative 
symptoms: Unadjusted 
OR (95% CI) 
P 
value 
Association with two or 
more negative symptoms: 





Asian (Indian, Chinese, 
any Asian background) 




593 33.6 1.12 (0.93- 1.35)  1.04 (0.86- 1.27) 0.648 
Activities of Daily Living 
impairment 




Present 2283 46.3 1.20 (1.08 to 1.32) <0.001 1.33 (1.20 to 1.52) <0.001 
Social impairment 




Present 2533 44.4 1.07 (0.97 to 1.18) 0.158 0.93 (0.83 to 1.04) 0.217 
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Factor Group  
Number 
in sample 
Prevalence of two 
or more negative 
symptoms (%) 
Association with two or 
more negative 
symptoms: Unadjusted 
OR (95% CI) 
P 
value 
Association with two or 
more negative symptoms: 









Present 3077 45.0 1.14 (1.03 to 1.25) 0.009 1.30 (1.17 to 1.44) <0.001 
Depression 




Present 2014 38.8 0.77 (0.69 to 0.85) <0.001 0.66 (0.59 to 0.74) <0.001 




8.5.3 Hospital admission, length of stay and readmission 
 
Figure 8.1 summarises the association of negative symptoms recorded prior to 2011 with 
mental health admission and readmission in 2011. The percentage hospital admissions were 
highest for individuals who six or more symptoms (36.8%) while percentage hospital 
readmission was highest for individuals with five symptoms (47.1%). Figure 8.2 summarises 
length of hospitalisation for inpatients during 2011. The median duration of stay was lowest 
for individuals who had no symptoms (30days) while highest for individuals with six or more 
symptoms (75 days). Further details including interquartile ranges are available in appendix 
4 table 6. Table 8.3 shows the findings from the logistic and linear regression analyses. 
confirmed that negative symptoms were associated with a higher likelihood of admission, 
readmission and a longer duration of hospitalisation. Specifically, after full adjustment 
(Table 8.3, model 3), patients with two or more negative symptoms before 2011 had a 24% 
greater likelihood of admission during 2011. Moreover, each of their admissions was, on 
average, an extra 21 days in duration, and when they were discharged, they had a 58% 
higher risk of readmission within 12 months. All of these associations remained independent 
and largely unaltered following adjustment for intensity of delusions/hallucinations among 
other covariates. Further analysis comparing patients aged under and over 40 years showed 
that the effects of negative symptoms on inpatient admission were broadly similar for both 
groups but with a slight increase in risk of readmission and reduced duration of admission in 
relation to negative symptoms for those under 40 compared with those over 40. However, 
the age × negative symptoms interaction term remained a non-significant factor (p>0.05) for 
all models.   
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Figure 8-1- Percentage of patients admitted to hospital (sample A) or readmitted to hospital 










Figure 8-2- Median duration of admission among mental health inpatients with 












Table 8:3- Association between number of negative symptoms ascertained prior to 2011 and mental health hospital admission, readmission 
and duration of admission in 2011 
 
 
Inpatient admission (OR, 
95% CI; n=7678)* 
Sample A 
Readmission within 12 months of inpatient 
admission (OR, 95% CI; n=1612)* 
Sample B 
Duration of inpatient admission (days; β-
coefficient, 95% CI; n=1609)† 
Sample C 
Associations with 2 or more negative symptoms (binary variable) 
Unadjusted 1.47 (1.32 to 1.63) 1.73 (1.41 to 2.12) 23.9 (11.2 to 36.7) 
 1. Age and sex 1.37 (1.23 to 1.53) 1.70 (1.38 to 2.09) 24.1 (11.3 to 36.9) 
 2. Model 1 plus marital status,  
employment and ethnicity 




Inpatient admission (OR, 
95% CI; n=7678)* 
Sample A 
Readmission within 12 months of inpatient 
admission (OR, 95% CI; n=1612)* 
Sample B 
Duration of inpatient admission (days; β-
coefficient, 95% CI; n=1609)† 
Sample C 
 3. Model 2 plus 
delusions/hallucinations, and depression 
1.77 (1.58 to 1.99) 1.54 (1.23 to 1.93) 21.0 (8.0 to 34.1) 
Associations with incremental number of negative symptoms (10-point scale ordinal variable)‡ 
Unadjusted 1.12 (1.09 to 1.15) 1.12 (1.07 to 1.17) 6.5 (3.5 to 9.4) 
 1. Age and sex 1.09 (1.06 to 1.12) 1.11 (1.06 to 1.16) 6.3 (3.3 to 9.2) 
 2. Model 1 plus marital status,  
employment and ethnicity 
1.16 (1.13 to 1.19) 1.01 (1.00 to 1.02) 5.6 (2.6 to 8.7) 
 3. Model 2 plus 
delusions/hallucinations, and depression 
1.16 (1.13 to 1.19) 1.01 (1.00 to 1.01) 5.8 (2.8 to 8.9) 
*Logistic regression.    †Linear regression     ‡ORs and β-coefficients are per one unit increase on the 10-point scale. 
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Table 8.4 shows the logistic and linear regression analyses that were performed to examine 
the relationship between individual negative symptoms and the frequency and duration of 
admission. Poor eye contact-OR 1.49 (95% CI 1.46- 1.81), poor motivation-OR 1.29 (95% CI 
1.03- 1.60), emotional withdrawal OR 1.49 (95% CI 1.19- 1.87) poor rapport OR 1.50 (95% CI 
1.16- 1.87) and mutism 1.56 (95% CI 1.50- 2.12) were associated with increased risk of 
readmission. Apathy was associated with increased duration of admission (p-value 0.032) 
but not with readmission risk (p-value 0.692). Emotional withdrawal and mutism were 
associated with both the risk of readmission and the duration of admission.
254 
 
Table 8:4- Associations between individual Clinical Record Interactive Search Negative Symptoms Scale (CRIS-NSS) components and 
readmission risk/duration of admission in 2011  
 Readmission risk- Sample B (binary logistic regression) (n=1612) Duration of admission- Sample C (linear regression) (n=1590) 
Unadjusted Adjusted* Unadjusted Adjusted* 
 







Poor motivation 1.40 (1.13 to 1.74) 0.002 1.29 (1.03 to 1.60) 0.026 23.0 (9.1 to 36.9) 0.001 19.1 (5.0 to 33.2) 0.008 
Blunted or flattened 
affect 
1.34 (1.08 to 1.65) 0.007 1.18 (0.95 to 1.48) 0.129 12.8 (−1.2 to 26.8) 0.073 8.3 (−5.7 to 22.4) 0.242 
Poor eye contact 1.60 (1.30 to 1.98) <0.001 1.48 (1.19 to 1.83) <0.001 18.0 (4.2 to 31.8) 0.011 14.8 (0.9 to 28.6) 0.036 
Emotional 
withdrawal 
1.62 (1.30 to 2.02) <0.001 1.49 (1.19 to 1.87) 0.001 32.5 (18.1 to 46.9) <0.001 30.0 (15.6 to 44.4) <0.001 
Poor rapport 1.63 (1.29 to 2.06) <0.001 1.50 (1.18 to 1.90) 0.001 23.1 (7.5 to 38.6) 0.004 21.1 (5.5 to 36.6) 0.008 
Social withdrawal 1.16 (0.88 to 1.54) 0.291 1.02 (0.76 to 1.36) 0.911 16.4 (−2.9 to 35.7) 0.095 9.2 (−10.1 to 28.6) 0.349 
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 Readmission risk- Sample B (binary logistic regression) (n=1612) Duration of admission- Sample C (linear regression) (n=1590) 
Unadjusted Adjusted* Unadjusted Adjusted* 
Poverty of speech 1.30 (0.98 to 1.70) 0.064 1.12 (0.85 to 1.49) 0.416 13.2 (−5.8 to 32.2) 0.173 8.5 (−10.5 to 27.5) 0.379 
Mute 1.71 (1.27 to 2.30) <0.001 1.56 (1.15 to 2.12) 0.004 28.5 (7.9 to 49.1) 0.007 29.2 (8.6 to 49.7) 0.005 
Apathy 1.02 (0.71 to 1.47) 0.914 0.93 (0.64 to 1.35) 0.692 32.5 (6.7 to 58.2) 0.013 27.4 (1.8 to 53.1) 0.036 
*Adjusted for age, sex, marital status, employment status, ethnicity, presence of hallucinations/delusions and depression. 
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After describing the distribution of negative symptoms and the psychometric properties of 
the CRIS-NSS, further analyses were performed to investigate the associations between the 
clinical outcomes described above and CRIS-NSS scores, using ordinal logistic regression. The 
findings are shown in appendix 4 table 1. For the analyses with hospitalisation outcomes 
in/following 2011, CRIS-NSS was generated restricting information extraction to electronic 
health records prior to 2011. Where data were missing on individual covariates (in 2362 
participants), this was indicated in the regression models as a separate category, 
supplemented by sensitivity analyses performed on the sample with complete data on all 
covariates to check the consistency of findings – findings are shown in appendix 4 table 2. 
For the supplementary analysis, the previous analyses were repeated within the subgroups 
of those aged under the age of 40 years and those over the age of 40 years and including an 
interaction term of age under or over 40 and binary CRIS-NSS exposure- findings are shown 





Using a SVM learning method with an NLP tool, it was possible to successfully to extract 
data on negative symptoms from the electronic mental health records of a large clinical 
sample of patients with schizophrenia. This approach did not require any specialised training 
or extra clinical assessments, and was able to generate a scale with robust construct and 
predictive validity from data recorded as part of routine clinical care. The results suggest 
that negative symptoms are documented in the electronic health records of a sizeable 
proportion of patients with schizophrenia, particularly in those who are relatively young, 
male and not in a relationship, consistent with ﬁndings from studies that assessed negative 
symptoms using quite different methods (Bobes et al. 2010; Cohen et al. 2013). These 
ﬁndings were based on the unprompted documentation of negative symptoms in the 
context of routine clinical care by staff who were not speciﬁcally trained in their assessment. 
Previous ﬁndings have usually been based on systematic ratings by a researcher using a 
dedicated rating scale. Negative symptoms are relatively difﬁcult to detect and assess 
(Blanchard JJ et al 2011), and may be less frequently documented than positive symptoms, 
such as delusions and hallucinations, because they are less clinically obvious. In addition, 
mental health services in the UK are often orientated towards the management of acute 
crises, and hence the treatment of positive symptoms (Jacobs R 2011). It is thus possible 
that the ﬁgures for the prevalence and the severity of negative symptoms derived from this 
approach are lower than would have been obtained from a trained assessor using a 
standardised instrument. In addition, this method may be more likely to identify the types 
of negative symptoms (e.g. poverty of speech) whose detection does not require specialised 
training. A substantial proportion (41%) of the sample had at least two negative symptoms. 
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Although negative symptoms were deﬁned and assessed in different ways to previous 
studies, this ﬁgure is comparable to that described in other samples of patients with 
schizophrenia ((Jager et al. 2009): 44%; (Bobes et al. 2010): 58%; (Cohen et al. 2013): 40%). 
Taken together, these ﬁndings suggest that negative symptoms are a relatively common 
feature of schizophrenia, rather than being limited to a subgroup of patients with a chronic, 
unremitting illness (Bagney et al. 2013). A clear association between negative symptoms and 
poor clinical outcomes was found, as indexed by impairments in daily living, increased risk of 
admission, increased duration of admission and increased risk of readmission. Hospital 
admissions are the main drivers of cost in the care of patients with schizophrenia 
(Department of Health. 2013), but have traditionally been linked to the severity of positive 
psychotic symptoms (Olfson M, Ascher-Svanum H 2011). This study indicates that negative 
symptoms are an equally important factor, and suggest that a greater emphasis on assessing 
and treating these features of schizophrenia may have signiﬁcant health economic beneﬁts. 
However, as these ﬁndings are drawn from observational data, it would be necessary to 
perform interventional clinical studies to determine whether an effective treatment for 
negative symptoms would lead to better clinical outcomes. 
 
A key strength of this study was the large size of the patient sample, and that it was 
representative of the overall clinical population of people with schizophrenia in a deﬁned 
geographic area. Previous studies of negative symptoms have usually involved smaller 
patient samples that were recruited to a research project (Jager et al. 2009; Bobes et al. 
2010; Cohen et al. 2013). Focusing the information extraction process on text from 
correspondence maximises the generalisability of this approach, as letters to primary care 
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physicians (which accounted for a large portion of the correspondence text) are unlikely to 
vary substantially between mental health services with respect to the language used to 
describe the symptoms of interest.  
 
In this analysis there were several limitations. Inpatient care outcomes were ascertained 
from CRIS, therefore only capture admissions to SLaM. Using an alternative like Hospital 
Episode Statistics data would have enabled a more comprehensive understanding of 
admissions. The outcomes chosen also do not include other clinical encounters such as in 
outpatient care. Adjustments were made for key demographic factors and the large sample 
size enabled multivariable analyses. However, there were several variables that were not 
included in the analyses including medication use which is a limitation. For the exposure, the 
patient’s entire record rather than discrete periods of illness was searched, and it was not 
possible to delineate the timing or duration of individual negative symptoms, or whether 
they were primary (i.e. a direct consequence of illness) or secondary (e.g. side effects of 
treatment) as these measures were not routinely documented in electronic health records. 
Although the association of negative symptoms in clinical documents prior to 1 January 
2011 with outcomes occurring after 1 January 2011 was investigated (to ensure that 
negative symptoms were always ascertained prior to outcomes), if negative symptoms were 
identiﬁed prior to 1 January 2011, it was not possible to ascertain when they occurred prior 
to this date, or their temporal relationships to subsequent clinical outcomes. The ﬁndings 
were thus derived from assessments made over a period that was not standardised, but was 
generally relatively long. This also introduces confounding by indication as unwell 
individuals may be more likely to be clinically reviewed more frequently and thereby have 
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their symptoms recorded more thoroughly. In contrast, most assessments of negative 
symptoms in the literature are derived from a single cross-sectional measurement (Gilbert 
et al. 2000; Chang et al. 2011). Measurement bias is likely to be low at the point of clinical 
care as clinical staff entering information during clinical care were not aware of study. At the 
stage of symptom applications development where training sets were developed and the 
clinical team were annotating individual symptoms, there is possibility of introducing a 
misclassification bias. This was handled with at least two team members conducting 
independent annotations and inter-rater agreement measured for each item. Also, while 
the annotator was aware the case notes were for an individual with SMI, they did not know 
the exact diagnosis or any other information other than the sentences on either side of the 
annotating word or phrase.  
 
A further limitation was the extent to which individual negative symptoms could be 
considered as having equal weight in a composite score. Weighting the 10 negative 
symptom applications equally resulted in a composite score (from 0 to 10) with a 
reasonable degree of internal consistency, as demonstrated by a Cronbach α value of 0.78. 
However, analysing the association of each negative symptom with clinical outcomes 
revealed varying degrees of association with poor clinical outcomes for different negative 
symptoms. Future studies are necessary to examine the propensity for different negative 
symptoms to co-occur in individual patients and the extent to which different clusters of 
symptoms are associated with clinical outcomes, particularly in the light of previous 
research which suggests that negative symptoms segregate into two subdomains relating to 
amotivation and reduced emotional expression (Kimhy et al. 2006). The application of NLP 
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to clinical records is unlikely to identify negative symptoms as accurately as a direct 
assessment using a specialised psychopathological rating scale. However, automated tools 
could be used to screen individuals and identify those with negative symptoms who would 
then beneﬁt from comprehensive assessment using a standardised instrument. In this way, 
automated methods could be used to complement standardised instruments. Automated 
information extraction tools could also be developed to identify other clinical parameters 
from electronic health records in order to support real-time clinical decision-making. These 
possibilities could be explored in future research. In summary, the findings suggest that 
negative symptoms can be identiﬁed in clinical records using automated methods, are 
common in patients with schizophrenia and are associated with poor clinical outcomes. The 
ﬁndings highlight the potential of automated information extraction tools in mental health 





8.7 Summary of findings from chapter 
 
Ten different negative symptoms were ascertained using NLP algorithms, with precision 
statistics above 0.80. Of patients with schizophrenia diagnoses, 41% had two or more 
negative symptoms recorded prior to the observation period. Negative symptoms were 
associated with younger age, male gender and single marital status, and with increased 
likelihood of hospital admission (OR 1.24, 95% CI 1.10 to 1.39), longer duration of admission 
(β-coefficient 20.5 days, 7.6–33.5), and increased likelihood of readmission following 
discharge (OR 1.58, 1.28 to 1.95). Negative symptoms were common and associated with 
adverse clinical outcomes, consistent with evidence that these symptoms account for much 
of the disability associated with schizophrenia. NLP provides a means of conducting research 





9 Symptoms identified in electronic medical records for individuals with 
severe mental illness by natural language processing in relation to 
general mortality and hospitalisation  
 
9.1 Chapter outline 
This chapter describes an investigation of mental health symptom profiles in the electronic 
clinical records of a large cohort of patients with schizophrenia, schizoaffective disorder, or 
bipolar disorder in relation to all-cause mortality and measures of hospitalisation to non-
mental health facilities. 
 
The paper reporting this chapter is currently under peer review  
Jayatilleke N, Chang CK, Stewart R. Symptoms identified in electronic medical records for 
individuals with severe mental illness by natural language processing in relation to general 
mortality and hospitalisation [In submission].  
 
Personal contributions to publication- Using concepts discussed with supervisors, I designed 
the study approach. I had full access to all the data in the study and took responsibility for 
data integrity, accuracy of the data analysis, interpretation of data, drafting and critical 
revisions of the manuscript. 
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9.2  Research question 
 
This study aimed to describe the associations with mortality and hospitalisation for each of 
six symptom dimensions (positive, negative, manic, disorganisation, catatonic and 






Symptom profiles, in a limited capacity, have been used to investigate adverse outcomes for 
individuals with SMI. To date, incorporation of symptoms in analyses investigating adverse 
outcomes have included the use of scores on global scales such the Health of the Nation 
Outcome scale as described in the study by Hayes et al., 2012. The use of specific symptoms 
has also been used, for example in the study reported by Fiedorowicz et al., 2009, which 
focused on manic and hypomanic symptoms in patients with bipolar disorder. It has long 
been recognised that people with SMI do not live as long as those without mental illness 
(Chang CK et al. 2011; Lawrence D et al 2013; Hoang U et al 2011). The majority of this 
excess mortality has been linked to physical illness with important individual lifestyle 
choices, side effects of psychotropic treatment and disparities in health care access, 
utilisation and provision contributing to these deaths as well as other poor physical health 
outcomes (De Hert et al. 2011). Higher suicide rates are also clearly important, but are by no 
means the predominating reason for loss of life expectancy in SMI (Druss BG, 2011). In its 
report as part of the World Psychiatric Association Action Plan 2008-2011, the authors note 
that this excess morbidity and mortality is largely due to modifiable lifestyle risk factors, but 
also that the screening and assessment of physical health disorders remains poor for people 
with SMI, even in developed countries (De Hert et al. 2011).The types of symptoms 
experienced may influence these outcomes. 
 
Colleagues have highlighted that, currently, there are no internationally agreed standards to 
measure how many people with SMI need treatment (Thornicroft G 2013). As a result, 
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specific issues pertinent to individuals with SMI remain unresolved, including knowledge of 
the mental and physical outcomes of treatment or the absence of treatment, and there 
needs to be further work to understand how inequalities can be addressed. Symptoms 
expressed by a patient in the course of their illness, guide clinician decisions on its 
management including suitability for specific interventions and treatment modality, and 
symptom profiles provide more detailed information that just a diagnosis (Adam 2013; 
Chmielewski et al. 2014). Information on specific symptoms is typically recorded in 
unstructured parts of an individual’s electronic health record (Hardoon et al. 2013) although 
NLP can be used to process large quantities of text and return structured information 
(Antolík 2005; Nikiforou et al. 2013; Chapman et al. 2011). The analysis described here 
utilised a unique opportunity arising from CRIS and the previously described natural 
language processing developments (Jackson et al. 2017; Patel et al. 2015) to ascertain 
symptoms spanning six domains, against which I investigated death and hospitalisation 
outcomes for a cohort of individuals with SMI testing the null hypothesis that symptom 






9.4.1 Setting and cohort definition 
 
The setting for this study has been described in chapter 5. Cohort members were defined as 
cases given a diagnosis of schizophrenia (ICD-10 code: F20.X), schizoaffective disorder 
(F25.X) or bipolar affective disorder (F31.X) and who were under active review by SLaM 
services at any time during the period between 1st January 2007 and 31st December 2010. 
The age of cohort members on 1st January 2011 was calculated from the year and month of 
birth and individuals aged 15 to 104 years were included. Diagnoses recorded in CRIS were 
based on the 10th edition of the World Health Organization International Classification of 
Diseases (ICD-10).  
 
9.4.2 Overview of analysis strategy 
 
As mentioned above, the cohort was defined as individuals who were alive on 1st January 
2011. For this cohort, I ascertained the following: symptom profiles prior to that date, 
covariates at that date, and outcomes over pre-defined periods from that date onwards. 
 
9.4.3 Data sources 
 
Demographic and clinical data- date of birth, gender and ethnicity were extracted in 
addition to employment, marital status and ethnicity nearest to 1st January 2011. Date of 
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birth was used to calculate age on 1st January 2011 and managed as a continuous variable. 
Ethnicity classifications were- “White”, “Black”, “Asian”, “mixed, unknown and others”. 
Marital status was classified as being “single”, “in a relationship (cohabiting, married or civil 
partnership)”, “separated”, “not disclosed or unknown”. Employment was classified as 
“employed”, “unemployed” or “unknown”.  The symptoms data obtained comprised the 
presence (count of occurrences and date first recorded) of any symptom, from the list 
shown in Table 5.2 (Chapter 5), recorded at any stage from their first contact at SLaM until 
the end of a pre-defined observation period on 31st December 2010. The specific symptom 
domains of research interest were classified as positive, negative, disorganisation, manic, 
catatonic, and depressive, extracted from open-text fields of clinical events and 
correspondence letters in CRIS. The precision and recall of each symptom are presented in 
appendix 1. Research papers by Jackson et al 2017 and Patel et al 2015 describe the 
methodology for identifying symptoms within CRIS. The process, described in more detail in 
chapter 5, involved using NLP information extraction within clinical records stored in CRIS to 
process large quantities of unstructured (human authored) text and return structured 
information on presence of symptoms. As described in chapter 5, a detailed review of the 
training data set was undertaken to identify and annotate key phrases within the records 
that were either relevant or irrelevant for keywords related to each symptom with inter-
rater reliability between annotators monitored. This training data set was used to construct 
an application using a hybrid classiﬁcation model, consisting of a support vector machine 
learning algorithm and rule-based text matching, using the Generalised Architecture for Text 




Mortality data- Data extraction for this data sources is outlined in chapter 5 and described in 
chapter 6. Deaths occurring in the cohort between 1st January and 31st December 2011 were 
analysed to measure short term impacts of the mental health conditions. 
 
Hospitalisation (Hospital Episode Statistics, HES) data- Data extraction for this data source is 
outlined in chapter 5 and described in chapter 7. A hospitalisation was defined as having at 
least one HES episode recorded. The total number of days in hospital within the observation 
period between 1st January 2011 and 31st December 2014 was collected to measure short 
term impacts of the mental health conditions over a four year period and to capture 
admissions to non-mental health hospitals. The date of admission and date of discharge 
were used to calculate use of inpatient care services. Hospitalisation data were stratified 




9.4.4 Statistical analysis 
 
To summarise the measurements for the symptom domains, each specific symptom was 
coded as “1” for ever being mentioned or “0” for absence of any trace of it in open text fields. 
The count of mentioned symptoms was then considered as a comprehensive indicator for 
each domain. This means that an individual who had two different symptoms recorded at any 
time would score two points, someone who had three different symptoms recorded would 
score three points, and so on. Standardised Z-scores were calculated for each symptom 
domain – i.e. the count of symptoms for each domain was divided by its standard deviation 
in the sample to unify the measurement scale for all domains and facilitate direct comparison.   
 
Cox regression procedures were used to model associations between the exposures of 
interest (positive, negative, catatonic, disorganisation, manic and depressive symptoms) and 
all-cause mortality. Proportional hazards assumptions were tested and indicated that it was 
appropriate to use Cox regression procedures. For each individual, the ‘at-risk’ period 
commenced from the date of contact was made with SLaM services during the observation 
period. The censoring date was the end of the observation period (31st December 2014) and 
the event date was the date of death during the observation period.  Adjustment for age, 
gender, ethnicity, employment status and marital status as potential confounders to 
association between mortality and the exposures was carried out. 
 
For the analyses of hospitalisation outcomes, univariate and multivariate linear regressions 
were applied individually for mental healthcare admissions and for non-mental admissions 
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with symptom domains as the major exposures of interest. Total length of hospital stay in 
days and number of admissions between 1st January 2011 and 31st December 2014 were used 
as dependent variables. Age, gender, ethnicity, employment status and marital status, 







Table 9.1 describes the characteristics of this cohort as at 1st January 2011: 14,824 
individuals with a primary diagnosis of SMI who met the inclusion criteria. The age group 
that included the most individuals was 35-44 years (25.3%) followed closely by 45-54 years 
(22.4%). Unemployment was noted for 36.8% of the cohort; 65.2% of the cohort were 
single; 51.6% were from a White ethnic background; 94.5% had at least one positive 
symptom and 94.0% had depressive symptoms. The lowest prevalence (51.1%) of at least 
one symptom was noted for catatonic symptoms; 821 individuals (5.5%) had at least one 
covariate other than date of birth missing. Table 9.2 presents the symptoms extracted 
within each of the six domains. Among positive symptoms, the most frequent was 
hallucinations (82.7%) and the least frequent was arousal (39.2%), while for negative 
symptoms, poor rapport (77.8%) was most common and poverty of thought (6.0%) was 
least. Among disorganisation symptoms, circumstantiality (77.2%) was most frequent and 
derailment (9.9%) was least. For manic symptoms, elevated mood (95.9%) was most 
frequent and insomnia (30.8%) was least. Among catatonic, posturing (27.8%) was most 
frequent and stupor (1.4%) was least while for depressive symptoms, most and least 





Table 9:1- Cohort characteristics of all individuals with a diagnosis of SMI received prior to 
31st December 2010 and had active contact with SLaM between 1st January 2007 and 31st 







Age on 1st January 2011(years) 15- 24  1017 
 25- 34  2867 
 35- 44  3747 
 45- 54  3317 
 55- 64 1867 
 65- 74 1133 
 75- 84 658 
 85- 94 202 
 95- 104 16 
Gender Males 7735 
 Females 6268 
Employment Unemployed 5455 
 Employed 1860 
 Unknown/ missing 7509 
Marital status Single 9668 
 Married/ civil partnership/ cohabiting 1897 








 Widowed/ surviving civil partner 506 
 Not disclosed/ unknown 1143 
Ethnicity White (British, Irish, any White background) 7654 
 Black (African, Caribbean, any Black background) 4941 
 Asian (Indian, Chinese, any Asian background) 847 
 Mixed/ unknown/ missing 1382 






























Table 9:2- Symptom groupings of all individuals with a diagnosis of SMI prior to 31st December 2010 and had active contact at SLaM between 
1st January 2007 and 31st December 2010 (n=14,824) 
 
Number of cases with individual symptoms ever recorded prior to 1st January 2011 
Positive symptoms Negative symptoms Disorganisation symptoms Manic symptoms Catatonic symptoms Depressive symptoms 
Agitation 10195  Blunted or flat affect 11257  Circumstantial speech 11438  Elevated mood 14217  Mannerism 1308  Anergia 458  
Aggression 10332  Emotional withdrawal 10608  Reduced coherence 9604  Disturbed sleep 11956  Rigidity 2900  Anhedonia 3404  
Arousal 5810  Social withdrawal 9550  Formal thought disorder 10838  Insomnia 4570  Posturing 4121  Loss of appetite 12375  
Hostility 6959  Abstract thinking- 2933  Thought block 2182  Pressured speech 13207  Perseverance 2649  Poor concentration 10976  
Delusions 11895  Poor rapport 11536  Tangential speech 3951  Irritability 10094  Stupor 212  Low energy 9219  
Hallucinations 12267  Apathy 1749  Derailment 1473  Elation 13889  Waxy flexibility 118  Guilt 6292  
Paranoia 11920  Poverty of speech 1505  Flight of ideas 3985  Grandiosity 5712  Immobility 559  Helplessness 2430  
Persecution 8274  Poverty of thought 893   Echolalia 327  Hopelessness 4908  
    Mutism 2546  Poor motivation 10412  
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    Catalepsy 13  Psychomotor retardation 6109  
    Echopraxia 53  Suicidal ideation 5256  
     Tearfulness 7459  
     Weight loss 7264  
     Worthlessness 2579  
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Table 9.3 summarises outcome associations of factors that were adjusted for in the 
subsequent analyses: age, gender, ethnicity, employment status and marital status.  The 
results shown in this table are univariate / unadjusted analysis outcomes. Increasing age 
was associated with worse outcomes on all three measures- mortality (p<0.001), number of 
admissions (p<0.001) and total inpatient care (p<0.001). Male gender was associated with 
higher number of admissions. Employed status was associated with higher mortality (HR 
2.40, 95% CI 1.99- 2.89) and significant overall inpatient hospitalisation (B value 0.75, 95% CI 
0.05- 1.44). Mortality was highest for individuals known to be widowed (HR 6.48, 95% CI 
5.27- 7.96). Widowed individuals also experienced higher numbers of admissions (B value 
0.59, 95% CI 0.20- 0.97). individuals from all other ethnic groups compared with White 
ethnic background experienced less mortality. Asians also experienced lower number of 




Table 9:3- Univariate analyses on the outcomes of mortality, number of non-mental health related admissions and total inpatient care at non-
mental health hospitals 
Variable Mortality 
HR (95%), p-value 
Admission number 
B value (95%), p-value 
Total inpatient care (days) 
B value (95%), p-value 
Age (per year increase) 1.08 (1.07- 1.09), p<0.001 0.02 (0.01- 0.03), p<0.001 0.06 (0.04- 0.72), p<0.001 
Gender    
Males REF REF REF 
Females 0.90 (0.78- 1.02), p=0.11 -0.19 (-0.32- -0.06), 
p<0.001 
-0.02 (-0.45- 0.41), p=0.93 
Employment status    
Unemployed REF REF REF 
Employed 2.40 (1.99- 2.89), p<0.001 0.17 (-0.04- 0.38), p=0.11 0.75 (0.05- 1.44), 0.04 
Unknown/ missing 1.14 (0.97- 1.33), p=0.10 0.06 (-0.09- 0.20), p=0.43 0.48 (0.00- 0.95), 0.05 
Marital status    
Single REF REF REF 
Married/ civil partnership/ cohabiting 
1.32 (1.08- 1.61), p=0.01 -0.17 (-0.37- 0.03), 0.10 -0.41 (-1.06- 0.25), p=0.23 
Divorced/ civil partnership dissolved/ separated 
1.59 (1.30- 1.95), p<0.001 0.13 (-0.08- 0.35), p=0.22 0.11 (-0.59- 0.81), p=0.77 
Widowed/ surviving civil partner 




HR (95%), p-value 
Admission number 
B value (95%), p-value 
Total inpatient care (days) 
B value (95%), p-value 
Not disclosed/ unknown 
0.91 (0.68- 1.22), p=0.53 0.06 (-0.19- 0.32), p=0.62 -0.87 (-1.71- -0.02), p=0.04 
Ethnicity    
White (British, Irish, any White background) REF REF REF 
Black (African, Caribbean, any Black background) 0.50 (0.43- 0.59), p<0.001 -0.10 (-0.25- 0.04), p=0.17 -0.47 (-0.95- 0.01), p=0.05 
Asian (Indian, Chinese, any Asian background) 0.61 (0.44- 0.84), p<0.001 -0.37 (-0.64- -0.09), p=0.01 -0.68 (-1.59- 0.24), p=0.15 






Table 9.4 describes the findings from Cox regression analyses of domain-specific symptom 
scores in relation to mortality during 2011. Examining proportional hazards assumptions for 
each symptom domain as an exposure, no significant deviations from this assumption were 
observed (p-values ranging from 0.7 to 0.9). After adjusting for age, sex, employment, 
marital status and ethnicity, higher levels of positive symptoms, negative symptoms and 
catatonic symptoms were associated significantly with increased risk of mortality with 
similar adjusted hazard ratios (1.08 (95% CI 1.03- 1.16), 1.09 (95% CI 1.02- 1.16) and 1.09 
(95% CI 1.03- 1.16) respectively). For disorganisation, manic and depressive symptom 
domains, the hazard ratios were weaker (1.04 (95% CI 0.98- 1.11), 1.02 (95% CI 0.96- 1.08) 
and 1.02 (95% CI 0.96- 1.09) respectively) and not statistically significant. The correlation 




Table 9:4- Cox regression analysis of mortality between 1st January 2011 to 31st December 
2011 in individuals with SMI according to domain-specific symptoms recorded prior to 2011 





Ratio* (95% CI) 
p-value  
Adjusted Hazard 
Ratio* (95% CI) 
p-value  
Positive  0.93 (0.87- 0.99) 0.03 1.08 (1.03- 1.16) 0.03 
Negative 0.92 (0.87- 0.97) <0.01 1.09 (1.02- 1.16) 0.04 
Disorganisation 0.87 (0.82- 0.92) <0.01 1.04 (0.98- 1.11) 0.16 
Manic 0.91 (0.86- 0.96) <0.01 1.02 (0.96- 1.08) 0.51 
Catatonic 1.00 (0.95- 1.05) 0.95 1.09 (1.03- 1.16) 0.01 
Depressive 0.87 (0.82- 0.92) <0.01 1.02 (0.96- 1.09) 0.41 
*Hazard ratios were derived from exposures entered as z-transformed independent variables – i.e. 
entered in standard deviation units. Adjustments were for age, gender, ethnicity, employment status 
and marital status 
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Associations between symptom levels and mental health hospitalisations are displayed in 
Table 9.5. with the primary aim of establishing construct validity before moving on to 
analyses of non-mental health hospitalisation. Mental health admissions were significantly 
raised in association with higher scores on each of the symptom domains analysed; 
combined mental healthcare inpatient days were also significantly increased. After 
adjustment, the regression model for combined inpatient days showed the largest effect 
size with catatonic symptoms (B-value 9.95, 95% CI 9.04- 10.9) and the smallest with manic 
symptoms (B-value 3.12, 95% CI 2.18- 4.06). After adjustment, associations with higher 
numbers of admissions were significant for positive (B-value 0.22, 95% CI 0.20- 0.24) , 
disorganisation (B-value 0.22, 95% CI 0.20- 0.24) and catatonic (B-value 0.22, 95% CI 0.20- 




Table 9:5- Linear regression models of number of mental healthcare inpatient admissions and total inpatient days in patients with SMI during 
2011-2014 by levels of symptoms recorded prior to 2011- positive, negative, disorganisation, manic, catatonic and depressive (n=14,824) 

















 Positive  0.24 (0.22- 0.25) < 0.01 0.22 (0.20- 0.24) < 0.01 6.73 (5.84- 7.62) < 0.01 6.61 (5.64- 7.57) < 0.01 
Negative 0.16 (0.14- 0.17) < 0.01 0.12 (0.11- 0.14) < 0.01 4.84 (3.94- 5.73) < 0.01 4.39 (3.44- 5.35) < 0.01 
Disorganisation 0.25 (0.23- 0.26) < 0.01 0.22 (0.20- 0.24) < 0.01 6.43 (5.54- 7.32) < 0.01 6.12 (5.17- 7.07) < 0.01 
Manic  0.15 (0.13- 0.16) < 0.01 0.12 (0.11- 0.14) < 0.01 3.39 (2.49- 4.28) < 0.01 3.12 (2.18- 4.06) < 0.01 
Catatonic  0.24 (0.22- 0.26) < 0.01 0.22 (0.20- 0.23) < 0.01 10.0 (9.15- 10.9) < 0.01 9.95 (9.04- 10.9) < 0.01 
Depressive  0.16 (0.15- 0.18) < 0.01 0.14 (0.12- 0.16) < 0.01 3.62 (2.73- 4.51) < 0.01 3.66 (2.71- 4.61) < 0.01 
* Hazard ratios were derived from exposures entered as z-transformed independent variables – i.e. entered in standard deviation units. Adjustments were 
for age, gender, ethnicity, employment status and marital status 
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In analyses of admissions to non-mental health hospitals (Table 9.6), higher manic (B value= 
0.09, 95% CI 0.02- 0.15), catatonic (B value= 0.08, 95% CI 0.02- 0.15) and depressive (B 
value=0.14, 95% CI 0.08- 0.21) symptoms were significantly associated with higher numbers 
of admissions after adjustment. No significant associations were found for positive, negative 
and disorganisation symptoms (B-values 0.05, 0.06 and 0.06 respectively). No associations 






Table 9:6- Linear regression analyses of general hospital admissions (all hospitals not identified as a mental health trust) and total inpatient 
care during 2011-2014 in patients with SMI by levels of symptoms recorded prior to 2011- positive, negative, disorganisation, manic, catatonic 
and depressive (n= 14,824) 

















 Positive  -0.01 (-0.07- 0.05) 0.72 0.05 (-0.01- 0.12) 0.12 -0.09 (-0.30- 0.11) 0.38 0.06 (-0.16- 0.29) 0.58 
Negative -0.02 (-0.08- 0.04) 0.55 0.06 (-0.01- 0.13) 0.09 -0.01 (-0.22- 0.20) 0.94 0.18 (-0.04- 0.41) 0.10 
Disorganisation -0.02 (-0.09- 0.04) 0.45 0.06 (-0.01- 0.12) 0.10 -0.21 (-0.42- -0.01) 0.04 -0.03(-0.25-0.19) 0.80 
Manic  0.03 (-0.03- 0.09) 0.35 0.09 (0.02- 0.15) 0.01 -0.09 (-0.30- 0.11) 0.38 0.02 (-0.19- 0.24) 0.84 
Catatonic  0.03 (-0.03- 0.09) 0.29 0.08 (0.02- 0.15) 0.01 -0.04 (-0.25- 0.17) 0.72 0.08 (-0.14- 0.29) 0.48 
Depressive  0.06 (0.00- 0.13) 0.05 0.14 (0.08- 0.21) <0.01 -0.10 (-0.31- 0.11) 0.34 0.06 (-0.16- 0.28) 0.58 
*adjusted for age, gender, ethnicity, employment status and marital status 
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9.6 Discussion  
 
Using a large mental healthcare EHR data source and extensive NLP-derived profiling of 
symptomatology in SMI, novel information on fifty-three symptoms across six symptom 
domains was extracted and analysed against mortality and hospitalisation as outcomes. 
Whilst primarily this was an analysis of physical health outcomes focusing on mortality and 
general hospital use, the associations with mental healthcare hospitalisation outcomes 
(both number of episodes and total duration) supported the construct validity of the 
symptoms. After adjustment, higher scores on positive, negative and catatonic symptom 
domains were significantly associated with an increased risk of mortality over a 12-month 
follow-up period, but hazard ratios were weaker and not significant for disorganisation, 
manic and depressive symptom domain scores. For admission to non-mental health 
hospitals, only manic, catatonic and depressive symptoms were associated with higher 
numbers of admissions and no symptom domain score predicted combined duration. In the 
early study on negative symptoms described in chapter 8, increased likelihood of mental 
health hospital admissions, duration of admissions and increased likelihood of readmission 
following discharge were associated with negative symptoms for a cohort of individuals with 
schizophrenia. Further developments have now enabled the investigation of a more 
comprehensive suite of symptoms to investigate physical health outcomes across SMI more 
broadly.  
 
In relation to the literature reviewed in chapter 2, the extraction of this novel information 
allowed a more comprehensive investigation of the association between SMI symptom 
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profiles and physical health outcomes than has previously been attempted. Considering 
adjusted models for mortality, symptoms most strongly associated with this outcome were 
the more schizophreniform domains, i.e. positive, negative and catatonic. Further 
investigations may identify whether people with more affective symptoms engage better 
with healthcare or receive more targeted care that reduce adverse outcomes. For example, 
a study looking at myocardial infarction in patients with SMI found that both schizophrenia 
and bipolar disorder were associated with less receipt of post-event care but only 
schizophrenia was associated with higher short-term mortality (Wu S-I, et al 2013). Studies 
of SMI cohorts to date have not investigated as wide a range of symptoms as described in 
this study, although there are some links to mortality already identified. In a prospective 
cohort study among individuals with bipolar disorder, clinically significant manic/hypomanic 
symptoms predicted cardiovascular mortality independent of diagnosis, treatment 
exposure, age, gender, and cardiovascular risk factors at intake; however, depressive 
symptom burden was not related to cardiovascular mortality, having measured the severity 
of affective psychopathology using weekly Psychiatric Status Ratings of symptom levels 
(Fiedorowicz et al. 2009). That study considered proportions of weeks exposed during 
follow-up for symptom variables, in order to reduce limitations from loss to follow-up; this 
was not a particular issue for my study because follow-up will have been near-complete 
with the linkages to national data sources. The number of individuals followed was also 
orders of magnitude higher in my cohort: the study reported by Fiedorowicz followed 435 
individuals recruited from a research cohort, whereas my cohort comprised more than 
14,000 individuals with SMI, albeit with more limited information available. In another study 
limited to assessing outcomes for manic symptoms, after adjusting for major depressive 
symptoms and demographic differences, the odds of mortality at follow-up for participants 
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with lifetime manic spectrum episodes in the 30-44 and 45-64 year age cohorts at baseline 
were higher than those with no lifetime manic spectrum episodes in the same age cohorts, 
with odds ratios of 1.39 and 1.41 respectively (Ramsey et al. 2013).  
 
Pre-structured information in UK mental health records on a limited range of symptoms is 
available from HoNOS: a set of scales to measure the health and social functioning of people 
with severe mental illness (Wing JK, Beevor AS, Curtis RH 1998). HoNOS is the most widely 
used routine clinical outcome measure used by English mental health services but the 
insight it provides as an exposure is limited to specific items measuring behaviour, 
impairment, symptoms and social functioning. HoNOS data were previously investigated as 
exposures in analyses of all-cause mortality using CRIS data reported by Hayes RD et al 
2011. The key findings from that study were that mortality was not significantly associated 
with the HoNOS “hallucinations and delusions” or “overactive-aggressive behaviour” scales 
which in my study would be included under the positive symptoms domain. There was a 
significant positive association between mortality and subclinical depression as recorded on 
HoNOS among individuals with schizophrenia (adjusted hazards ratio of 1.5) but a negative 
association with subclinical and more severe depression among patients with schizoaffective 
disorder (adjusted hazard ratios 0.10 and 0.30 respectively) (Hayes et al. 2012). However, 
HoNOS provides very limited information on symptom profiles and certainly does not cover 
all the domains discussed here. In my analysis, no association was found between the 




For non-mental health hospitalisation, my findings suggest that any effect is on the number 
of admissions rather than their duration and an opposite pattern from mortality was 
observed in that the manic and depressive symptom scores were the strongest predictors. 
These exposures might therefore be increasing the risk of multiple, short duration 
admissions rather than long-duration stays which would fit with the association with 
number of admissions but not total duration. People distressed by their SMI often do not 
seek out services or choose to fully engage in them (Corrigan et al. 2014), and one factor 
that impedes care seeking and undermines the service system is mental illness stigma. 
However, it is unclear whether medical help-seeking behaviour varies within SMI – for 
example, whether individuals who experience manic symptoms to have a greater propensity 
for medical help-seeking. Catatonic symptoms were associated with a higher risk of both 
mortality and number of admissions, although it should be borne in mind that not all 
catatonic symptoms mentioned in text will have been specific to ‘catatonic syndrome’, and 
at least some might reflect other phenomena such as adverse drug events and/or might 
have occurred secondary to underlying physical health conditions. Therefore, further 
investigation of this issue is required before definitive inferences can be made. 
 
Associations between symptom profiles and general hospitalisations are under-researched 
in that they are either overlooked or only ascertained in conjunction with mental health 
admissions. For example, a study investigating whether better primary care can reduce 
hospital admissions used the SMI quality indicators measured routinely in the Quality and 
Outcomes Framework (QOF) in English general practice (Jacobs et al. 2015). The study 
tested the impact of SMI QOF indicators on length of stay and its associated costs using 
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linked administrative data from around 8,500 general practitioner (GP) practices and from 
Hospital Episode Statistics. SMI admissions were defined by a main ICD-10 diagnosis of F20–
F31, and covariates included information on GP practice and patient population 
characteristics, area deprivation and other potential confounders such as access to care. 
Analyses carried out at a GP practice level for admissions found a positive association 
between QOF achievement and admissions: i.e. found that practices with better QOF 
markers also had higher admissions. This was observed for emergency admissions both for 
mental and physical health, with an additional 10% in QOF achievement associated with an 
approximately 1.9% increase in the practice emergency SMI admission rate (Jacobs et al. 
2015). However, there was no significant association of QOF achievement with either length 
of stay or cost. The authors suggested that higher quality primary care, as measured by QOF 
may not effectively prevent the need for secondary care but acknowledged that they were 
not able to confirm whether patients received their QOF checks prior to admission rather 
than post-discharge. Better quality primary care may also be picking up unmet need for 
secondary care, and QOF measures may not accurately reflect quality of primary care. In 
another study evaluating the relationship between baseline levels of and changes in Positive 
and Negative Syndrome Scale (PANSS) clinical symptom scores and risks for subsequent 
psychiatric hospitalisation, reductions in PANSS total scores during a three-month period 
were associated with a significantly lower risk for psychiatric hospitalisation with an odds 
ratio of 0.78 (Glick et al. 2015). Ten-point reductions in PANSS total score during three 
months were also associated with reduced predicted number of psychiatric hospitalisations 




I believe that my study provides unique contributions to the evidence base, being one of the 
first to investigate detailed SMI symptom profiles as predictors of physical health outcome 
measures. Key strengths of the study included the large cohort size and comprehensiveness 
of the patient sample, and its likely representativeness of people with SMI in its local 
catchment, since SLaM is a near-monopoly provider of secondary mental health care. 
Electronic health records are available for all patients in SLaM and therefore, it was possible 
to include many records for symptoms extraction. This provided high levels of statistical 
power whilst also enabling adjustment for key demographic factors. Using nationally 
available data sources such as Office for National Statistics mortality data as well as Hospital 
Episode Statistics meant that mortality data and hospital admission data were 
comprehensive and reduced the potential for bias arising from incomplete follow-up. 
Coverage is anticipated to be good for both these linked data sources as there is a legal 
requirement to record every death, while the hospitalisation data have an administrative 
function and are linked to payments to hospitals. The linkage to a national data source also 
meant that loss to follow up is very limited unlike that described in other studies 
(Fiedorowicz et al. 2009).  
 
There are limitations to this study. From a study design perspective, there are two main 
issues to consider. Firstly, even with the approach taken of ascertaining symptoms recorded 
at any stage, detection bias is likely; for example, individuals who died soon after being seen 
by the mental health service will have fewer opportunities to have symptoms recorded on 
their record, and there was no attempt to account for the duration of patient records. 
Secondly, there is likely to be underestimation of some symptoms. For example, it is 
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possible to have missed some aspects of a psychosis presentation – either because 
particular symptoms were systematically missed, or because of target symptoms included in 
this study were described in non-standard language (e.g. ‘hearing voices’, rather than 
‘auditory hallucination’). Similar to Fiedorowicz (2009) measures of symptoms in my study 
can only approximate cumulative lifetime exposure as I used extracted symptoms recorded 
at any stage in the patient record. It is also possible that the SMI diagnosis had been first 
recorded at an earlier presentation and at least some members of the cohort might have a 
different presenting complaint (e.g. an individual with a history of schizophrenia with 
reported symptoms now currently receiving care for alcohol or drug dependence). The 
analysis presented in this chapter did not differentiate affective vs. non-affective psychosis 
but instead aimed to characterise symptom profiles across SMI in order to investigate 
outcomes.  Considering symptoms, within the catatonia domain, further exploration of the 
domain is required before making inference for the reasons mentioned previously. Mortality 
was measured over quite a short time-period and therefore, the outcome might reflect 
shorter term impacts of mental health conditions. Further, the study was limited to 
assessing the variation in access to secondary care because Hospital Episode Statistics were 
used as the data source, and did not incorporate any information from primary care. HES as 
a data source also may not reflect all healthcare utilisation as some individuals may access 
private health care, although this is likely to have been rare for the SLaM catchment. In 
addition, the hospitalisation component of this study could only look at met need. This 
study did not attempt to split hospitalisation outcomes into emergency and elective care. 
However, people with SMI use more emergency care than those without: for example, a 
review of admission patterns found that individuals with SMI attended the emergency 
department 3.2 times more often and experienced 4.9 times as many emergency inpatient 
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admissions than those without mental ill health in 2013/14. In addition, for elective care, 
people with mental illness used less planned inpatient care than those without. (Dorning, H. 
Davies, A. Blunt 2015).  
 
Despite these limitations, this study comprising data from a large number of individuals with 
SMI provides meaningful implications. Symptoms data might, for example, be used to 
profile behavioural traits that could impact on preventative measures such as screening 
programmes, or might be investigated as factors influencing the effectiveness of 
interventions. There are also more direct financial implications as measures to reduce 
severity of symptoms or minimise the development of new symptoms may mean less costs 
of hospitalisation. No economic analyses were attempted to quantify this; however, in a US 
study, a 10-point reduction in Positive and Negative Syndrome Scale (PANSS) total score was 
associated with a savings in psychiatric hospitalisation cost of $192 over three months and 
$1,135 over a year (Glick et al. 2015). Reductions in PANSS total scores significantly reduced 
risks for psychiatric hospitalisations, total number of psychiatric hospitalisations, total nights 
for psychiatric admissions, and the costs of these hospitalisations highlighting the benefits 
of symptom control on the direct costs of care in schizophrenia (Glick et al. 2015). Policy 
implications include a need to recognise and address the fact that, while collectively 
individuals with SMI can be grouped together by similarities, specific pathophysiological 
links between sub-groups of syndromes can impact some individuals and not others. From a 
research perspective, this study provides a precedent for a new wave of studies utilising in-
depth information on large routine clinical databases to understand better the key issues 
pertinent to the health care of individuals with SMI and other mental disorders at least. In 
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addition to further refining the NLP applications developed to date to maximise their 
potential, there may also be opportunities to explore the measurement of functioning in a 
more thorough manner through applying similar NLP techniques, improving on than what is 





9.7 Summary of findings from chapter 
 
NLP-extracted symptoms of SMI showed construct validity in their robust prediction of 
adverse mental health outcomes. Considering mortality and non-psychiatric hospitalisation, 
higher levels of schizophreniform symptoms (positive and negative) were associated with 
increased risk of mortality, while higher levels of manic and depressive symptoms were 
associated with higher numbers of hospitalisations. Higher levels of catatonic symptoms 
were associated with both of these outcomes. Total duration of hospitalisation within the 




10  Discussion 
 
10.1 Chapter outline 
Having considered all findings from previous chapters in relation to existing research, this 
chapter aims to summarise the key findings in the context of the broader strengths and 
limitations of the thesis and consider how my findings fit into the wider context of care for 
individuals with serious mental illnesses. I discuss other possible implications and ideas for 






10.2 Summary of findings 
 
Overall, this thesis provides evidence that using linkages and electronic health records, it is 
possible to understand the physical health issues that are pertinent to the morbidity and 
mortality of individuals with SMI. The objectives of this thesis are described and discussed 
below.  
 
Objective 1- To describe the relative contributions of major disease groups to the gap in life 
expectancy between individuals with SMI and the general population. 
 
This analysis aimed to estimate contributions of specific causes of death to the gap between 
people with SMI and the general population. Natural causes accounted for 79.2% of lost life-
years in women with SMI and 78.6% in men. Deaths from circulatory disorders accounted 
for more life-years lost in women than men (22.0% versus 17.4%, respectively), as did 
deaths from cancer (8.1% versus 0%), but the contribution from respiratory disorders was 
lower in women than men (13.7% versus 16.5%). For women, cancer contributed more in 
those with non-affective than affective disorders, while suicide, respiratory and digestive 
disorders contributed more in those with affective disorders. In men, respiratory disorders 
contributed more in non-affective disorders. Other contributions were similar between 
gender and affective/non-affective groups. Loss of life expectancy in people with SMI was 




Objective 2- To describe the most common reasons for admission to non-psychiatric 
hospitals by individuals with SMI and what are the relative frequencies of these admissions 
compared to the general population. 
 
This analysis aimed to delineate frequencies of and causes for non-psychiatric hospital 
admissions in SMI and compare to general population in the same area. The commonest 
discharge diagnosis categories in the SMI cohort were urinary conditions, digestive 
conditions, unclassified symptoms, neoplasms, and respiratory conditions. Standardised 
admission ratios were raised for most major categories, except neoplasms for which there 
was a significantly lower risk in SMI compared to the general population. Hospitalisation 
risks were specifically higher for poisoning and external causes, injury, endocrine/metabolic 
conditions, haematological, neurological, dermatological, infectious and non-specific (‘Z-
code’) causes. The five commonest specific ICD-10 diagnoses at discharge were ‘chronic 
renal failure’ (N18), a non-specific code (Z04), ‘dental caries’ (K02), ‘other disorders of the 
urinary system’ (N39) and ‘pain in throat and chest’ (R07), all of which were higher than 
expected (standardised admission ratios ranging 1.57-6.66). A range of reasons for non-
psychiatric hospitalisation in SMI were thus apparent, with self-harm, self-neglect and/or 






Objective 3- As a proof of principle for ascertaining meaningful symptom profiles from 
routine mental health record text fields, to describe the prospective association between 
the number of recorded negative symptoms and mental healthcare outcomes (admission, 
duration of admission, and readmission) among individuals with schizophrenia. 
 
This analysis aimed to use NLP to develop a suite of language models to capture key 
symptoms of SMI from clinical text, to facilitate the secondary use of mental healthcare data 
in research. Using a Support Vector Machine learning method with an NLP tool, it was 
possible to successfully extract data on negative symptoms from the electronic mental 
health records of a large clinical sample of patients with schizophrenia. This approach 
enabled the use of data recorded as part of routine clinical care for analyses to investigate 
associations with adverse health outcomes. Negative symptoms of schizophrenia 
ascertained in this way were scaled, evaluated, and found to be associated with increased 
risk of psychiatric hospitalisation, longer duration of inpatient episodes, and higher risk of 





Objective 4- To describe the association with mortality and hospitalisation for each of six 
symptom dimensions (positive, negative, manic, disorganisation, catatonic and depressive) 
extracted from the clinical records of individuals with SMI.  
 
Having ascertained symptom mentions in the electronic clinical records of a large cohort of 
individuals with SMI, this analysis was carried out to assess its associations with subsequent 
all-cause mortality and hospitalisation. In a cohort of over 14,000 SMI cases, higher numbers 
of positive, negative and catatonic symptoms were associated with higher mortality. Higher 
numbers of non-mental healthcare hospital admissions were significantly associated with 
manic, catatonic and depressive symptom domains, but no associations were found with 





10.3 Strengths and limitations 
 
I have considered specific strengths and limitations in the chapters covering individual 
component analyses but will now consider some broader strengths and limitations which 
need to be borne in mind when interpreting thesis findings. 
 
The major strength of this PhD study is the novel methodology using electronic secondary 
mental health care data with linkages to mortality and hospitalisation data. CRIS is a unique 
resource which allows access to “real world” clinical data. Large studies have typically been 
carried out using information from registries and comparatively CRIS provides beyond this. 
The more recent advances to information ascertainment through natural language 
processing techniques meant that I could obtain information on an extensive list of 
symptoms which has not been included in previous studies on this topic. It also meant that I 
had larger sample sizes than conventional studies and more informative clinical notes as a 
data source compared with administrative data sources. 
 
An important limitation to note is that the primary purpose of an EHR is to record patient 
care; thus, rich and diverse contextual information is potentially available but it has not 
been recorded for research purposes and there may be inaccuracies, and factors influencing 
recording, which need to be borne in mind; in addition, clearly much of the information 
resource is embedded in free-text fields requiring extraction. Throughout this thesis, 
recognising that it is not collected under research standards, higher quality information was 
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sought by focusing on fields with higher clinical relevance and/or where there are higher 
incentives for accuracy. This, for example, was a key justification for developing multiple 
NLP algorithms for symptom profiling, as symptoms tend to be recorded for purely clinical 
reasons, whereas diagnostic codes represent fields which are compulsory and driven to 
some extent by management priorities, so may suffer in accuracy (particularly when it 
comes to updating diagnostic changes) as a consequence.  
 
Considering bias, confounding and chance- systematic error could have been introduced as 
a result of design or conduct of the study leading to an inaccurate estimate of the 
association between exposure and outcome. The data were obtained from historical cohorts 
as opposed to a retrospective study. However, the inclusion criteria for the individual 
analyses may have introduced selection bias. Some loss to follow up may have taken place 
but the impact is reduced by including two data sources with national coverage. ONS 
captured anyone who died in the UK and HES identified anyone who was admitted to any 
hospital across the whole of England. Loss due to migration from the UK is a possibility and 
must be noted for this study as the catchment area has relatively higher proportion of 
minority ethnic groups who were born outside the UK and who might therefore have been 
more likely to emigrate.  
 
Misclassification bias occurs when categorisation is not accurate with respect to exposure or 
outcome. Random misclassification is likely to underestimate an effect. However, a non-
random misclassification, where an exposure is dependent on the outcome or outcome is 
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dependent on the exposure, could over- or underestimate effects. More unwell individuals 
have more clinical documentation, where symptoms are more likely to be recorded. In 
essence, this describes a similar concept to that of confounding by indication where 
symptoms appear to be most comprehensively recorded in the most unwell patients. This 
study could not assess disease severity to able to differentiate presentations between more 
or less unwell individuals. However, the large sample size was at least able to include 
individuals receiving mental health services regardless of whether this involved inpatient or 
outpatient care, unlike the large number of hospitalisation-based registries cited in Chapter 
2. Also, there is less measurement bias at the point of clinical care as clinical staff entering 
information during clinical care are not aware of the research use of the data. At the stage 
of symptom applications development where training sets were developed and the clinical 
team were annotating individual symptoms, there is possibility of introducing a 
misclassification bias. This was handled with at least two team members conducting 
independent annotations and inter-rater agreement measured for each item. Also, while 
the annotator was aware the case notes were for an individual with SMI, they did not know 
the exact diagnosis or any other information other than the sentences on either side of the 
annotating word or phrase. 
 
Adjustments were made for key demographic factors and the large sample sizes allowed 
multivariable analyses. However, there were several variables that were not included in the 
analyses which I think would be useful to evaluate further, including individual lifestyle 
factors such as smoking, medication use as well as area-level factors such as deprivation. 
Also, the non-randomised design inevitably does not allow residual confounding to be 
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excluded. Prospective recording of data on the EHR meant that reverse causality is less 
likely. 
 
The large sample sizes assisted in considering the role of chance by providing small standard 
errors around estimates. However, it should be borne in mind that relatively small effects 
could therefore be identified as statistically significant, and clinical importance should not 
be assumed for all significant findings. Considering type 2 statistical error (i.e. the false 
rejection of the null hypothesis), multiple comparisons increase the risk of this and should 
be viewed with caution. For this reason, numbers of outcomes were minimised to those felt 
to be most clinically important (e.g. mortality, hospitalisation risk etc.) and exposures such 
as symptoms were grouped into dimensions rather than analysed individually, except for 
explicitly exploratory or confirmatory investigation.  
 
The generalisability of analyses must be noted as the findings clearly refer to individuals 
with SMI who had made contact with secondary mental health services within the specified 
time period. However, as the study is based in a secondary healthcare setting with near-
monopoly provision to a geographic catchment, it is unlikely to bias findings to a large 
extent as SMIs by nature are disorders where most cases will have received secondary care 
input (NICE 2014). SLaM itself serves an inner and outer urban catchment, so there may be 
limited generalisability to rural areas; furthermore, its academic status and some specialist 






10.4.1 Research implications 
 
This study built on innovative methodology using a comprehensive secondary mental health 
data source. As described in Chapter 2, large databases used for investigating, in this 
instance, mortality outcomes in SMI have tended to be limited by the data extracted from 
administrative resources (or else have involved original data collection but on much smaller 
samples). The primary purpose of the developments described was to improve the depth of 
information available on individuals with SMI from the EHR, as administrative information 
resources (including CRIS at its initial development in 2008) tend to contain little 
information beyond a diagnosis and basic demographic details. Until now, within mental 
health EHRs, symptom profiles have therefore been ‘invisible’ when it comes to deriving 
data for research, service development or clinical audit. Given that symptoms are key 
determinants of interventions received and outcomes experienced, this has been a major 
deficiency. Therefore, the methodology developed in this study at least opens up 
tools/techniques to use the large amounts of SMI symptomatology data contained within 
electronic health record systems, and provide new insight into the value of using SMI 
symptoms as predictors of a range of outcome measures. Further research is clearly 
required to capitalise on this resource – in particular, to clarify the best ways to group the 
>70 individual symptoms currently identifiable and their distributions (e.g. 
number/frequency of annotation points) in individual records. Another line of research and 
development might also include further improvements to define time periods for exposure 
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measures. This would enable the more effective capture of underlying constructs, as would 
the ability to estimate symptom severity and/or trajectory. 
 
The HES data linkage allowed a novel investigation of non-mental health hospitalisations for 
people with mental disorders, supplementing the extensive work on mortality outcomes 
reviewed in Chapter 2, and surprisingly representing one of the first investigations of its 
kind. Assuming that other linkages with mental healthcare datasets can be set up, the 
degree of replicability across sites and services would be an important next step for future 
research. For example, the specific association with hospitalisations related to sickle cell 
disease is likely to be related to the ethnic group profile in SLAM’s catchment and other 
catchments might have their own unique features. Of relevance, the CRIS system is now 
being deployed at three additional Trusts through the D-CRIS programme, and to a number 
of others through the UK-CRIS initiative, to significantly extend this research 
capability. Although HES linkages have not yet been set up at other sites, the work described 
here might in time be more widely re-evaluated in other mental health services, improving 
the precision of estimates and clarifying levels of between-site heterogeneity. 
 
Future studies could be usefully designed to include more extensive cohorts with 
adjustment for additional confounders. Higher capture rates of lifestyle-related factors (e.g. 
smoking, physical activity, diet etc.) might be achievable through novel data linkages or 
targeted supplementary data collection in targeted groups, as well as through further NLP 
development. This would help in the assessment the other key confounding or mediating 
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factors that might determine physical morbidity and mortality in SMI beyond symptom 
profiles – factors highlighted as deficiencies of previous research in Chapter 2 but which this 
thesis remained unable to address.  
 
Further to this, the developments to date on symptom ascertainment could also be more 
widely used within CRIS to address other study questions, addressing the broader question 
of whether symptom profiles and derived ‘phenotypes’ provide better predictive data than 
diagnostic categories. As discussed in Chapter 1, the relative utility of a dimensional rather 
than categorical classification of mental disorders has been an area of controversy for as 
long as psychiatric research and clinical practice have been in existence. On the one hand, 
genetic and imaging evidence has tended to support cross-diagnostic dimensions as more 
realistic ways to conceptualise psychopathology; on the other hand, clinical practice 
requires diagnoses for communicating complex symptom profiles. Ultimately the two 
approaches can only really be compared with respect to their predictive validity, but this has 
been challenging to date because of the lack of fine-grain detail across sufficient samples 
with sufficient representativeness. Symptoms recorded in EHR text fields remain a 
suboptimal reflection of individual subjective experiences; however, they do at least present 
a finer-grain measurement than diagnostic codes in administrative data resources, and large 
sample sizes might provide at least some opportunities for head-to-head comparisons.  
 
As described in Chapter 1, there are important recognised health inequalities experienced 
by people with SMI, and as described in Chapter 2, these remain relatively under-
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investigated in terms of causal pathways – e.g. characteristics of people with SMI who are 
most at risk, or adverse health states responsible for life expectancy differences. My findings 
in Chapters 6 and 7 suggest that there should be an increasing focus on identifying and 
evaluating appropriate models for delivering more effective care, particularly, to reduce the 
gap in life expectancy and reduce admissions for the conditions for which the standardised 
admission ratios were high. Although some of this involves the design and evaluation of 
novel interventions to improve physical health outcomes, there is also likely to be a need to 
develop further observational studies to help define at risk groups and pathways of 
causation. For example, findings in Chapter 9 suggest that symptom profiles are much 
stronger predictions of mental health outcomes compared to mortality or acute care 
hospitalisation, supporting the earlier findings for negative symptoms specifically, reported 
in Chapter 8. Therefore, there are still questions to be answered concerning whether people 
with SMI are simply at a generically high risk of adverse physical health outcomes or 
whether there are sub-groups at particularly high risk who might be more effectively 
targeted by future preventative interventions.  
 
10.4.2 Clinical and policy implications 
 
 
My literature review described in Chapter 2 concluded that there is consistent evidence that 
all-cause mortality for individuals with schizophrenia and bipolar disorder is higher than that 
observed in the general population. My study reported in Chapter 6 found that the gap in 
life expectancy was accounted for by a wide range of recorded causes of death, rather than 
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just one or two predominating ones, with moderate variation in the pattern of contribution 
by gender, and between people with affective and non-affective SMI diagnoses. When 
assessing the specific contribution from each grouped cause of death to life expectancy, it 
was difficult to identify a single group or two. On a similar vein, a range of reasons for non-
psychiatric hospitalisation was apparent in findings reported in Chapter 7, with self-harm, 
self-neglect and/or reduced healthcare access, and medically unexplained symptoms as 
potential underlying explanations. These findings on hospitalisation rates and causes of 
death support awareness-raising initiatives of physical conditions leading to early death and 
hospitalisation. Because this represents multiple physical-mental health interfaces, such 
awareness-raising needs to be multifaceted, directed to mental healthcare, physical 
healthcare and primary care, and to the range of professionals working in these sectors, as 
well as to policy makers. This may include packages of care to help improve lifestyle, diet 
and proper medication management.  
 
As described in this thesis, EHRs and routine data sources have enabled research utilising 
rich and diverse contextual information but have drawbacks in that the primary purpose of 
an EHR is to record patient care and not recorded for research purposes with inaccuracies, 
and factors influencing recordings. Considering future improvements in data feeding these 
platforms, its quality is clearly only as good as the information entered in the first place on 
the EHR. Imposed initiatives to improve data quality are likely to have limited traction with 
service staff; however, highlighting output from clinical records directly to clinical teams 
might in itself be educational and result in better quality of recording. This may be best 
focused at a team or individual level, for example through clinical dashboards, or 
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enhancements in the summary displays on EHR systems. As an example, any demonstration 
that symptom profiles have prognostic significance beyond and across diagnostic categories 
might justify the automated profiling of individuals real-time from their records, which 
might in turn promote the more accurate recording of symptoms through a virtuous circle. 
This is particularly relevant as symptom dimensions rated at presentation have shown to be 
better at predicting outcomes such as time to first remission than a categorical diagnosis 
(Ajnakina et al. 2018). Furthermore, diagnostic categories in Psychiatry have changed over 
the years based on both clinical and biological evidence. If a cross-diagnostic construct were 
to prove to have higher clinical utility than current diagnostic categories then there would 
be a reasonable argument to re-appraise traditional nomenclature.  
 
In Chapter 7, standardised admission ratios were raised for SMI with respect to most major 
disease categories (except neoplasms) with specifically higher hospitalisation risks for 
poisoning and external causes, injury, endocrine and metabolic conditions, haematological, 
neurological, dermatological, infectious and non- specific (‘Z-code’) causes. The five 
commonest specific ICD-10 diagnoses at discharge were ‘chronic renal failure’, a non-
specific code, ‘dental caries’, ‘other disorders of the urinary system’, and ‘pain in throat and 
chest’, all of which were higher than expected (SARs ranging 1.57–6.66). Focussed policy 
and interventions to minimise unnecessary non-psychiatric hospitalisation are required. 
Trials to identify appropriate interventions could be a next step, although it is likely that a 
complex and supportive strategy to assess and address contextual issues and limitations in 
patient capacity is required. This was most effective at reducing early hospital readmissions 
in mental healthcare (Lepping et al.,2015). Extrapolating findings from such studies to 
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physical health improvements and developing policy that introduces alternative models of 
working for all clinical staff caring for individuals with SMI could be considered. New models 
of care to enable optimum professional contact without the need for hospitalisation might 
include home visits and community based work; however, reductions in health inequalities 
would need to involve primary and emergency room care as well as mental healthcare 
support.  
 
Further work could usefully identify and disentangle substance use among individuals 
known to have SMI with aim to developing a robust national policy on how they can be 
managed in acute settings. As reported in Chapter 7, I found that admissions to general 
hospitals with a primary discharge diagnosis of a mental and behavioural disorder was 30-
fold higher for individuals with SMI. Based on the inclusion criteria for the study, these 
individuals were also known to have contact with their mental health services. A proportion 
of these admissions are likely to be due to alcohol and/or other substance use disorders 
which clearly needs to be more effectively highlighted in policy and practice.  
 
The use of resource-intensive hospital services where clear diagnoses were not found has 
commissioning implications for SMI care.  As reported in Chapter 7, I found that more 
individuals with SMI were assigned to “symptoms, signs and findings, not elsewhere 
classified- (R00-R99)” and “factors influencing health status and contact with health 
services- (Z00- Z99).  This might indicate inappropriate use of general hospital services due 
to lack of engagement with other sectors, such as primary care; however, it might also 
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indicate under-diagnosis. Both lack of engagement and under-diagnosis could result in 
higher risk of adverse outcomes and might be amenable to more assertive, engaging and 
accessible models of service delivery. The need for ongoing improvements to databases is 
one implication to improve the granularity of information on given hospitalisation episodes. 
Improving awareness among clerical staff who input data that feed into these databases is 
also key. Education of clinical staff might be another consideration as the coding process 
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Appendix Table 1: Performance of symptom information extraction applications for 
individual symptoms 
Symptoms Precision  Recall 
Abstract thinking 0.89 1.00 
Affect Instability 0.73 0.75 
Aggression 0.79 0.96 
Agitation 0.97 0.80 
Anergia 0.86 1.00 
Anhedonia 0.88 0.93 
Appetite 0.83 0.87 
Blunted Flat Affect 0.94 0.56 
Catatonic Syndrome 0.74 0.92 
Circumstantial Speech 0.88 0.95 
Coherence 0.80 0.90 
Concentration 0.88 0.85 
Delusion 0.90 1.00 
Derailment of Speech 0.88 0.95 
Disturbed Sleep 0.77 0.97 
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Symptoms Precision  Recall 
Echolalia 0.87 0.97 
Echopraxia 0.74 0.92 
Elation 0.83 1.00 
Elevated Mood 0.75 0.93 
Emotion Instability 0.70 0.83 
Foi 0.97 0.99 
Ftd 0.83 0.88 
Grandiosity 0.88 0.93 
Guilt 0.77 0.95 
Hallucination 0.95 0.97 
Helpless 0.84 0.99 
Hopeless 0.84 0.98 
Hostility 0.87 1.00 
Immobility 0.82 0.96 
Insomnia 0.88 0.93 
Irritability 0.82 0.98 
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Symptoms Precision  Recall 
Low Mood 0.84 0.83 
Mannerism 0.66 0.79 
Mdma 0.89 1.00 
Mood Instability 0.70 0.80 
Mutism 0.90 1.00 
Paranoia 0.90 1.00 
Persecution 0.92 0.99 
Perseverance 0.78 0.98 
Poor Motivation 0.93 0.77 
Posturing 0.83 0.95 
Poverty of Speech 0.92 0.97 
Poverty of Thought 0.92 0.97 
Pressurised Speech 0.77 0.90 
Psychomotor 0.83 0.80 
Social Withdrawal 0.79 0.88 
Stereotype 0.77 0.94 
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Symptoms Precision  Recall 
Stupor 0.79 0.87 
Tangential Speech 0.93 1.00 
Tremor 0.95 0.83 
Waxy Flexibility 0.87 0.87 




1. Developed GATE Symptoms Applications 
1. Anhedonia App 
Description 
Anhedonia means the inability to experience pleasure from activities usually found 
enjoyable. Application to identify patients who have experienced anhedonia. 
Classes produced: Positive, Negative and Unknown. 
Positive mentions were fairly self-explanatory – past or present symptoms included (X 
had been anhedonic, X has anhedonia etc.) 
Negative mentions again were self-explanatory (no anhedonia, no evidence of 
anhedonia, not anhedonic etc.) 
‘Unknown’ annotations included: i) used in a list, not applying to patient (e.g. typical 
symptoms include …); ii) uncertain (might have anhedonia, ?anhedonia, possible 
anhedonia); iii) not clearly present (monitor for anhedonia, anhedonia has improved); iv) 
listed as potential treatment side-effect; v) vague (‘she is not completely anhedonic’, 
‘appears almost anhedonic’) 
Search Terms: 
[Aa]nhedon* 
Precision and Recall 




2. Anergia App 
Description 
Application to extract occurrences of Anergia.  
Classes produced: Positive, Negative and Unknown. 
Positive mentions were fairly self-explanatory – past or present symptoms included 
(feeling of anergia etc.) 
Negative mentions again were self-explanatory (no anergia, no evidence of anergia, no 
feeling of anergia etc.) 
Search Terms 
[Aa]nergia 
Precision and Recall 
P=0.86, R=1.0 
 
3. Energy App 
Description: 
Application to extract occurrences of energy.  
Classes produced: Positive, Negative and Unknown. 
Positive mentions were fairly self-explanatory (full of energy etc.) 
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Negative mentions again were self-explanatory (no energy etc.) 
Search Terms 
[Ee]nergy 
Precision and Recall 
P=0.81, R=0.76 
 
4. Helpless App 
Description: 
Application to extract occurrences of helplessness. 
Classes produced: Positive, Negative and Unknown. 
Positive mentions were fairly self-explanatory (Ideas of helplessness secondary to her 
physical symptoms present ,  ideation Compounded by anxiety and a sense of 
helplessness, hopelessness etc.) 
Negative mentions again were self-explanatory (Denies uselessness or helplessness ,  No 
thoughts of hopelessness or helplessness etc.) 
Search Terms 
[Hh]elpless 





5. Hopeless App 
Description 
Application to extract occurrences of hopelessness.  
Classes produced: Positive, Negative and Unknown. 
Positive mentions were fairly self-explanatory (feeling very low and hopeless , says feels 
hopeless   etc.) 
Negative mentions again were self-explanatory (Denies hopelessness ,  No thoughts of 
hopelessness or helplessness etc.) 
Unknown mentions again were self-explanatory (unable to say if he feels hopeless etc) 
Search Terms 
[Hh]opeles 
Precision and Recall 
P=0.84, R=0.98 
 
6. Psychomotor App 
Description 
Application to extract occurrences of psychomotor. 
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Classes produced: Positive and Negative. 
Positive mentions were fairly self-explanatory (few spontaneous movements- 
psychomotor retardation etc.) 
Negative mentions again were self-explanatory (No psychomotor retardation etc.) 
Unknown mentions again were self-explanatory (unable to say if he feels hopeless etc) 
Search Terms 
[Pp]sychomotor 
Precision and Recall 
P=0.83, P=0.80 
 
7. Tearful App 
Description 
Application to extract occurrences of tearful.  
Classes produced: Positive, Negative and Unknown.  
Positive annotations include: appeared tearful; was tearful (including was XX and tearful; 
was tearful and YY); became tearful; moments of tearfulness; a bit tearful.  
Negative annotations include: not tearful; no tearfulness; denies feeling tearful; no 
tearful episodes.  
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‘Unknown’ annotations were mostly ambiguous statements (e.g. less tearful; couldn’t 
remember being tearful) and statements applying to another person (e.g. mother was 
tearful) or a person who was not clearly enough the patient. 
Search Terms: 
[Tt]earful 
Precision and Recall: 
P=0.91, R=0.99 
 
8. Weight loss App 
Description: 
Application to extract occurrences of weight loss.  
Classes produced: Positive, Negative and Unknown. 
Positive annotations include: appeared tearful; was tearful (Significant weight loss, 
pleased with her weight loss).  
Negative annotations include: no weightloss;  denies weightloss.  
Unknown annotations include: To maintain adequate dietary intake and avoid weight 
loss, The latter reduced in line with weight loss. 
Search Terms: 
[Ww]eight  [0 to 2 words in between] [Ll]oss 
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[Ll]oss [0-2 words in between] [Ww]eight 
Precision and Recall: 
P=0.75, R=0.97 
 
9. Worthless App 
Description: 
Application to extract occurrences of worthlessness.  
Classes produced: Positive, Negative and Unknown. 
Positive annotations include: appeared tearful; was tearful (feeling worthless, feels 
hopeless and worthless).  
Negative annotations include: no worthlessness;  denies worthlessness etc. 
Unknown annotations include:  his father had told him that he was worthless, would call 
them worthless etc 
Search Terms: 
[Ww]orthless 
Precision and Recall: 




10. Appetite App 
Description: 
Application to extract symptoms of Appetite. Appetite is one of the symptoms of 
depression. One can experience lack of appetite (more common) or over-eating.  
Classes produced: Positive, Negative and Unknown.  
Positive annotations applied to adjectives implying a good or normal appetite: fine; OK; 
reasonable; alright; preserved; satisfactory. Often described in combination with other 
symptoms (e.g. sleep and appetite normal; sleep and appetite: both preserved).  
Negative annotations applied to adjectives implying a poor/declining appetite: loss of; 
reduced; decrease in; not so good; diminished; lack of; not great. Also often in 
combination with other symptoms (poor sleep and appetite; loss of energy and 
appetite).  
‘Unknown’ annotations include insufficiently informative adjectives: not changed; varies; 
increased; improving. Also hypothetical mentions, as a potential side effect, as an early 
warning sign, as a description of a diagnosis (rather than patient experience), describing 
a relative rather than the patient, ‘appetite suppressants’. 
From the text – we’d like to extract mentions of normal/good or reduced/poor appetite, 
rest of the appetite instances are irrelevant (hence un-highlighted).  
Normal appetite and reduced appetite will encapsulate the following descriptive terms: 
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Good or normal 
appetite 
Poor or reduced 
appetite 
Alright Absent 
Eats well Decreasing 
Eating well Deficit 
Excellent Diminished 
Fine  
Fair Gone down 
Good Loss of  




Not too bad Lacking 
No problem(s) Lack of 
No concern(s) Lacks  
Not a concern Less 




OK(ay) No interest 
Preserved Not as good 




















11. Suicide App 
Description: 
A non-fatal, self- directed potentially injurious behaviour with intent to die as a result of 
the behaviour; might not result in injury. 
Definition of Suicide Attempt from ICD 10 online (Intentional self-harm: X60 – X84) 
X60 - Intentional self-poisoning by and exposure to non-opioid analgesics, antipyretics 
and anti-rheumatics 
X61 - Intentional self-poisoning by and exposure to antiepileptic, sedative-hypnotic, anti 
parkinsonism and psychotropic drugs, not elsewhere classified  
X62 - Intentional self-poisoning by and exposure to narcotics and psychodysleptics 
[hallucinogens], not elsewhere classified 
X63 - Intentional self-poisoning by and exposure to other drugs acting on the autonomic 
nervous system 
X64 - Intentional self-poisoning by and exposure to other and unspecified drugs, 
medicaments and biological substances 
X65 - Intentional self-poisoning by and exposure to alcohol 
X66 - Intentional self-poisoning by and exposure to organic solvents and halogenated 
hydrocarbons and their vapours 
X67 - Intentional self-poisoning by and exposure to other gases and vapours 
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X68 - Intentional self-poisoning by and exposure to pesticides 
X69 - Intentional self-poisoning by and exposure to other and unspecified chemicals and 
noxious substances 
X70 - Intentional self-harm by hanging, strangulation and suffocation 
X71 - Intentional self-harm by drowning and submersion 
X72 - Intentional self-harm by handgun discharge 
X73 - Intentional self-harm by rifle, shotgun and larger firearm discharge 
X74 - Intentional self-harm by other and unspecified firearm discharge 
X75 - Intentional self-harm by explosive material 
X76 - Intentional self-harm by smoke, fire and flame 
X77 - Intentional self-harm by steam, hot vapours and hot objects 
X78 - Intentional self-harm by sharp object 
X79 - Intentional self-harm by blunt object 
X80 - Intentional self-harm by jumping from a high place 
X81 - Intentional self-harm by jumping or lying before moving object 
X82 - Intentional self-harm by crashing of motor vehicle 
X83 - Intentional self-harm by other specified means 




asphyxiat*, to shoot herself,  to shoot himself, to stab herself, to stab himself, after a 
suicide attempt, another attempt to end [0 to 1 word in between] life, another suicidal 
attempt, another suicide attempt, attempt on her life, attempt on his life, attempt to 
commit suicide, attempt to end her life, attempt to end his life, attempt to kill herself, 
attempt to kill himself, attempt to suicide, attempt to take her life, attempt to take his 
life, attempted to commit suicide, attempted to end her life, attempted to end his life, 
attempted to kill herself, attempted to kill himself, attempted to take her life, attempted 
to take his life, attempts [1 to 3 words in between] suicide, attempts [0 to 2 words in 
between] suicide, attempts suicide, depression with suicide attempt, E850, 
E851,E852,E853,E854,E855, E856, 
E857,E858,E950,E951,E952,E953,E954,E955,E956,E957,E958,E959,E980,E981,E982,E983
,E984,E985,E986, E987,E988,E989,failed suicidal attempt, failed suicide attempt, first 
attempt at her life, first attempt at his life, following a suicide attempt, following her 
suicidal attempt, following her suicide attempt, following his suicidal attempt, following 
his suicide attempt, he jumped off a bridge, his suicide attempt was not successful, 
history of suicide attempt, in an attempt to kill herself, in an attempt to kill himself, 
leapt in front of motor, leapt in front of moving, leapt in front of traffic, leapt in front of 
vehicle, next time he attempts suicide, next time she attempts suicide, previous [1 word 
in between] attempt by, previous [1 word in between ] attempt to, previous [1 word in 
between ] attempt to take [1 word in between ] life, previous [1 word in between ] 
attempt to take life, previous [1 word in between ] attempt by, previous [1 word in 
between ] attempt to, previous [1 word in between ] attempt to take [1 word in 
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between ]  life, previous [1 word in between ]attempt to take [1 word in between ] life, 
previous [1 word in between ] attempt to take life, previous attempt by, previous 
attempt to, previous attempt to take [1 word in between ]  life, previous attempt to take 
[1 word in between ] life, previous attempt to take life, she jumped off a bridge, shot 
herself, shot himself, stabbed herself, stabbed himself, suicidal [1 to 3 words  in 
between ]attempt, suicidal [1-3 words in between ]attempt, suicidal [1 to 2 words  in 
between ] attempt, suicidal [1to 2 words in between ] attempt, suicidal  [1 word in 
between ] attempt, suicidal [1 to 3  words in between ]attempt, suicidal [1 to 3 words in 
between ] attempt, suicidal [1 to 3 words in between] attempt, suicidal attempt due to 
depression, suicidal attempt was not successful, suicidal behaviour, suicidal gesture, 
suicide [1 to 3 words in between]  attempt, suicide [1 to 2 words in between]  attempt, 
suicide [1 to 3 words in between]  attempt, suicide [1 to 2 words in between]  attempt, 
suicide [1 word in between]  attempt, suicide [1 to 3 words in between]  attempt, 
suicide [1 to 3 words in between]  attempt, suicide [1 to 2 words in between]  attempt, 
suicide [0 to 2 words in between]  attempt,  suicide attempt age, suicide attempt due to 
depression, suicide attempt failed, suicide attempt was not successful, suicide 
behaviour, suicide behaviour, suicide gesture, took firearm to self, took gun to self, took 
handgun to self, took knife to self, took rifle to self, tried to end her life, tried to end his 
life, tried to kill herself, tried to kill himself, tried to take her life, tried to take his life, 
walked in front of cars, walked in front of motor, walked in front of moving, walked in 
front of traffic, walked in front of vehicles, X60, X61, X62, X63, X64, X65, X66, X67, X68, 
X69, X70, X71, X72, X73, X74, X75, X76, X77, X78, X79, X80, X81, X82, X83, X84, Y87.0, 
Z72.8, Z91.5, crash*, cutting her wrist, cutting his wrist, drown*, firearm*, handgun, 
hang*, impulsive O/d, ingested*, jumped off, overdose, overdosing, poison*, putting 
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plastic bag over her head, putting plastic bag over his head, stabbing himself, stabbing 
herself,  attempted to hang himself,  attempted to hang herself, started to cut, starting 
to cut, strangl*, strangul*, submerg*, suffocate herself, suffocate himself, suffocated 
herself, suffocated himself, taken an O/D, taken an OD, took [8 - 100] tablets, took an 
OD, took O/D, tried to cut, walked into traffic, wrist cutting 
Important Notes Before Coding 
Any mention where the patient has undergone/experience intentional harm to self 
(physical harmful action directed at self) should be counted as suicide attempt. Literal 
mentions of "self-harm" are ignored because of danger of over-including DSH events 
which are different to a suicide attempt. 
Classification/ Coding Rules 
Rules followed when coding Suicide Attempt in CRIS Notes: 
Code Suicide attempt as positive if it meets the description of a Suicide attempt (See 
“Definition of  a Suicide Attempt” above) 
Code Suicide attempt as negative if patient or clinical staff are denying or negating the 
suicide attempt (e.g. “she never attempted suicide”) 
Code Suicide attempt as negative if patient or clinical staff are referring to family 
member who attempted suicide (e.g. “mum attempted suicide”) 
Code Suicide attempt as negative where mention of suicide attempt is irrelevant (e.g. 
“in theory suicide attempts are harsh”) 
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Code Suicide attempt as negative where mention of suicide attempt is confusing or 
uncomprehensive 
Coding Suicide attempt as negative where mention of suicide attempt a literal mention 
of "self-harm" 
Precision and Recall: 
P=0.86, R=0.97 
 
12. Abstract Thinking App 
Description: 
Application to extract occurences of concrete thinking.  
Classes produced: Positive, Negative and Unknown.  
Positive annotations includes: Occurrences of Concrete thinking or concrete cognition. 
Unknown indicates- Concrete answers about one particular area. 
Negative annotations includes:  no evidence of concrete thinking. 
Search Terms: 
[Cc]oncrete 
Precision and Recall: 
P=0.89, R=0.60 
Comments/ Coding Rules: 
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Very few occurrences of the negative class (e.g. No evidence of concrete thinking) 
Concrete thinking or concrete cognition is the main positive occurrences. 
Concrete answers about one particular area classed as ‘Unknown’ 
 
13. Apathy App 
Description: 
Application to extract the presence of apathy, developed as part of the Negative 
Symptoms of Schizophrenia project. 
Classes produced: Positive, Negative and Unknown.   
Positive mentions include any indication that apathy was being reported as a symptom: 
e.g. continues to demonstrate A; symptoms include A; he is withdrawn, attributable to 
A; his apathy … ; some degree of A noted; presentation with A; his report of A; given 
patient’s level of A. Most apathy statements were found to be accompanied by ‘negative 
symptoms’ (i.e. rather than depressive).  
Very few negative mentions found. Usual statements (denied A; no evidence of A etc.) 
‘Unknown’ annotations include: apathy mentioned as a hypothetical cause of something 
else (e.g. inactivity) rather than described as being present; apathy mentioned as a 
possibility in the future (e.g. may develop A), or as a possible side effect of medication 
(rather than actually present), or as an early warning sign. Also *apathy* found in quite 





Precision and Recall: 
P=0.86, R=1.0 
 
14. Circumstantial App 
Description: 
Application to extract occurrences where circumstantiality is apparent. 
Classes produced: Positive, Negative and Unknown. 
Positive mentions include: Signs of over inclusiveness and circumstantially, Loose 
associations and circumstantiality, circumstantial in nature etc. 
Negative mentions include: No signs of Circumstantially, no evidence of circumstantial. 









15. Delusion App 
Description: 
Application to extract occurrences where delusions are apparent.  
Classes produced: Positive, Negative and Unknown. 
Positive mentions include:  paranoid delusions; continued to express delusional ideas of 
the nature etc.  
Negative mentions include: No delusion, denied delusion etc. 
Unknown mentions include: Present or Absent of Delusion is not clear. 
Search Terms: 
[Dd]elusion 
Precision and Recall: 
P=0.90, R=1.0 
 
16. Disturbed Sleep App 
Description: 
Application to extract the occurrences of disturbed sleep.  
Classes produced: Positive, Negative and Unknown.  
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Positive mentions include the following sorts of phrases: complains of poor sleep, poor 
sleep, sleep disturbed, sleep difficulty, sleeping poorly, not sleeping very well, cannot 
sleep, sleep pattern poor, difficulties with sleep 
Negative mentions include the following sorts of phrases: no sleep disturbance, sleeping 
without problems, no significant problems with sleep, sleep and [appetite] undisturbed, 
sleeping well, denied [xxx] and sleep disturbance.  
‘Unknown’ annotations include the following: call [nurse] if sleep disturbance, sleeping 
tablets, hoping to sleep, encourage to sleep, medication to help sleep, has been asleep 
all day, less disturbed sleep today, sleep disturbance as an early warning sign, sleeping 
habits present no problem, xxx might lead to sleep problems, settled down to sleep. 
Search Terms: 
Not sleep, sleep not, poor [0-5 words in between] sleep, sleep poor, sleep [0-5 words in 
between] poor, sleep [0-5] interrupt, interrupt [0-5 words in between] sleep,  disturb [0-
5 words in between] sleep, sleep [0-5 words in between] disturb, inadequate [0-5 words 
in between] sleep, sleep [0-5 words in between] inadequate, disorder [0-5 words in 
between]sleep, sleep [0-5 words in between] disorder, prevent [0-5 words in between] 
sleep,  sleep [0-5 words in between] prevent, stop [0-5 words in between] sleep, sleep 
[0-5 words in between] stop, sleep [0-5 words in between] problem, problem [0-5 words 
in between] sleep 





17. Insomnia App 
Description: 
Application to extract the occurrence of Insomnia.  
Classes produced - Positive, Negative and Unknown.  
Positive mentions included any insomnia described (including initial insomnia, middle 
insomnia), any assumed application to the patient - 'the insomnia', complaining of 
insomnia, taking X for insomnia, contributes to her insomnia, problems with insomnia, 
this has resulted in insomnia, this will address his insomnia. Negative mentions again 
were self-explanatory (no anhedonia, no evidence of anhedonia, not anhedonic etc.) 
‘Unknown’ annotations included: i) used in a list, not applying to patient (e.g. typical 
symptoms include …); ii) uncertain (might have anhedonia, ?anhedonia, possible 
anhedonia); iii) not clearly present (monitor for anhedonia, anhedonia has improved); iv) 
listed as potential treatment side-effect; v) vague (‘she is not completely anhedonic’, 
‘appears almost anhedonic’) 
Search Terms: 
[Ii]nsom* 





18. Irritability App 
Description: 
Application to extract the occurrence of Irritability.  
Classes produced - Positive, Negative and Unknown.  
Positive mentions included both observed and self-reported/subjective irritability, ‘can 
be irritable’, ‘became irritable’, ‘appeared irritable’, ‘complained of feeling irritable’. 
Negative mentions included no evidence of, no longer, no sign of (again, both observed 
and subjective) 
‘Unknown’ annotations included unclear statements, irritable bowel syndrome, 
‘becomes irritable when unwell’, early warning sign, [relative] gets irritable, listed as 
potential side effect / withdrawal symptom, ‘can be irritable if …’ [NB some ambiguity 




Precision and Recall: 
P=0.82, R=0.98 
 




Application to establish the level of motivation, developed as part of the Negative 
Symptoms of Schizophrenia project.  
Classes produced - Positive, Negative and Unknown.   
Positive annotations applied to any statement describing motivation as poor or 
diminished: lack of; lacking in; does not have the M to …; finds it difficult to M herself; 
poor M; is not motivated to …; a motivation; zero motivation; unmotivated; reduced M.  
Negative annotations applied to any statement describing motivation as good or normal: 
denies difficulties with M; good M; appears motivated to …; highly motivated.  
No ‘unknown’ annotations. NB annotations above were applied regardless of what the 
motivation was focused on (i.e. including both general statements of good/poor 
motivation, and also task-specific statements of motivation to do XX or YY) 
Search Terms: 
[Mm]otivat 
Precision and Recall: 
P=0.93, R=0.77 
 




Application to extract whether poverty of thought is present.  
Classes produced: Positive, Negative and Unknown. 
Positive mentions include: poverty of thought was very striking, evidence of poverty of 
thought etc. 
Negative mentions include: no poverty of thought, no evidence of poverty of thought 
etc. 
Unknown mentions include:  Present or Absent of Poverty of thought is not clear. 
Search Terms: 
[Pp]overt  [Oo]f  [Tt]hough 
Precision and Recall: 
P=0.92, R=0.97 
 
21. Aggression App 
Description: 
Application to identify mentions of aggression. 
Classes produced: Positive, Negative and Unknown. 
Positive mentions include: Reported to be quite aggressive towards …,  Violence and 




Negative mentions include: no aggression, no evidence of aggression etc. 
Unknown mentions include: annotations included unclear statements.  
Search Terms: 
[Aa]ggress 
Precision and Recall: 
P=0.79, R=0.96 
 
22. Agitation App 
Description: 
Application to identify mentions of agitation. 
Classes produced: Positive, Negative, and Unknown. 
Positive mentions include: very agitated at present, he was agitated, He was initially 
calm but then became agitated and started staring and pointing at me towards.. etc. 
Negative mentions include: did not seem distracted or agitated, not agitated, no 
evidence of agitation.  





Precision and Recall: 
P=0.79, R=0.96 
 
23. Arousal App 
Description: 
Application to identify mentions of arousal. 
Classes produced: Positive, Negative and Unknown. 
Positive mentions include: became irritable and aroused on occasion, ZZZZZ  became 
very aroused when talking.., increasingly aroused and hostile towards staff etc. 
Negative mentions include: denies arousal at the hostel, he is not currently aroused or 
agitated etc. 
Unknown mentions include: annotations include unclear statement. 
Search Terms: 
[Aa]rous* 
Precision and Recall: 
P=0.87, R=1.0 
 




Application to extract the presence of Blunted Flat Affect. 
Classes produced: Positive and Negative. 
Positive annotations include: His affect remains very blunted,  Objectively flattened 
affect, State   ZZZZZ  continues to appear flat in affect etc. 
Negative annotations include: incongruent affect, Stable affect etc. 
Search Terms: 
[Aa]ffect 
[Bb]lunt [0 to 2 words in between] [Aa]ffect 
[Ff]lat [0 to 2 words in between] [Aa]ffect 
[Rr]estrict [ 0 to 2 words in between [Aa]ffect 
[Aa]ffect [0 to 2 words in between] [Bb]lunt 
[Aa]ffect [0 to 2 words in between] [Ff]lat 
[Aa]ffect [0 to 2 words in between] [Rr]estrict 
Precision and Recall: 
P=0.94, R = 0.56 
 




Application to extract occurrences where catalepsy is apparent. 
Classes produced: Positive, Negative and Unknown. 
Positive annotations include: to long-standing narcolepsy and catalepsy, Of note, today 
he presented catalepsia etc. 
Negative annotations include: No catalepsy, no evidence of catalepsia etc. 
Unknown annotations include: annotations include unclear statements. 
Search Terms: 
[Cc]atalep* 
Precision and Recall: 
P=0.74, R=0.92 
 
26. Echolalia App 
Description: 
Application to extract occurrences where echolalia is apparent. 
Classes produced: Positive, Negative and Unknown. 
Positive annotations include: No neologisms, but repeated what I said almost like 
echolalis; intermittent echolalia etc. 
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Negative annotations include: no echolalia, no evidence of echolalia, cannot remember 
any echolalia or stereotyped utterances etc. 
Unknown annotations include:  annotations include unclear statements.  
Search Terms: 
[Ee]chola* 
Precision and Recall: 
P=0.87, R=0.97 
 
27. Echopraxia App 
Description: 
Application to extract occurrences where echopraxia is apparent. 
Classes produced: Positive, Negative and Unknown. 
Positive annotations include: displayed a lot of echolalia and echopraxia, some of which 
may be triggers for  ZZZZZ 's echopraxia etc 
Negative annotations include: He did not elicit any echolalia, echopraxia or coprolalia, 
There were no repetitive behaviours, echolalia, echopraxia etc. 
Unknown annotations include: annotations include unclear statements such as Mrs  
ZZZZZ  to review her mimicry behaviours with a view to providing another opinion 
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regarding whether they are best understood as tics (echopraxia), or whether they may 
be compulsive rituals 
Search Terms:  
[Ee]chopra* 
Precision and Recall: 
P=0.74, R=0.92 
 
28. Immobility  App 
Description: 
Application to extract occurrences where immobility is apparent. 
Classes produced: Positive, Negative and Unknown. 
Positive annotations include: on occasions she feels miserable and low due to her 
immobility, Recent immobility is a sudden change over the last week or so etc. 
Negative annotations include: immobile swelling approx 5cm above ankle on anterior 
shin, no immobility etc. 
Unknown annotations include: annotations include unclear statements such as to have 





Precision and Recall: 
P=0.82, R=0.96 
 
29. Mannerism  App 
Description: 
Application to extract occurrences where mannerism is apparent. 
Classes produced: Positive, Negative and Unknown. 
Positive annotations include: covering his face with a scarf, laughing inappropriately, and 
talking to himself, prating, and exhibiting frequent mannerisms, the episodes/repetitive 
mannerisms could be attributed to excitement and an attention seeking component etc .  
Negative annotations include: Somewhat dramatic in his mannerisms, using hand 
gestures to emphasise his speech, no mannerisms apart from moving his mouth etc. 
Unknown annotations include: annotations include unclear statements. 
Search Terms: 
[Mm]annerism 
Precision and Recall: 
P=0.66, R=0.79 
 




Application to extract occurrences where perseverance is apparent. 
Classes produced: Positive, Negative and Unknown. 
Positive annotations include: which might manifest themselves in poor organisation 
skills and a tendency to  perseverate; Thought: Contents - perseverates re 
hospitalisation in … etc 
Negative annotations include: no evidence of any flights of ideas, perseveration or 
circumstantialities noted; indicated that she was happy to persevere with her current 
regime etc 
Unknown annotations include: annotations include unclear statements. 
Search Terms: 
[Pp]ersev* 
Precision and Recall: 
P=0.78, R=0.98 
 
31. Posturing App 
Description: 
Application to extract occurrences where posturing is apparent. 
Classes produced: Positive, Negative and Unknown. 
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Positive annotations include: he remained in an immobile posture, Stillposturing in the 
corridor  or sitting in a dark interview room etc.  
Negative annotations include: No abnormal movement or posture, He maintains an 
aggresive posture while he paces the unit etc. 
Unknown annotations include: annotations include unclear statements such as Her 
posture changed and she looked quite tearful etc. 
Search Terms: 
[Pp]ostur 
Precision and Recall: 
P=0.83, R=0.95 
 
32. Rigid App 
Description: 
Application to extract occurrences where rigidity is apparent. 
Classes produced: Positive, Negative and Unknown. 
Positive annotations include: he did have some rigidity, rigid body movements etc.  
Negative annotations include: No rigidity noted, No rigidity in all four limbs etc. 
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Unknown annotations include: annotations include unclear statements such as He 
stated that  rigid time slot would not be suitable, Her impression impression was a 
damaged man with rigid patterns of self-sabotage etc. 
Search Terms: 
[Rr]igid 
Precision and Recall: 
P=0.82, R=0.73 
 
33. Stereotype App 
Description: 
Application to extract occurrences where stereotype is apparent. 
Classes produced: Positive, Negative and Unknown. 
Positive annotations include: he developed catatonic features - mannerisms and 
stereotypes; unable to sit still during interview with stereotypic and purposeless actions 
etc.  
Negative annotations include: no stereotypic behaviour, no evidence of stereotype etc. 
Unknown annotations include: annotations include unclear statements such as  he 





Precision and Recall: 
P=0.77, R=0.94 
 
34. Stupor App 
Description: 
Application to extract occurrences where stupor is apparent. 
Classes produced: Positive, Negative and Unknown. 
Positive annotations include: Admitted with depressive stupor, Tonight  ZZZZZ  
presented in a psychotic stupor etc. 
Negative annotations include: not in the state of stupor /confusional state, not 
suggestive of depressive stupor etc. 
Unknown annotations include: annotations include unclear statements such as On a few 









35. Waxy Flexibility App 
Description: 
Waxy flexibility is a psychomotor symptom of catatonia as associated with 
schizophrenia, bipolar disorder, or other mental disorders which leads to a decreased 
response to stimuli and a tendency to remain in an immobile posture. 
Application to extract occurrence where waxy flexibility is apparent. 
Classes produced: Positive, Negative and Unknown. 
Positive annotations include: she presents as catatonic with waxy flexibility, exhibiting 
waxy flexibility etc. 
Negative annotations include: His right pre-tibial region was swollen and waxy and 
slightly pink, no waxy flexibility etc. 
Unknown annotations include: annotations include unclear statements. 
Search Terms: 
[Ww]axy 
Precision and Recall: 
P=0.87, R=0.87 
 




Application to extract occurrences where circumstantial is apparent. 
Classes produced: Positive, Negative and Unknown. 
Positive annotations include: loose associations a loss of goal, overinclusiveness and 
circumstantially; He had thought derailment and circumstantially etc. 
Negative annotations include: The five Risk items (R) are concerned with forecasting the 
future social, living and treatment circumstances etc. 
Unknown annotations include: annotations include unclear statements. 
Search Terms: 
[Cc] ircumstan* 
Precision and Recall: 
P=0.88, R=0.95 
 
37. Coherence App 
Description: 
Application to extract occurrences where coherence is apparent. 
Classes produced: Positive, Negative and Unknown. 
Positive annotations include: he was rather incoherent in his speech , At the start of the 
interview his talk was incoherent etc.  
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Negative annotations include: he could not hold a coherent conversation, she was 
worried about him as he was sounding confused and incoherent etc. 
Unknown annotations include: annotations include unclear statements. 
Search Terms: 
[Cc] ircumstan* 
Precision and Recall: 
P=0.80, R=0.90 
 
38. Derailment of Speech App 
Description: 
Application to extract occurrences where derailment of speech is present. 
Classes produced: Positive, Negative and Unknown. 
Positive annotations include: he derailed frequently, There was evidence of flight of 
ideas and thought derailment in his language etc. 
Negative annotations include: The thought stream is normal as he uses sentences in 
consequences, with no derailment, Erratic compliance can further derail her stability etc. 





Precision and Recall: 
P=0.85, R=1.0 
 
39. Elation App 
Description: 
Application to extract occurrences where elation is apparent. 
Classes produced: Positive, Negative and Unknown. 
Positive annotations include: mildly elated in mood, elated in mood on return from 
leave, She appeared elated and aroused etc.  
Negative annotations include: ZZZZZ  was coherant and more optimistic/apirational than 
elated throughout the conversation, no elated behaviour etc. 
Unknown annotations include: annotations include unclear statements such as To others 
- no history of harm to others but in his elated state there is a risk of accidental harm to 
others as is pushing boundaries etc. 
Search Terms: 
[Ee]lat* 





40. Elevated Mood App 
Description: 
Application to extract occurrences where elevated is apparent. 
Classes produced: Positive, Negative and Unknown. 
Positive annotations include: ZZZZZ 's paranoia and elevated mood have been resulting 
in conflict with others on the unit;  Elevated mood, lability. Self medication with drugs;  
Negative annotations include: No overt evidence of mood elevation; No period of 
elevated mood/irritability etc.  
Unknown annotations include: annotations include unclear statements such as He was 
visited by his girlfriend and that elevated his mood etc. 
Search Terms: 
[Mm]ood 
Precision and Recall: 
P=0.75, R=0.93 
 
41. Emotional Withdraw App 
Description: 
Application to extract occurrences of emotional withdrawal, developed as part of the 
Negative Symptoms of Schizophrenia project. 
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Classes produced: Positive, Negative and Unknown. 
Positive annotations include: Her mother described has becoming withdrawn, not 
communicating; . Sabri was visible on the ward appears withdrawn etc.  
Negative annotations include: He was not withdrawn; He was not observed to be sad or 
withdrawn during the assessment etc. 
Unknown annotations include: annotations include unclear statements. 
Search Terms: 
[Ww]ithdraw 
Precision and Recall: 
P=0.75, R=0.93 
 
42. Flight of Idea App (foi) 
Description: 
Application to extract occurrences where flight of ideas is apparent. 
Classes produced: Positive, Negative and Unknown. 
Positive annotations include: Mrs  ZZZZZ  was very elated with by marked flights of ideas; 
marked pressure of speech associated with flights of ideas etc. 
Negative annotations include: no evidence of flight of ideas, no flight of idea etc. 




[Ff]light [Oo]f [Ii]dea 
Precision and Recall: 
P=0.97, R=0.99 
 
43. Formal thought disorder(ftd)  
Description: 
Application to extract occurrences where formal thought disorder is apparent. 
Classes produced: Positive, Negative and Unknown. 
Positive annotations include: deteriorating into a more thought disordered state with 
outbursts of aggression; There was always a degree thought disorder etc. 
Negative annotations include: Thoughts: No FTD; No signs of FTD. 
Unknown annotations include: annotations include unclear statements. 
Search Terms: 
[Ff][Tt][Dd] 
[Ff]ormal [Tt]ought [Dd]isorder 





44. Grandiosity App 
Description: 
Application to extract occurrences where grandiosity is apparent. 
Classes produced: Positive, Negative and Unknown. 
Positive annotations include: ZZZZZ  was wearing slippers and was animated  elated and 
grandiose, few grandiose statements regarding having been 'brought up with royalty' 
etc. 
Negative annotations include: No evidence of grandiose of delusions in the content of 
his speech,  No evidence of grandiose ideas etc. 
Unknown annotations include: annotations include unclear statements. 
Search Terms: 
[Gg]randios 
Precision and Recall: 
P=0.88, R=0.93 
 
45. Hallucination App 
Description: 
Application to extract occurrences where hallucination is apparent. 
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Classes produced: Positive, Negative and Unknown. 
Positive annotations include: recalled experiencing auditory hallucinations, visual 
distortions and auditory hallucinations etc. 
Negative annotations include: No evidence of responding to any hallucinations or 
delusions, Not objectively hallucinated etc. 
Unknown annotations include: annotations include unclear statements. 
Search Terms: 
[Hh]allucinat* 
[Aa]udit [ 0 to 3 words in between] [Hh]allucinat* 
[Vv]isual [ 0 to 3 words in between] [Hh]allucinat* 
[Oo]lfact [ 0 to 3 words in between] [Hh]allucinat* 
[Tt]actil [0 to 3 words in between] [Hh]allucinat* 
[Tt]hird person [0 to 3 words in between] [Hh]allucinat* 
[Ff]irst person [ 0 to 3 words in between] [Hh]allucinat* 
3rd person [0 to 3 words in between] [Hh]allucinat* 
1st person [ 0 to 3 words in between] [Hh]allucinat* 
[Hh]allucinat* [0 to 3 words in between] [Aa]udit 
[Hh]allucinat* [0 to to 3 words in between] [Vv]isual 
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[Hh]allucinat* [0 to 3 words in between] [Oo]lfact 
[Hh]allucinat* [0 to 3 words in between] [Tt]actil 
[Hh]allucinat* [ 0 to 3 words in between] [Tt]hird person 
[Hh]allucinat* [0 to 3 words in between] [Ff]irst person 
[Hh]allucinat* [ 0 to 3 words in between] [3rd person] 
[Hh]allucinat* [0 to 3 words in between [1st person] 
Precision and Recall: 
P=95, R=0.97 
 
46. Hostility App 
Description: 
Application to extract occurrences where hostility is apparent. 
Classes produced: Positive, Negative and Unknown. 
Positive annotations include: increased hostility and paranoia, she presented as hostile 
to the nurses etc. 
Negative annotations include: no hostile, Denied any feelings of hostility etc. 





Precision and Recall: 
P=0.87, R=1.0 
 
47. Mutism App 
Description: 
Application to extract occurrences where mutism is apparent. 
Classes produced: Positive and Unknown. 
Positive annotations include: She has periods of 'mutism'  Issues with landlord, he did 
not respond any further and remained mute etc. 
Unknown annotations include: annotations include unclear statements such as that her 
mother is mute, Body language muted etc. 
Search Terms: 
[Mm]ute, [Mm]utism 
Precision and Recall: 
P=0.90, R=1.0 
 




Application to extract occurrences where paranoia is apparent. 
Classes produced: Positive, Negative and Unknown. 
Positive annotations include: vague paranoid ideation,  cause him to feel paranoid etc. 
Negative annotations include: denied any paranoid, no paranoid feeling etc. 
Unknown annotations include: annotations include unclear statements. 
Search Terms: 
[Pp]aranoi* 
Precision and Recall: 
P=0.90, R=1.0 
 
49. Persecutory Ideation App 
Description: 
Application to extract occurrences where persecution is apparent. 
Classes produced: Positive, Negative and Unknown. 
Positive annotations include: she was having delusions of persecution, She suffered 
persecutory delusion etc. 
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Negative annotations include: Denies persecutory delusions, He denied any worries of 
persecution etc. 
Unknown annotations include: annotations include unclear statements. 
Search Terms: 
[Pp]ersecu* 
Precision and Recall: 
P=0.92, R=0.99 
 
50. Poverty of Speech App 
Description: 
Application to identify poverty of speech, developed as part of the Negative Symptoms 
of Schizophrenia project. 
Classes produced: Positive, Negative and Unknown. 
Positive annotations include: He continues to display negative symptoms including 
blunting of affect, poverty of speech; He does have negative symptoms in the form of 
poverty of speech etc. 
Negative annotations include: No poverty of speech, There was no pressure or poverty 
of speech etc. 




[Pp]overty [0 to 2 words in between] [Ss]peech 
[Ii]mpoverish [ 0 to 2 words in between] [Ss]peech 
[Ss]peech [ 0 to 2 words in between] [Pp]overty 
[Ss]peech [ 0 to 2 words in between] [Ii]mpoverish 
Precision and Recall: 
P=0.92, R=0.97 
 
51. Pressured Speech App 
Description: 
Application to extract occurrences where pressured speech is apparent. 
Classes produced: Positive, Negative and Unknown. 
Positive annotations include: Talking with pressured speech; He had pressured speech 
etc.  
Negative annotations include: no pressure of speech, Her speech appeared normal in 
rate, volume and pressure etc. 





Precision and Recall: 
P=0.85, R=0.98 
 
52. Social Withdrawal App 
Description: 
Application to identify social withdraw. 
Classes produced: Positive, Negative and Unknown. 
Positive annotations include: She is withdrawn socially from friends and family, Mr  
ZZZZZ  became very isolated and socially withdrawn etc.  
Negative annotations include: not being socially withdrawn, no evidence of socially 
withdrawn etc. 
Unknown annotations include: annotations include unclear statements. 
Search Terms: 
[Ww]ithdraw* 





53. Tangential Speech App 
Description: 
Application to extract occurrences where tangential speech is apparent. 
Classes produced: Positive, Negative and Unknown. 
Positive annotations include: He was very tangential lacked goal directed thinking, There 
was evidence of tangential etc. 
Negative annotations include: no evidence of formal thought disorder or tangentiality of 
thoughts; however there was no overt tangentiality or loosening of associations etc. 
Unknown annotations include: annotations include unclear statements. 
Search Terms: 
[Tt]angent* 
Precision and Recall: 
P=0.93, R=1.0 
 
54. Thought Block App 
Description: 
Application to extract whether thought block is present.  
Classes produced: Positive, Negative and Unknown. 
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Positive annotations include: Showed some thought block;  thought block and paucity of 
thought etc.  
Negative annotations include: Denies problems with thought insertion; No formal 
thought disorder etc.  
Unknown annotations include: annotations include unclear statements.  
Search Terms: 
[Tt]hought block 
Precision and Recall: 
P=0.82, R=0.95 
 
55. Guilt App 
Description: 
Application to identifies when patients have occurrences of guilt or not.  
Classes produced: Positive, Negative and Unknown. 
Positive annotations include: she then feels guilty/angry towards mum; Being hungry is 
easier to deal with than feeling guilty etc.  
Negative annotations include: no feeling of guilt; Denies feeling hopeless or guilty etc. 





Precision and Recall: 
P=0.77, R=0.95 
56.  Concentration App 
Description: 
Application to identifies when patients have poor or good concentration.  
Classes produced: Positive, Negative and Unknown. 
Positive annotations include: My concentration is still poor, she found it difficult to 
concentrate etc. 
Negative annotations include: Good attention and concentration, Participating well and 
able to concentrate on activities etc. 
Unknown annotations include: annotations include unclear statements. 
Search Terms: 
[Cc]oncentrat 
Precision and Recall: 
P=0.68, R=0.80 




Application to extract occurrences of low mood. 
 Classes produced: Positive and Negative.  
Positive annotations: applied to any description of ‘low’ applied to mood: describes 
mood as generally low; appears a bit low in mood; experiencing signs of anxiety and low 
mood; feels low in mood; subjectively – low in mood; remains low in mood; difficulties 
with low mood; complaining of … low mood …; his recent misery and low mood; 
suffering from low mood.  
Negative annotations: applied to adjectives describing mood as: normal; good; 
euthymic; alright; reactive.  
No ‘unknown’ annotations: NB no attempt to distinguish the above annotations in terms 











Appendix 2- Additional table for Chapter 6 




Chiang method (II) - Used by ONS for calculation of subnational life expectancy at birth results and 95% confidence limits. 













<1 0 1 0.1 2,533 20 0.007896 0.0078401 0.992160 100000 784 99294 7198691 71.99 0.000003049 160076312 842044805 0.08420 0.2902 71.42 72.56
1-4 1 4 0.5 11,130 1 0.000090 0.0003593 0.999641 99216 36 396793 7099397 71.55 0.000000129 6151051 681968493 0.06928 0.2632
5-9 5 5 0.5 15,519 2 0.000129 0.0006442 0.999356 99180 64 495742 6702604 67.58 0.000000207 8649449 675817442 0.06870 0.2621
10-14 10 5 0.5 16,409 4 0.000244 0.0012181 0.998782 99116 121 495280 6206862 62.62 0.000000370 13188429 667167993 0.06791 0.2606
15-19 15 5 0.5 16,133 9 0.000558 0.0027854 0.997215 98996 276 494289 5711582 57.70 0.000000860 25810071 653979564 0.06673 0.2583
20-24 20 5 0.5 21,482 10 0.000466 0.0023248 0.997675 98720 230 493026 5217293 52.85 0.000000539 13384127 628169493 0.06446 0.2539
25-29 25 5 0.5 15,997 22 0.001375 0.0068527 0.993147 98490 675 490765 4724267 47.97 0.000002120 43098955 614785366 0.06338 0.2517
30-34 30 5 0.5 16,026 35 0.002184 0.0108605 0.989140 97816 1062 486422 4233501 43.28 0.000003333 54211405 571686411 0.05975 0.2444
35-39 35 5 0.5 19,800 34 0.001717 0.0085492 0.991451 96753 827 481698 3747080 38.73 0.000002131 26639208 517475006 0.05528 0.2351
40-44 40 5 0.5 16,076 39 0.002426 0.0120568 0.987943 95926 1157 476739 3265381 34.04 0.000003682 34536469 490835799 0.05334 0.2310
45-49 45 5 0.5 13,404 59 0.004402 0.0217688 0.978231 94770 2063 468690 2788642 29.43 0.000007857 53461530 456299330 0.05081 0.2254
50-54 50 5 0.5 13,027 108 0.008290 0.0406107 0.959389 92706 3765 454120 2319953 25.02 0.000014650 69406482 402837800 0.04687 0.2165
55-59 55 5 0.5 10,051 136 0.013531 0.0654412 0.934559 88942 5820 430157 1865832 20.98 0.000029429 91009253 333431318 0.04215 0.2053
60-64 60 5 0.5 10,220 176 0.017221 0.0825516 0.917448 83121 6862 398451 1435675 17.27 0.000035524 63630177 242422065 0.03509 0.1873
65-69 65 5 0.5 9,190 320 0.034820 0.1601602 0.839840 76259 12214 350763 1037224 13.60 0.000067322 68405970 178791888 0.03074 0.1753
70-74 70 5 0.5 7,427 445 0.059917 0.2605539 0.739446 64046 16687 278510 686461 10.72 0.000112808 57157515 110385918 0.02691 0.1640
75-79 75 5 0.5 5,231 414 0.079144 0.3303543 0.669646 47358 15645 197679 407951 8.61 0.000176524 33004917 53228403 0.02373 0.1541
80-84 80 5 0.5 2,884 355 0.123093 0.4706350 0.529365 31713 14925 121253 210272 6.63 0.000330290 20223485 20223485 0.02011 0.1418
85+ 85 11 0.5 1,840 347 0.188587 1.0000000 0.000000 16788 16788 89019 89019 5.30 0.000000000 0 0 0.00000 0.0000
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Primary cause of admission (ICD-10 codes)
Crude admission rates in general population during 2009-10
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Appendix 4- Additional tables for Chapter 8 
Appendix 4 Table 1: Multivariable ordinal logistic regression analysis of factors associated with negative symptoms in patients with schizophrenia 
Factor Group Number in CRIS-NSS mean Standard Unadjusted Adjusted model (n=7676)* 
  sample score (range 0-10) Deviation Odds ratio (95% CI) P value Odds ratio (95% CI) P value 
Age (years) 16-19 203 1.28 2.15 0.30 (0.22-0.40) <0.001 0.46 (0.33-0.64) <0.001 
 20-29 1337 2.45 2.64 Reference  Reference  
 30-39 1775 1.97 2.21 0.77 (0.67-0.87) <0.001 0.78 (0.68-0.89) <0.001 
 40-49 1983 1.66 1.95 0.62 (0.55-0.71) <0.001 0.62 (0.55-0.71) <0.001 
 50-59 1137 1.43 1.79 0.53 (0.46-0.61) <0.001 0.52 (0.45-0.61) <0.001 
 60-69 654 1.07 1.53 0.37 (0.31-0.44) <0.001 0.36 (0.30-0.44) <0.001 
 70+ 589 0.72 1.19 0.25 (0.21-0.30) <0.001 0.25 (0.20-0.31) <0.001 
Gender Male 4592 1.90 2.22 Reference  Reference  
 Female 3084 1.41 1.91 0.66 (0.60-0.71) <0.001 0.79 (0.72-0.86) <0.001 
Marital status Single 5795 1.88 2.20 Reference  Reference  
(most recent) Married/cohabiting 785 1.16 1.61 0.57 (0.50-0.66) <0.001 0.74 (0.64-0.86) <0.001 
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Factor Group Number in CRIS-NSS mean Standard Unadjusted Adjusted model (n=7676)* 
 Divorced/separated 776 1.35 1.86 0.64 (0.56-0.74) <0.001 0.86 (0.74-0.99) 0.040 
 Widowed 208 0.85 1.39 0.40 (0.31-0.52) <0.001 0.81 (0.60-1.09) 0.160 
Employment (most Unemployed 4956 2.03 2.23 Reference  Reference  
recent) Employed 341 1.51 1.87 0.68 (0.56-0.83) <0.001 0.64 (0.52-0.78) <0.001 
 In education 311 1.64 2.10 0.70 (0.57-0.86) 0.001 0.78 (0.63-0.97) 0.026 
 Retired 7 0.57 0.79 0.33 (0.08-1.29) 0.110 0.68 (0.16-2.87) 0.599 
ADL impairment Absent 4700 1.73 2.09 Reference  Reference  
 Present 2283 1.97 2.23 1.21 (1.11-1.33) <0.001 1.35 (1.22-1.49) <0.001 
Social impairment Absent 4432 1.76 2.10 Reference  Reference  
 Present 2533 1.88 2.20 1.07 (0.98-1.17) 0.108 0.95 (0.86-1.05) 0.292 
Delusions / Absent 3904 1.77 2.17 Reference  Reference  
hallucinations Present 3077 1.85 2.11 1.14 (1.05-1.24) 0.003 1.19 (1.09-1.30) <0.001 
Depression Absent 4976 1.90 2.16 Reference  Reference  




Appendix 4 Table 2: Multivariable binary logistic regression analysis of factors associated with negative symptoms in patients with schizophrenia including cases with full covariate data only 
Factor Group Number in Prevalence of two or more Association with two or more negative symptoms: odds ratio (95% CI), p- 
  sample negative symptoms (%)   value  
    Unadjusted  Adjusted model (n=5316)* 
Age (years) 16-19 203 27.6 0.35 (0.25-0.49) <0.001  0.44 (0.29-0.68) <0.001 
         
 20-29 1337 52.0 Reference   Reference  
         
 30-39 1775 47.0 0.82 (0.71-0.94) 0.006  0.80 (0.67-0.95) 0.012 
         
 40-49 1983 42.6 0.69 (0.60-0.79) <0.001  0.64 (0.54-0.76) <0.001 
         
 50-59 1137 37.2 0.55 (0.47-0.64) <0.001  0.45 (0.37-0.55) <0.001 
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Factor Group Number in Prevalence of two or more Association with two or more negative symptoms: odds ratio (95% CI), p- 
 60-69 654 29.1 0.38 (0.31-0.46) <0.001  0.32 (0.25-0.41) <0.001 
         
 70+ 589 18.0 0.20 (0.16-0.26) <0.001  0.13 (0.09-0.18) <0.001 
         
Gender Male 4592 45.3 Reference   Reference  
         
 Female 3083 34.7 0.64 (0.59-0.71) <0.001  0.74 (0.65-0.83) <0.001 
         
Marital status Single 5795 44.6 Reference   Reference  
(most recent) 
        
Married/cohabiting 785 31.6 0.57 (0.49-0.67) <0.001 
 
0.77 (0.63-0.94) 0.012   
         
 Divorced/separated 776 33.4 0.62 (0.53-0.73) <0.001  0.91 (0.75-1.12) 0.376 
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Factor Group Number in Prevalence of two or more Association with two or more negative symptoms: odds ratio (95% CI), p- 
         
 Widowed 208 21.2 0.33 (0.24-0.47) <0.001  0.85 (0.54-1.32) 0.466 
         
Employment (most Unemployed 4956 47.9 Reference   Reference  
recent) 
        
Employed 341 39.6 0.71 (0.57-0.89) 0.003 
 
0.65 (0.51-0.83) <0.001   
         
 In education 311 39.6 0.71 (0.56-0.90) 0.004  0.78 (0.61-1.02) 0.065 
         
 Retired 7 14.3 0.18 (0.02-1.51) 0.114  0.51 (0.06-4.65) 0.547 
         
ADL impairment Absent 4700 41.9 Reference   Reference  
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Factor Group Number in Prevalence of two or more Association with two or more negative symptoms: odds ratio (95% CI), p- 
 Present 2283 46.3 1.20 (1.08-1.32) <0.001  1.29 (1.13-1.47) <0.001 
         
Social impairment Absent 4432 42.7 Reference   Reference  
         
 Present 2533 44.4 1.07 (0.97-1.18) 0.158  0.93 (0.82-1.05) 0.258 
         
Delusions / Absent 3904 41.9 Reference   Reference  
hallucinations 
        
Present 3077 45.0 1.14 (1.03-1.25) 0.009 
 
1.23 (1.10-1.38) <0.001   
         
Depression Absent 4976 45.2 Reference   Reference  
         
 Present 2014 38.8 0.77 (0.69-0.85) <0.001  0.69 (0.61-0.78) <0.001 
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Factor Group Number in Prevalence of two or more Association with two or more negative symptoms: odds ratio (95% CI), p- 




Appendix 4 Table 3: Association between number of negative symptoms ascertained prior to 2011 and mental health hospital admission, re-admission and duration of admission in 2011 in 
patients aged under 40 years and patients aged over 40 years 
 
Inpatient admission 
(odds ratio, 95% 
CI)* 
Re-admission within 12 
months of inpatient 
admission (odds ratio, 
95% CI)* 
Duration of inpatient 
admission (days; B- 
coefficient, 95% CI)** 
Associations with 2 or more negative symptoms (binary variable) in 
patients aged between 16 and 39 years. n=3315 n=792 n=785 
Unadjusted 1.36 (1.17-1.59) 1.82 (1.36-2.43) 25.4 (6.2, 44.6) 
1. Age and sex 1.40 (1.20-1.63) 1.88 (1.40-2.54) 20.8 (1.5, 40.1) 
2. Model 1 plus marital status and employment 1.25 (1.06-1.46) 1.70 (1.24-2.31) 15.0 (-4.9, 34.9) 
3. Model 2 plus delusions / hallucinations, and depression 1.22 (1.03-1.43) 1.68 (1.23-2.29) 14.5 (-5.5, 34.5) 
Associations with 2 or more negative symptoms (binary variable) in 
patients aged over 40 years. n=4361 n=820 n=805 





(odds ratio, 95% 
CI)* 
Re-admission within 12 
months of inpatient 
admission (odds ratio, 
95% CI)* 
Duration of inpatient 
admission (days; B- 
coefficient, 95% CI)** 
1. Age and sex 1.33 (1.13-1.56) 1.56 (1.16-2.08) 26.7 (9.8, 43.6) 
2. Model 1 plus marital status and employment 1.26 (1.07-1.49) 1.48 (1.10-1.99) 24.3 (7.2, 41.4) 
3. Model 2 plus delusions / hallucinations, and depression 1.24 (1.05-1.45) 1.48 (1.10-1.99) 24.4 (7.5, 41.4) 
 
*Logistic regression; **Linear regression 





Appendix 4 Table 4: Percentage of patients admitted to hospital in 2011 by number of negative symptoms (n=7678) 
Number of negative Number of Percentage admitted to 
symptoms patients hospital in 2011 (%) 
   
0 3408 21.7 
1 1121 18.9 
2 974 22.7 
3 717 27.2 
4 492 28.1 
5 382 32.5 





Appendix 4 Table 5: Percentage of patients readmitted to hospital following discharge in 2011 by number of negative symptoms (n=1612) 
 
Number of negative Number of Percentage admitted to hospital in 2011 (%) 
symptoms patients  
   
0 612 29.9 
1 195 34.4 
2 213 40.4 
3 176 44.9 
4 131 43.5 
5 119 47.1 





Appendix 4 Table 6: Median duration of admission amongst mental health inpatients with schizophrenia in 2011 by number of negative symptoms (n=1,609) 
Number of negative Number of Median duration of admission in days (inter-quartile range) 
symptoms patients  
0 696 30.0 (13- 73) 
1 200 37.5 (17-86) 
2 194 46.0 (17- 87) 
3 165 40.0 (21- 89) 
4 116 48.0 (16- 107) 
5 110 51.5 (20- 128) 






Appendix 5- Additional table for Chapter 9 
 
Appendix 5 Table 1- Pearson’s correlation coefficients between symptoms domains 
 Negative Positive  Manic Disorganisation Catatonic Depressive 
Negative 1 0.67 0.62 0.63 0.51 0.65 
Positive -- 1 0.69 0.73 0.48 0.59 
Manic -- -- 1 0.66 0.41 0.67 
Disorganisation -- -- -- 1 0.49 0.59 
Catatonic  -- -- -- -- 1 0.46 
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